image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
7ce7ae4666e8e6c7bcda4a7f74f14fa2e46a9df93821f425be4d2a807db63de2.png | simple | <table><tr><td>Attribute</td><td>Value</td><td>% of total<sup>a</sup></td></tr><tr><td>Genome size (bp)</td><td>4,071,168</td><td>100</td></tr><tr><td>DNA cding region (bp)</td><td>3,565,936</td><td>87.5</td></tr><tr><td>DNA G+C content (bp)</td><td>1,880,879</td><td>46.1</td></tr><tr><td>Total number of genes<sup>b</sup></td><td>4095</td><td>n/a</td></tr><tr><td>RNA genes</td><td>116</td><td>n/a</td></tr><tr><td>rRNA operons</td><td>10</td><td>n/a</td></tr><tr><td>Protein-coding genes</td><td>3912</td><td>100</td></tr><tr><td>CDSs with predicted functions</td><td>3170</td><td>81</td></tr><tr><td>Uncharacterized/Hypothetical genes</td><td>742</td><td>18.1</td></tr><tr><td>CDSs assigned to COGs</td><td>3506</td><td>89.6</td></tr><tr><td>CDSs with signal peptides</td><td>302</td><td>7.7</td></tr><tr><td>CDSs with transmembrane helices</td><td>1012</td><td>25.8</td></tr></table> |
739191dd48cc02b95518a97a7bdc1b1cf2628c715cee8b28d0391b626f62839f.png | simple | <table><tr><td>Parameters<sup>a</sup></td><td>ND</td><td>HFD</td><td>HFD + ACG</td><td>HFD + QHD</td><td>HFD + RGZ</td></tr><tr><td>Body weight (g)</td><td>29.69 ± 2.89</td><td>45.85 ± 2.23<sup>##</sup></td><td>34.69 ± 2.84<sup><i>∗∗</i></sup></td><td>32.75 ± 2.66<sup><i>∗∗</i></sup></td><td>33.54 ± 2.57<sup><i>∗∗</i></sup></td></tr><tr><td>Food intake (g/day)</td><td>2.60 ± 0.09</td><td>2.77 ± 0.14</td><td>2.65 ± 0.10</td><td>2.62 ± 0.08</td><td>2.73 ± 0.08</td></tr><tr><td>Liver weight (g)</td><td>1.06 ± 0.10</td><td>2.45 ± 0.14<sup>##</sup></td><td>1.35 ± 0.38<sup><i>∗∗</i>&</sup></td><td>1.56 ± 0.45<sup><i>∗∗</i></sup></td><td>1.67 ± 0.43<sup><i>∗∗</i></sup></td></tr><tr><td>Liver/body weight ratio</td><td>3.60 ± 0.37</td><td>5.36 ± 0.30<sup>##</sup></td><td>3.95 ± 1.39<sup><i>∗</i></sup></td><td>4.78 ± 1.52</td><td>5.04 ± 1.46</td></tr><tr><td>ALT (U/L)</td><td>30.31 ± 7.54</td><td>91.65 ± 20.78<sup>##</sup></td><td>55.18 ± 13.66<sup><i>∗∗</i></sup></td><td>71.98 ± 19.55</td><td>81.68 ± 20.5</td></tr><tr><td>AST (U/L)</td><td>20.42 ± 4.26</td><td>87.83 ± 18.26<sup>##</sup></td><td>60.46 ± 13.51<sup><i>∗∗</i></sup></td><td>74.84 ± 11.91</td><td>82.44 ± 16.76</td></tr></table> |
e868575bfaebaeb67b67f7c5e7c96924a1efea4ef27aaf1a24bd4ce9646511b3.png | simple | <table><tr><td></td><td>I</td><td></td><td>II</td><td></td><td>III</td><td></td><td>IV</td><td></td><td>V</td><td></td><td>X</td><td></td></tr><tr><td></td><td>4856</td><td>4858</td><td>4856</td><td>4858</td><td>4856</td><td>4858</td><td>4856</td><td>4858</td><td>4856</td><td>4858</td><td>4856</td><td>4858</td></tr><tr><td>Function</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Exon</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Insert</td><td>9,942</td><td>91</td><td>16,423</td><td>334</td><td>10,263</td><td>156</td><td>11,219</td><td>6</td><td>8,645</td><td>112</td><td>11,106</td><td>437.11</td></tr><tr><td> Deletion</td><td>13825.97</td><td>78.05</td><td>17536.07</td><td>320.82</td><td>13684.02</td><td>192.04</td><td>15121.4</td><td>5.6</td><td>13436</td><td>93.73</td><td>11907.1</td><td>309.85</td></tr><tr><td> bs</td><td>19107.81</td><td>4110.87</td><td>41335.02</td><td>21232.1</td><td>19126.52</td><td>11330.5</td><td>12926.4</td><td>173.73</td><td>45618</td><td>1944.89</td><td>11563.6</td><td>6003.35</td></tr><tr><td> syn</td><td>9165.53</td><td>2406.68</td><td>19484.52</td><td>10292</td><td>7775.01</td><td>6870.87</td><td>5243.72</td><td>106.48</td><td>23642</td><td>876.37</td><td>5839.05</td><td>3192.57</td></tr><tr><td> Total</td><td>42876.05</td><td>4279.99</td><td>75293.76</td><td>21886.6</td><td>43073.55</td><td>11679.1</td><td>39267</td><td>184.94</td><td>67698</td><td>2151.1</td><td>34576.3</td><td>6750.32</td></tr><tr><td>Intron</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Insert</td><td>26409.16</td><td>435.8</td><td>20319.57</td><td>782.81</td><td>8397.01</td><td>867.75</td><td>13536.1</td><td>16.81</td><td>19268</td><td>201.52</td><td>14540.4</td><td>459.24</td></tr><tr><td> Deletion</td><td>11806.45</td><td>305.71</td><td>22268.03</td><td>648.06</td><td>26590.53</td><td>654.37</td><td>23657.7</td><td>16.81</td><td>11769</td><td>126.54</td><td>15570.8</td><td>520.11</td></tr><tr><td> bs</td><td>19263.15</td><td>5281.69</td><td>31731.94</td><td>14167.6</td><td>14306.02</td><td>10605</td><td>16828.7</td><td>173.73</td><td>36974</td><td>2371.36</td><td>14998.3</td><td>6877.58</td></tr><tr><td> Total</td><td>57478.76</td><td>6023.21</td><td>74319.54</td><td>15598.4</td><td>49293.56</td><td>12127.2</td><td>54022.6</td><td>207.36</td><td>68011</td><td>2699.41</td><td>45109.5</td><td>7856.92</td></tr><tr><td>UTR</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Insert</td><td>11495.75</td><td>695.99</td><td>21850.5</td><td>1803.03</td><td>11507.01</td><td>1322.96</td><td>8536.29</td><td>44.83</td><td>19789</td><td>243.7</td><td>7785.4</td><td>586.5</td></tr><tr><td> Deletion</td><td>24,079</td><td>852</td><td>17,675</td><td>1,655</td><td>23,325</td><td>1,046</td><td>15,487</td><td>22</td><td>16,456</td><td>248</td><td>18,662</td><td>580.97</td></tr><tr><td> bs</td><td>23457.55</td><td>6036.22</td><td>25747.41</td><td>18421.7</td><td>15239.02</td><td>11842.7</td><td>13658.1</td><td>263.4</td><td>31558</td><td>3791.37</td><td>10876.7</td><td>7137.63</td></tr><tr><td> Total</td><td>59032.24</td><td>7584.3</td><td>65273.15</td><td>21880.2</td><td>50071.06</td><td>14211.2</td><td>37681.6</td><td>330.65</td><td>67802</td><td>4283.45</td><td>37324.1</td><td>8305.1</td></tr><tr><td>IG</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Insert</td><td>23923.59</td><td>1144.8</td><td>28670.08</td><td>3054.24</td><td>11351.51</td><td>1856.42</td><td>27194.2</td><td>140.11</td><td>38432</td><td>328.05</td><td>34805.3</td><td>1593.52</td></tr><tr><td> Deletion</td><td>59032.24</td><td>787.05</td><td>44814.4</td><td>2771.91</td><td>23791.53</td><td>1593.25</td><td>58290.7</td><td>117.69</td><td>53950</td><td>313.99</td><td>49689.2</td><td>1659.91</td></tr><tr><td> bs</td><td>34021.21</td><td>9997.48</td><td>54556.66</td><td>39538.3</td><td>32966.04</td><td>20420.6</td><td>41827.8</td><td>1333.8</td><td>84675</td><td>5740.94</td><td>43277.7</td><td>22901.3</td></tr><tr><td> Total</td><td>116977.1</td><td>11929.33</td><td>128041.2</td><td>45364.4</td><td>68109.09</td><td>23870.2</td><td>127313</td><td>1591.6</td><td>177057</td><td>6382.99</td><td>127772</td><td>26154.7</td></tr></table> |
0bdd06b531ff18062c66a72cc5b42ef236524954c90d35d8bfd00fc6002f46c1.png | simple | <table><tr><td>Suboptimal factors N (%)</td><td>All patients</td><td>ethnic Dutch</td><td>Surinamese/Antillean</td><td>'Other non-western'</td></tr><tr><td>Education & Counselling</td><td>11 (22.45)</td><td>5 (33.33)</td><td>3 (20.00)</td><td>3 (15,79)</td></tr><tr><td>Prescriptions & types of inhalation devices</td><td>13 (26.53)</td><td>4 (26.67)</td><td>2 (13.33)</td><td>7 (36,84)</td></tr><tr><td>Routine follow-ups</td><td>9 (18.37)</td><td>3 (20.00)</td><td>4 (26.67)</td><td>2 (10,53)</td></tr><tr><td>Referrals and shared care*</td><td>10 (20.41)</td><td>2 (13.33)</td><td>5 (33.33)</td><td>3 (15,79)</td></tr><tr><td>Patient Compliance & effort undertaken to promote compliance</td><td>4 (8.16)</td><td>1 (6.67)</td><td>1 (6.67)</td><td>2 (10,53)</td></tr><tr><td>Other</td><td>2 (4.08)</td><td>-</td><td>-</td><td>2 (10,53)</td></tr><tr><td>Total number of factors (%)</td><td>49 (100.0)</td><td>15 (30.61)</td><td>15 (30.61)</td><td>19 (38,78)</td></tr></table> |
b15711c1e4287b2063945ae1471a21a6d92e2971a1b12e4684109680d771d3fa.png | simple | <table><tr><td>Point</td><td>Stress shielding rate in the traditional prosthesis group (<i>η</i>%)</td><td>Stress shielding rate in the anatomic prosthesis group (<i>η</i>%)</td></tr><tr><td>1</td><td> </td><td>18.6 (1.6)</td></tr><tr><td>2</td><td> </td><td>21.2 (2.1)</td></tr><tr><td>3</td><td> </td><td>24.9 (1.9)</td></tr><tr><td>4</td><td> </td><td>19.2 (1.7)</td></tr><tr><td>5</td><td> </td><td>25.4 (2.0)</td></tr><tr><td>6</td><td>36.5 (1.8)</td><td>28.3 (2.4)</td></tr><tr><td>7</td><td>43.6 (2.6)</td><td>31.4 (2.8)</td></tr><tr><td>8</td><td>33.0 (2.9)</td><td>26.3 (2.4)</td></tr><tr><td>9</td><td>38.0 (3.1)</td><td>27.0 (1.2)</td></tr><tr><td>10</td><td>5.6 (0.8)</td><td>3.7 (0.4)</td></tr><tr><td>11</td><td>35.6 (2.3)</td><td>22.7 (1.8)</td></tr><tr><td>12</td><td>29.3 (2.6)</td><td>18.4 (1.9)</td></tr><tr><td>13</td><td>36.1 (2.9)</td><td>18.7 (1.4)</td></tr><tr><td>14</td><td>22.7 (1.8)</td><td>15.1 (1.7)</td></tr><tr><td>15</td><td>25.0 (1.6)</td><td>18.5 (1.2)</td></tr><tr><td>16</td><td>1.5 (0.2)</td><td>1.41 (0.1)</td></tr><tr><td>17</td><td>17.9 (1.9)</td><td>10.3 (0.8)</td></tr><tr><td>18</td><td>12.6 (1.1)</td><td>4.3 (0.3)</td></tr></table> |
a36a329675404415aa61f4e26ff336cee03331a831db7b65d676135a04e0daf2.png | complex | <table><tr><td> </td><td colspan="2"><i>Exercise</i></td><td colspan="2"><i>Control</i></td><td><i>P</i></td><td><i>η</i><sub><i>p</i></sub><sup><i>2</i></sup></td></tr><tr><td> </td><td><i>Baseline</i></td><td><i>PI</i></td><td><i>Baseline</i></td><td><i>PI</i></td><td> </td><td> </td></tr><tr><td colspan="7"><i>MAP (mm Hg)</i></td></tr><tr><td> X</td><td>96</td><td>90</td><td>98</td><td>96</td><td>0.160</td><td>0.05</td></tr><tr><td> s.d.</td><td>13</td><td>12</td><td>14</td><td>15</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="7"><i>pDBP (mm Hg)</i></td></tr><tr><td> X</td><td>77</td><td>73</td><td>77</td><td>75</td><td>0.518</td><td>0.01</td></tr><tr><td> s.d.</td><td>10</td><td>10</td><td>9</td><td>11</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="7"><i>pSBP (mm Hg)</i></td></tr><tr><td> X</td><td>134</td><td>125</td><td>140</td><td>138</td><td>0.046a</td><td>0.09</td></tr><tr><td> s.d.</td><td>21</td><td>19</td><td>27</td><td>28</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="7"><i>cSBP (mm Hg)</i></td></tr><tr><td> X</td><td>127</td><td>118</td><td>133</td><td>132</td><td>0.027a</td><td>0.11</td></tr><tr><td> s.d.</td><td>19</td><td>17</td><td>26</td><td>28</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="7"><i>pPP (mm Hg)</i></td></tr><tr><td> X</td><td>57</td><td>52</td><td>62</td><td>63</td><td>0.037a</td><td>0.10</td></tr><tr><td> s.d.</td><td>14</td><td>12</td><td>22</td><td>24</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="7"><i>cPP (mm Hg)</i></td></tr><tr><td> X</td><td>49</td><td>43</td><td>53</td><td>55</td><td>0.011a</td><td>0.14</td></tr><tr><td> s.d.</td><td>13</td><td>10</td><td>21</td><td>23</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="7"><i>pSBP-cSBP (mm Hg)</i></td></tr><tr><td> X</td><td>6.4</td><td>6.8</td><td>6.8</td><td>6.1</td><td>0.419</td><td>0.02</td></tr><tr><td> s.d.</td><td>4.9</td><td>3.7</td><td>4.8</td><td>4.4</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="7"><i>AIx (%)</i></td></tr><tr><td> X</td><td>119</td><td>104</td><td>102</td><td>115</td><td>0.045a</td><td>0.09</td></tr><tr><td> s.d.</td><td>47</td><td>49</td><td>43</td><td>67</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="7"><i>Heart rate (b.p.m.)</i></td></tr><tr><td> X</td><td>59</td><td>59</td><td>65</td><td>62</td><td>0.406</td><td>0.02</td></tr><tr><td> s.d.</td><td>9</td><td>12</td><td>16</td><td>14</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="7"><i>DP</i></td></tr><tr><td> X</td><td>7591</td><td>7429</td><td>7795</td><td>8685</td><td>0.468</td><td>0.01</td></tr><tr><td> s.d.</td><td>2359</td><td>1985</td><td>3737</td><td>3111</td><td> </td><td> </td></tr></table> |
725787880f2d2d1586bee13a7ed68554d95022f8e9d1ce42a7d46535f5977045.png | complex | <table><tr><td></td><td colspan="2">All characters</td><td colspan="2">Forrest-only</td><td colspan="2">Jenny-only</td></tr><tr><td></td><td>Audio-visual</td><td>Audio-only</td><td>Audio-visual</td><td>Audio-only</td><td>Audio-visual</td><td>Audio-only</td></tr><tr><td><i>Dimensional emotion attributes</i>ArousalValenceDirection</td><td>0.676 ±0.0060.851 ±0.0040.555 ±0.011</td><td>0.305 ±0.0780.564 ±0.0440.068 ±0.050</td><td>0.600 ±0.0080.784 ±0.0060.543 ±0.012</td><td>0.443 ±0.0780.440 ±0.054-0.059 ±0.072</td><td>0.688 ±0.0060.858 ±0.0030.576 ±0.012</td><td>0.330 ±0.0760.598 ±0.0790.053 ±0.145</td></tr><tr><td><i>Emotion categories</i>AdmirationAnger/RageCompassionContemptDisappoint.FearFears conf.GloatingGratificationGratitudeHappinessHappy-forHateHopeLovePrideReliefRemorseResentmentSadnessSatisfactionShame</td><td>0.392 ±0.0060.719 ±0.0050.337 ±0.0100.433 ±0.0080.408 ±0.0080.749 ±0.0030.048 ±0.0090.644 ±0.0140.155 ±0.0100.317 ±0.0120.618 ±0.0060.478 ±0.0130.441 ±0.0110.333 ±0.0100.568 ±0.0080.473 ±0.0110.353 ±0.0190.557 ±0.022n/a0.737 ±0.0050.112 ±0.0070.316 ±0.006</td><td>0.343 ±0.0940.377 ±0.0420.182 ±0.0130.157 ±0.0430.367 ±0.0950.546 ±0.108n/a0.045 ±0.038n/an/a0.289 ±0.107n/a0.097 ±0.0700.217 ±0.0600.396 ±0.0320.156 ±0.054-0.003 ±0.0010.323 ±0.107n/a0.464 ±0.023n/a0.185 ±0.112</td><td>0.306 ±0.0150.693 ±0.0060.232 ±0.019n/a0.431 ±0.0070.729 ±0.004n/an/a0.242 ±0.0170.267 ±0.0240.561 ±0.0070.408 ±0.0280.478 ±0.0270.202 ±0.0080.472 ±0.0080.536 ±0.0090.505 ±0.028n/an/a0.750 ±0.005n/a0.290 ±0.006</td><td>n/a0.141 ±0.100n/an/a0.456 ±0.1290.504 ±0.072n/an/an/an/a0.381 ±0.060n/an/an/a0.327 ±0.092n/an/a0.453 ±0.364n/a0.522 ±0.006n/a0.034 ±0.036</td><td>n/a0.809 ±0.0070.459 ±0.0180.404 ±0.020n/a0.633 ±0.005n/an/an/a0.165 ±0.0150.738 ±0.005n/an/a0.439 ±0.0260.660 ±0.009n/an/a0.464 ±0.006n/a0.695 ±0.009n/a0.201 ±0.015</td><td>0.643 ±0.1970.626 ±0.1090.363 ±0.042n/an/a0.392 ±0.013n/an/an/an/a0.532 ±0.108n/an/a0.804 ±0.0520.432 ±0.040n/an/an/an/a0.228 ±0.040n/an/a</td></tr><tr><td><i>Emotion onset cues</i>AudioContextFaceGestureNarratorVerbal</td><td>0.418 ±0.0080.384 ±0.0100.713 ±0.0060.619 ±0.010n/a0.637 ±0.008</td><td>0.037 ±0.051n/an/an/a0.251 ±0.0470.368 ±0.107</td><td>0.354 ±0.0130.424 ±0.0110.687 ±0.0100.532 ±0.011n/a0.565 ±0.007</td><td>n/an/an/an/a0.202 ±0.0450.455 ±0.042</td><td>0.203 ±0.0070.547 ±0.0100.880 ±0.0040.769 ±0.009n/a0.783 ±0.005</td><td>n/an/an/an/a0.578 ±0.2860.626 ±0.168</td></tr></table> |
3828e84190c0abb7d2651262721e7c31dbbdc959328c83ca7dd6b8dd82a5626d.png | complex | <table><tr><td rowspan="2">Domain</td><td colspan="2">SED PAQ</td><td colspan="2">SED ACC</td><td colspan="2">LPA PAQ</td><td colspan="2">LPA ACC</td><td colspan="2">MVPA PAQ</td><td colspan="2">MVPA ACC</td></tr><tr><td>Mean (SD)</td><td>% (Day)</td><td>Mean (SD)</td><td>% (Day)</td><td>Mean (SD)</td><td>% (Day)</td><td>Mean (SD)</td><td>% (Day)</td><td>Mean (SD)</td><td>% (Day)</td><td>Mean (SD)</td><td>% (Day)</td></tr><tr><td>Transport (min/day)</td><td>3 (9)</td><td>1</td><td>13 (6)</td><td>3</td><td>20 (13)</td><td>11</td><td>11 (4)</td><td>5</td><td>2 (7)</td><td>1</td><td>7 (4)</td><td>7</td></tr><tr><td>School time (min/day)</td><td>247 (114)</td><td>52</td><td>271 (38)</td><td>55</td><td>50 (41)</td><td>27</td><td>103 (22)</td><td>53</td><td>35 (39)</td><td>20</td><td>41 (14)</td><td>46</td></tr><tr><td>Physical education (min/week)</td><td>36 (42)</td><td>1</td><td>66 (44)</td><td>2</td><td>17 (50)</td><td>2</td><td>50 (28)</td><td>4</td><td>116 (72)</td><td>13</td><td>39 (23)</td><td>8</td></tr><tr><td>Leisure time (min/day)</td><td>183 (94)</td><td>39</td><td>182 (50)</td><td>37</td><td>98 (70)</td><td>56</td><td>56 (16)</td><td>29</td><td>49 (57)</td><td>30</td><td>21 (9)</td><td>23</td></tr><tr><td>Organized sports activities (min/week)</td><td>56 (39)</td><td>7</td><td>41 (36)</td><td>4</td><td>12 (41)</td><td>4</td><td>37 (27)</td><td>9</td><td>100 (80)</td><td>35</td><td>32 (28)</td><td>16</td></tr></table> |
4468588315320bb13e70db0f7f2998b72804b26ddc7b81d0fb10f3c24f382abf.png | simple | <table><tr><td></td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>8</td><td>9</td><td>10</td></tr><tr><td>1. Playfulness</td><td>–</td><td>013</td><td>−001</td><td>406<sup>**</sup></td><td>396<sup>**</sup></td><td>−295<sup>**</sup></td><td>289<sup>**</sup></td><td>308<sup>**</sup></td><td>361<sup>**</sup></td><td>402<sup>**</sup></td></tr><tr><td>2. Disruptive (SR)</td><td>009</td><td>–</td><td>298<sup>**</sup></td><td>−299<sup>**</sup></td><td>256<sup>*</sup></td><td>−317<sup>**</sup></td><td>043</td><td>041</td><td>019</td><td>283<sup>**</sup></td></tr><tr><td>3. Disruptive (PR)</td><td>−010</td><td>225<sup>*</sup></td><td>–</td><td>−258<sup>*</sup></td><td>097</td><td>−306<sup>**</sup></td><td>−307<sup>**</sup></td><td>046</td><td>155<sup>*</sup></td><td>362<sup>**</sup></td></tr><tr><td>4. Disruptive (TR)</td><td>018</td><td>279<sup>**</sup></td><td>−236<sup>*</sup></td><td>–</td><td>362<sup>**</sup></td><td>−405<sup>**</sup></td><td>−328<sup>**</sup></td><td>−015</td><td>313<sup>**</sup></td><td>340<sup>**</sup></td></tr><tr><td>5. Social competence (SR)</td><td>107</td><td>−105</td><td>−102</td><td>008</td><td>–</td><td>−326<sup>**</sup></td><td>288<sup>**</sup></td><td>−014</td><td>290<sup>**</sup></td><td>−296<sup>**</sup></td></tr><tr><td>6. Social competence (TR)</td><td>−031</td><td>−287<sup>**</sup></td><td>−405<sup>**</sup></td><td>−279<sup>**</sup></td><td>284<sup>**</sup></td><td>–</td><td>−264<sup>*</sup></td><td>−023</td><td>279<sup>*</sup></td><td>−311<sup>**</sup></td></tr><tr><td>7. Social status (PR)</td><td>156<sup>*</sup></td><td>−104</td><td>−089</td><td>−213<sup>*</sup></td><td>062</td><td>−295<sup>**</sup></td><td>–</td><td>088</td><td>275<sup>*</sup></td><td>−288<sup>**</sup></td></tr><tr><td>8. Class clown (SR)</td><td>019</td><td>007</td><td>061</td><td>245<sup>*</sup></td><td>027</td><td>−039</td><td>068</td><td>–</td><td>296<sup>**</sup></td><td>315<sup>**</sup></td></tr><tr><td>9. Class clown (PR)</td><td>004</td><td>095</td><td>273<sup>**</sup></td><td>256<sup>*</sup></td><td>091</td><td>−088</td><td>310<sup>**</sup></td><td>297<sup>**</sup></td><td>–</td><td>−322<sup>**</sup></td></tr><tr><td>10. Class clown (TR)</td><td>−023</td><td>276<sup>**</sup></td><td>288<sup>**</sup></td><td>278<sup>**</sup></td><td>046</td><td>−294<sup>**</sup></td><td>335<sup>**</sup></td><td>023</td><td>−288<sup>**</sup></td><td>–</td></tr></table> |
2e75b7f9eb844325b24db8310eaed6890b0890d2966218a25aea682489442067.png | simple | <table><tr><td>Position</td><td>δ<sub>H</sub> mult (<i>J</i> Hz)</td><td>δ<sub>C</sub> mult</td><td>HMBC</td></tr><tr><td>1</td><td></td><td>195.5, C</td><td>2</td></tr><tr><td>2</td><td>3.70, d (2.4)</td><td>68.4, CH</td><td></td></tr><tr><td>3</td><td>3.86, ddd (7.2, 1.9, 1.9)</td><td>72.5, CH</td><td>2, 4, 5 </td></tr><tr><td>4</td><td>1.51, m; 1.24, m</td><td>32.1, CH<sub>2</sub></td><td>2, 3 </td></tr><tr><td>5</td><td>3.42, m; 2.71, t (12.0)</td><td>37.9, CH<sub>2</sub></td><td>3</td></tr><tr><td>6-NH</td><td>8.43, s</td><td></td><td></td></tr><tr><td>7</td><td></td><td>168.9, C</td><td>5, 8, 9 </td></tr><tr><td>8</td><td>5.76, dd (11.4, 2.8)</td><td>124.8, CH</td><td>10</td></tr><tr><td>9</td><td>6.02, ddd (11.4, 11.4, 2.6)</td><td>141.8, CH</td><td>10</td></tr><tr><td>10</td><td>3.53, m; 2.09, m</td><td>25.9, CH<sub>2</sub></td><td>8</td></tr><tr><td>11</td><td>1.35, m</td><td>50.3, CH</td><td>9, 10, 20, 22, 23 </td></tr><tr><td>12</td><td>2.51, m</td><td>43.4, CH</td><td>10, 14 </td></tr><tr><td>13</td><td>5.62, ddd (9.9, 2.8, 2.8)</td><td>129.6, CH</td><td></td></tr><tr><td>14</td><td>5.83, dt (10.0, 2.1)</td><td>131.9, CH</td><td></td></tr><tr><td>15</td><td>1.48, m</td><td>48.4, CH</td><td>13, 14, 19</td></tr><tr><td>16</td><td>1.29, m</td><td>48.5, CH</td><td>17, 30</td></tr><tr><td>17</td><td>2.20, m</td><td>34.3, CH</td><td>18, 29, 30 </td></tr><tr><td>18</td><td>2.05, m; 0.63, ddd (11.9, 11.8, 6.8)</td><td>39.9, CH<sub>2</sub></td><td>19, 29 </td></tr><tr><td>19</td><td>1.08, m</td><td>50.4, CH</td><td>14, 18, 21</td></tr><tr><td>20</td><td>2.00, m</td><td>43.2, CH</td><td>13, 18, 21 </td></tr><tr><td>21</td><td>2.01, m; 1.10, m</td><td>38.1, CH<sub>2</sub></td><td>19, 22, 23 </td></tr><tr><td>22</td><td>2.32, m</td><td>49.6, CH</td><td>21, 23, 24 </td></tr><tr><td>23</td><td>6.47, dd (15.1, 10.0)</td><td>147.8, CH</td><td>21, 22 </td></tr><tr><td>24</td><td>7.30, d (15.2)</td><td>130.4, CH</td><td>22</td></tr><tr><td>25</td><td></td><td>184.7, C</td><td>23, 24 </td></tr><tr><td>26</td><td></td><td>102.8, C</td><td></td></tr><tr><td>27</td><td></td><td>179.9, C</td><td>2</td></tr><tr><td>28-NH</td><td>8.43, s</td><td></td><td></td></tr><tr><td>29</td><td>0.81, d (6.0)</td><td>18.1, CH<sub>3</sub></td><td>17, 18</td></tr><tr><td>30</td><td>1.42, m; 1.30, m</td><td>22.7, CH<sub>2</sub></td><td>16, 31 </td></tr><tr><td>31</td><td>0.87, t (7.1)</td><td>13.7, CH<sub>3</sub></td><td>30</td></tr></table> |
1e50e3634f1717737d57da92876fbd5bc1e1669d557fc0a565b3463a28610f36.png | complex | <table><tr><td rowspan="2">Data Type</td><td colspan="2">Control</td><td colspan="2">Cold</td><td colspan="2">Freezing</td></tr><tr><td>Total Reads</td><td>Unique Reads</td><td>Total Reads</td><td>Unique Reads</td><td>Total Reads</td><td>Unique Reads</td></tr><tr><td>Clean reads</td><td>10,823,011</td><td>4,415,425</td><td>10,833,023</td><td>4,746,716</td><td>10,781,132</td><td>4,296,444</td></tr><tr><td>Rfam</td><td>229,925</td><td>18,696</td><td>400,604</td><td>28,495</td><td>1,947,224</td><td>38,460</td></tr><tr><td>Transcriptome</td><td>4,933,169</td><td>1,201,107</td><td>4,509,305</td><td>1,232,313</td><td>3,892,472</td><td>1,219,439</td></tr><tr><td>Known miRNA</td><td>1,597,215</td><td>24,334</td><td>1,287,494</td><td>27,292</td><td>987,515</td><td>24,278</td></tr><tr><td>Novel miRNA</td><td>172,273</td><td>1355</td><td>82,573</td><td>1121</td><td>62,290</td><td>944</td></tr></table> |
05e719ed36874b04eda8c380c617e55bba163d1dd87d9b449dcc295b727ca7a4.png | complex | <table><tr><td rowspan="2">Treatment phase</td><td rowspan="2">Parameter</td><td colspan="4">Experts</td><td>Faesibility study [28]</td></tr><tr><td>Unit</td><td>Median</td><td>Min</td><td>Max</td><td>Median</td></tr><tr><td rowspan="4">Positioning</td><td>Time patient verification</td><td>min</td><td>15</td><td>10</td><td>25</td><td>11.5</td></tr><tr><td>Time verification reachability</td><td>min</td><td>15</td><td>7</td><td>20</td><td>14.5</td></tr><tr><td>Time target definition</td><td>min</td><td>8</td><td>5</td><td>15</td><td>n/a</td></tr><tr><td>Chance of repositioning</td><td>-</td><td>0.30</td><td>0.10</td><td>0.75</td><td>n/a</td></tr><tr><td rowspan="6">Test</td><td>Time to place navigator</td><td>min</td><td>2</td><td>1</td><td>10</td><td>1</td></tr><tr><td>Time MRI scan</td><td>min</td><td>2.5</td><td>1</td><td>15</td><td>2.5</td></tr><tr><td>Time for treatment planning</td><td>min</td><td>2</td><td>1</td><td>5</td><td>n/a</td></tr><tr><td>Time to fill LUT</td><td>min</td><td>2.75</td><td>0</td><td>5</td><td>n/a</td></tr><tr><td>Test sonication and check focal point</td><td>min</td><td>3</td><td>1</td><td>5</td><td>4</td></tr><tr><td>Chance of adjustment focal point per coronal plane</td><td>-</td><td>0.55</td><td>0.20</td><td>0.90</td><td>n/a</td></tr><tr><td rowspan="4">Therapeutic</td><td>Time therapeutic phase</td><td>min</td><td>0.50</td><td>0.25</td><td>0.75</td><td>n/a</td></tr><tr><td>Cooling time after each sonication</td><td>min</td><td>3.5</td><td>1</td><td>10</td><td>n/a</td></tr><tr><td>Chance of abortion per coronal plane</td><td>-</td><td>0,10</td><td>0,05</td><td>0,20</td><td>n/a</td></tr><tr><td>Chance of resonication per coronal plane</td><td>-</td><td>0.20</td><td>0.10</td><td>0.30</td><td>n/a</td></tr><tr><td rowspan="2">Post-treatment</td><td>Time clinical ward</td><td>min</td><td>240</td><td>120</td><td>300</td><td>n/a</td></tr><tr><td>Chance of complications</td><td>-</td><td>0.015</td><td>0.01</td><td>0.03</td><td>n/a</td></tr></table> |
6954905c23fa48719a8712342694aa1d4daad49800810abe3ee1973c082be1bc.png | simple | <table><tr><td>Symbol</td><td>Definition</td><td>Theory</td><td>Experiment</td></tr><tr><td>PRR</td><td>Packet Reception Rate</td><td>Varying</td><td>Varying</td></tr><tr><td>BER</td><td>Bit Error Rate</td><td>Varying</td><td>Varying</td></tr><tr><td>SNR</td><td>Signal to Noise Ratio</td><td>Varying</td><td>Varying</td></tr><tr><td>RSSI</td><td>Receiver Signal Strength Indicator</td><td>Varying</td><td>Varying</td></tr><tr><td><i>f<sub>data</sub></i></td><td>Date frame size in bits</td><td>272</td><td>272</td></tr><tr><td><i>f<sub>ack</sub></i></td><td>ACK frame size in bits</td><td>64</td><td>64</td></tr><tr><td><i>E<sub>b</sub></i></td><td>The average energy per bit</td><td>Varying</td><td>Varying</td></tr><tr><td><i>N</i><sub>0</sub></td><td>Noise power spectral density</td><td>Varying</td><td>Varying</td></tr><tr><td><i>R</i></td><td>Data bit rate</td><td>1.2 to 152 kbps</td><td>9.6, 20, 38, 76 kbps</td></tr><tr><td><i>B</i></td><td>Channel bandwidth</td><td>Varying</td><td>Varying</td></tr><tr><td><i>N</i></td><td>Channel noise power</td><td>Varying</td><td>Varying</td></tr><tr><td><i>k</i></td><td>Boltzmann’s constant</td><td>1.38 × 10<sup>−23</sup> J/K</td><td>1.38 × 10<sup>−23</sup> J/K</td></tr><tr><td><i>T</i></td><td>Effective temperature in Kelvin</td><td>Varying</td><td>Varying</td></tr><tr><td><i>E</i></td><td>Node energy consumption</td><td>Varying</td><td>Varying</td></tr><tr><td><i>n</i></td><td>The number of neighbors</td><td>10</td><td>1</td></tr><tr><td><i>P<sub>l</sub></i></td><td>Power in listening</td><td>2.85 mA</td><td>2.85 mA</td></tr><tr><td><i>P<sub>tx</sub></i></td><td>Power in transmitting</td><td>25.4 mA</td><td>25.4 mA</td></tr><tr><td><i>P<sub>rx</sub></i></td><td>Power in receiving</td><td>15.1 mA</td><td>15.1 mA</td></tr><tr><td><i>t<sub>l</sub></i></td><td>Listening time</td><td>11 ms</td><td>11 ms</td></tr><tr><td><i>t<sub>tone</sub></i></td><td>Polling time</td><td>12 ms</td><td>12 ms</td></tr><tr><td><i>α</i></td><td>One hop link reliability requirement</td><td>1</td><td>1</td></tr></table> |
b06c84e2c2eda60047ec3070e9504dd6b8e41e2f3262177c172361cc18284fa3.png | simple | <table><tr><td>Prognostic-risk group</td><td>Cytogenetic profile alone</td><td>Cytogenetic profile and molecular abnormalities</td></tr><tr><td>Favorable</td><td>t(8:21)(q22; q22)inv(16)(p13; 1q22)t(15;17)(q22; q12)</td><td>t(8:21)(q22; q22) with no c-KIT mutationinv(16)(p13; 1q22)t(15;17)(q22; q12)Mutated NPM1 without FLT3-ITD (CN-AML)Mutated biallelic CEBPA (CN-AML)</td></tr><tr><td>Intermediate</td><td>CN-AMLt(9;11)(p22; q23)Cytogenetic abnormalities not included in the favorable or adverse prognostic risk groups</td><td>t(8:21)(q22;q22) with mutated c-KITCN-AML other than those included in the favorable or adverse prognostic groupt(9;11)(p22; q23)Cytogenetic abnormalities not included in the favorable or adverse prognostic risk groups</td></tr><tr><td>Adverse</td><td>inv(3)(q21q26.2)t(6;9)(p23; q34)11q abnormalities other than t(9;11)−5 or del(5q)−7Complex karyotype</td><td>TP53 mutation, regardless of cytogenetic profileCN with FLT3-ITDCN with DNMT3ACN with KMT2A-PTDinv(3)(q21q26.2)t(6;9)(p23;q34)11q abnormalities other than t(9;11)−5 or del(5q)−7Complex karyotype</td></tr></table> |
a1b26cff313837b894060096afd2506bed4a5c194c2dbc93928dc8f8ab3e491f.png | complex | <table><tr><td rowspan="2">Age Groups (Years)</td><td rowspan="2">No. of Samples</td><td colspan="2">Specific activities of DBH (pmol/men/mg protein)a</td></tr><tr><td>Normal</td><td>Arsenicosis Patient</td></tr><tr><td>Group 1 (10-18)</td><td>9</td><td>376.4 ± 79.6</td><td>190.2 ± 57.0b</td></tr><tr><td>Group 2 (20-40)</td><td>14</td><td>427.5 ± 60.2</td><td>348.8 ± 74.7c</td></tr><tr><td>Group 3 (45-70)</td><td>9</td><td>399.6 ± 86.7</td><td>415.7 ± 85.1d</td></tr></table> |
5ecef2e422dd5f615ee1061185ed149f10f168944a2cf227981c98a4cf8b1ea0.png | simple | <table><tr><td>Geographical regions and environmental variables</td><td>Malkangiri (Non-coastal)</td><td>Puri (Coastal)</td></tr><tr><td>Physical components</td><td></td><td></td></tr><tr><td>Temperature (Maximum, Minimum)</td><td>47 °C, 11 °C</td><td>36 °C, 13 °C</td></tr><tr><td>Average yearly rainfall in mm</td><td>1465</td><td>1586</td></tr><tr><td>Natural components</td><td></td><td></td></tr><tr><td>Height from the sea level in metres</td><td>196</td><td>6</td></tr><tr><td>Forest cover in percentage</td><td>38</td><td>3</td></tr><tr><td>Social components</td><td></td><td></td></tr><tr><td>Total population in million</td><td>0.61</td><td>1.69</td></tr><tr><td>Population Density per Sq. Km</td><td>106</td><td>488</td></tr><tr><td>Literacy Rate in percentage</td><td>49</td><td>85</td></tr></table> |
46fd0162476c4967aa532a3c73281eca9ae8068fa7000d1884efb906ba600b6c.png | complex | <table><tr><td>Independent variables</td><td>Total <i>N</i></td><td>Children with DH<i>N</i> (%)</td><td>PR (95% CI)</td><td><i>P</i><sup>*</sup></td></tr><tr><td>Age (cont.)</td><td> </td><td> </td><td>0.97(0.78 to 1.19)</td><td>0.784</td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> (ref.: male)</td><td>26</td><td>11 (42.3)</td><td>1.00</td><td rowspan="2">0.923</td></tr><tr><td> Female</td><td>22</td><td>9 (40.9)</td><td>0.97(0.49 to 1.91)</td></tr><tr><td>Dental erosion</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> (ref.: absent)</td><td>24</td><td>6 (25.0)</td><td>1.00</td><td rowspan="2">0.033</td></tr><tr><td> Present</td><td>24</td><td>14 (58.3)</td><td>2.33(1.07 to 5.09)</td></tr><tr><td>Bitter taste</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> (ref.: no)</td><td>39</td><td>13 (33.3)</td><td>1.00</td><td rowspan="2">0.004</td></tr><tr><td> Yes</td><td>9</td><td>7 (77.8)</td><td>2.33(1.32 to 4.13)</td></tr><tr><td>Temperature of soft drink</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> (ref.: room temperature)</td><td>19</td><td>9 (47.4)</td><td>1.00</td><td rowspan="2">0.517</td></tr><tr><td> Cold/iced</td><td>29</td><td>11 (37.9)</td><td>0.80(0.41 to 1.57)</td></tr><tr><td>Usual drinking method</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> (ref.: Swallowing immediately)</td><td>39</td><td>14 (35.9)</td><td>1.00</td><td rowspan="2">0.054</td></tr><tr><td> Holding the beverage in the mouth before swallowing</td><td>9</td><td>6 (66.7)</td><td>1.86(0.99 to 3.49)</td></tr><tr><td>Simplified Oral Hygiene Index (cont.)</td><td> </td><td> </td><td>0.47(0.24 to 0.94)</td><td>0.033</td></tr></table> |
a05de6d867fe46dbe522781196b3b11307c4d83359d367439c4e9bdcf7b0eb86.png | simple | <table><tr><td>Variable</td><td>Number of TRBs (n = 43)</td><td>Odds ratio†</td><td>95% CI</td></tr><tr><td>Male</td><td>28</td><td>1.0</td><td>0.7-1.4</td></tr><tr><td>Age ≥65 years</td><td>6</td><td>5.3</td><td>3.7-7.6</td></tr><tr><td>Travel region‡</td><td>7</td><td>18.4</td><td>6.9-49.5</td></tr><tr><td> Sub-Saharan Africa</td><td>2</td><td>10.6</td><td>2.1-53.2</td></tr><tr><td> Middle East</td><td>14</td><td>4.0</td><td>2.2-7.5</td></tr><tr><td> South East Asia</td><td></td><td></td><td></td></tr></table> |
b858a9d6c96747a1861e544c96e2957e38eadfd5e64ca8639b4ad23fd4ac5566.png | complex | <table><tr><td rowspan="2">Species</td><td>Fructose</td><td>Mannitol</td><td>Sucrose</td><td>Trehalose</td><td>Total sugars </td></tr><tr><td colspan="5">(g/100 g fresh weight)</td></tr><tr><td><i>Agaricus bisporus </i></td><td>0.03</td><td>5.6</td><td>nd</td><td>0.16</td><td>5.79</td></tr><tr><td><i>Lentinus edodes </i></td><td>0.69</td><td>10.01</td><td>nd</td><td>3.38</td><td>14.03</td></tr><tr><td><i>Pleurotus ostreatus </i></td><td>0.01</td><td>0.54</td><td>nd</td><td>4.42</td><td>4.97</td></tr><tr><td><i>Pleurotus eryngii </i></td><td>0.03</td><td>0.60</td><td>0.03</td><td>8.01</td><td>8.67</td></tr><tr><td>Dry powder formulations</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> <i>Agaricus blazei </i></td><td>0.27</td><td>60.89</td><td>nd</td><td>5.74</td><td>66.91</td></tr><tr><td> <i>Lentinus edodes </i></td><td>nd</td><td>23.3</td><td>nd</td><td>13.22</td><td>38.31</td></tr></table> |
5f4c2fea735530c2b050d93bd73c9313473a38437ab877b5abe69156943541d8.png | simple | <table><tr><td>Antimicrobial agent</td><td>MIC</td></tr><tr><td>Cefazolin</td><td>> 16</td></tr><tr><td>Ampicillin/sulbactam</td><td>8</td></tr><tr><td>Ceftriaxone</td><td>≦ 0.5</td></tr><tr><td>Cefepime</td><td>≦ 0.5</td></tr><tr><td>Gentamicin</td><td>≦ 1</td></tr><tr><td>Levofloxacin</td><td>≦ 0.25</td></tr><tr><td>Imipenem</td><td>≦ 0.5</td></tr><tr><td>Meropenem</td><td>≦ 0.5</td></tr><tr><td>Piperacillin/tazobactam</td><td>≦ 2</td></tr><tr><td>Trimethoprim/sulfamethoxazole</td><td>≦ 5</td></tr></table> |
f0fa278f7fce0b78ebc5a5a3b17fca944db6d8d093326de107b4a2c16336ecab.png | simple | <table><tr><td>Clinical analysis</td><td>Number</td><td>Percentage (%)</td></tr><tr><td>Clinical phenotype</td><td>212</td><td> </td></tr><tr><td> DMD</td><td>148</td><td>69.81%</td></tr><tr><td> BMD</td><td>52</td><td>24.53%</td></tr><tr><td> IMD</td><td>12</td><td>5.66%</td></tr><tr><td>Blood test</td><td>190</td><td> </td></tr><tr><td> Testing for Crn level</td><td>190</td><td>100%</td></tr><tr><td> Testing for cystatin C level</td><td>190</td><td>100%</td></tr><tr><td>Vignos scale</td><td>187</td><td> </td></tr><tr><td> Degree (1–6)</td><td>173</td><td>92.51%</td></tr><tr><td> Degree (7–9)</td><td>14</td><td>7.49%</td></tr><tr><td>Mutation analysis</td><td>195</td><td> </td></tr><tr><td> Large rearrangements</td><td>136</td><td>69.74%</td></tr><tr><td> Smaller mutations</td><td>42</td><td>21.54%</td></tr><tr><td> No large rearrangements</td><td>17</td><td>8.72%</td></tr></table> |
2ef82242ce99dfd8c744e4f07ce21968e38c4dd076cb3236a045ecd9026d91cd.png | complex | <table><tr><td rowspan="2">Noise type</td><td rowspan="2">Noise reduction technique</td><td colspan="7">Noise intensity (dB)</td></tr><tr><td>20</td><td>18</td><td>16</td><td>14</td><td>12</td><td>10</td><td>8</td></tr><tr><td>Gaussian</td><td>Wavelet</td><td>90.71</td><td>90.00</td><td>90.36</td><td>87.86</td><td>88.57</td><td>86.07</td><td>71.79</td></tr><tr><td></td><td>Contourlet</td><td>89.29</td><td>88.57</td><td>87.50</td><td>87.51</td><td>78.93</td><td>65.00</td><td>44.64</td></tr><tr><td></td><td>TV</td><td>87.14</td><td>89.64</td><td>86.79</td><td>85.00</td><td>72.21</td><td>37.89</td><td>25.12</td></tr><tr><td></td><td>WVTV</td><td>87.14</td><td>86.43</td><td>86.43</td><td>85.71</td><td>86.79</td><td>87.14</td><td>85.16</td></tr><tr><td colspan="9">

</td></tr><tr><td>Rayleigh</td><td>Wavelet</td><td>90.36</td><td>89.64</td><td>89.64</td><td>91.43</td><td>89.64</td><td>87.86</td><td>88.57</td></tr><tr><td></td><td>Contourlet</td><td>89.64</td><td>88.57</td><td>88.57</td><td>86.07</td><td>89.29</td><td>84.64</td><td>72.36</td></tr><tr><td></td><td>TV</td><td>87.86</td><td>87.86</td><td>85.36</td><td>88.57</td><td>85.43</td><td>87.59</td><td>51.25</td></tr><tr><td></td><td>WVTV</td><td>86.43</td><td>86.79</td><td>87.86</td><td>85.00</td><td>86.79</td><td>86.07</td><td>83.57</td></tr><tr><td colspan="9">

</td></tr><tr><td>Exponential</td><td>Wavelet</td><td>90.00</td><td>90.00</td><td>88.93</td><td>88.21</td><td>88.21</td><td>88.21</td><td>77.14</td></tr><tr><td></td><td>Contourlet</td><td>90.36</td><td>87.14</td><td>87.86</td><td>84.29</td><td>72.50</td><td>61.84</td><td>48.25</td></tr><tr><td></td><td>TV</td><td>90.71</td><td>89.29</td><td>87.50</td><td>86.07</td><td>82.86</td><td>75.00</td><td>62.37</td></tr><tr><td></td><td>WVTV</td><td>85.71</td><td>85.36</td><td>85.36</td><td>85.71</td><td>84.29</td><td>85.57</td><td>83.93</td></tr></table> |
60130a963a1aa821f16d1c46d7342aaf92942d09d1cee7b96d927bcce5c324f0.png | simple | <table><tr><td>Swiss Prot Acc. No.</td><td>Symbol</td><td>Entrez Gene Name</td><td>Fold Change</td><td>Location</td><td>Protein Class</td></tr><tr><td>P08758</td><td>ANXA5</td><td>annexin A5</td><td>-1.98</td><td>Plasma membrane</td><td>transfer/carrier protein</td></tr><tr><td>Q07507</td><td>DPT</td><td>dermatopontin</td><td>-2.15</td><td>Extracellular space</td><td>extracellular matrix binding protein</td></tr><tr><td>Q96KK5</td><td>HIST1H2AH</td><td>histone cluster 1, H2ah</td><td>-2.85</td><td>Nucleus</td><td>histone</td></tr><tr><td>P02545</td><td>LMNA</td><td>lamin A/C</td><td>-1.85</td><td>Nucleus</td><td>structural protein</td></tr><tr><td>P62937</td><td>PPIA</td><td>peptidylprolyl isomerase A (cyclophilin A)</td><td>-1.64</td><td>Cytoplasm</td><td>isomerase</td></tr><tr><td>P18124</td><td>RPL7</td><td>ribosomal protein L7</td><td>-1.82</td><td>Cytoplasm</td><td>ribosomal protein</td></tr><tr><td>P62917</td><td>RPL8</td><td>ribosomal protein L8</td><td>-1.76</td><td>Cytoplasm</td><td>ribosomal protein</td></tr></table> |
21f7dfe0120290809152c396de7380c34f6c457b8aee7edbb18aa196fc2e5697.png | simple | <table><tr><td>Primer</td><td>Sequence (5′-3′)</td></tr><tr><td>FLAG-NS1-F</td><td>CAGAATTCTAATGGATTCCAACACTGTG (EcoRI)</td></tr><tr><td>FLAG-NS1-R</td><td>GGGGTACCCACTTCTGACTCAATTGTTC (KpnI)</td></tr><tr><td>HA-ANXA2-F</td><td>GGGGTACCCCGTCTACTGTTCACGAAATCCTG (KpnI)</td></tr><tr><td>HA-ANXA2-R</td><td>GAAGATCTTCGTCATCTCCACCACACAGGTA (BglII)</td></tr><tr><td>ANXA2-159F</td><td>TGGATGAGGTCACCATTGTCA</td></tr><tr><td>ANXA2-159R</td><td>TCAATAGGCCCAAAATCACC</td></tr><tr><td>GAPDH-F</td><td>GGCATCCTGGGCTACACTGA</td></tr><tr><td>GAPDH-R</td><td>TGTTGCTGTAGCCAAATTCGTT</td></tr></table> |
e3224b10dbf2498c5dfd969ae371eb0dddd973fd9857066ee2f537376ce12544.png | simple | <table><tr><td></td><td>Stabilizer</td><td>DLC (%)</td><td>EE (%)</td></tr><tr><td>Abm-NPs-1</td><td>PLGA-<i>b</i>-PEG</td><td>41.46 ± 0.05</td><td>96.74 ± 0.12</td></tr><tr><td>Abm-NPs-2</td><td>PLA-<i>b</i>-PEG</td><td>40.97 ± 0.05</td><td>95.60 ± 0.11</td></tr><tr><td>Abm-NPs-3</td><td>PCL-<i>b</i>-PEG</td><td>40.76 ± 0.03</td><td>95.10 ± 0.07</td></tr></table> |
21f3a98296591d05375830beed4488bb7591fbc5cbe1dc7080c40c229eb9ead5.png | simple | <table><tr><td></td><td>All childrena (<i>n</i> = 838)</td><td>Female (<i>n</i> = 405)</td><td>Male (<i>n</i> = 433)</td></tr><tr><td></td><td>Frequency (%)</td><td>Frequency (%)</td><td>Frequency (%)</td></tr><tr><td>No. of years of schooling (<i>y</i>)</td><td></td><td></td><td></td></tr><tr><td>0</td><td>14 (1.7)</td><td>6 (1.5)</td><td>8 (1.8)</td></tr><tr><td>1</td><td>40 (4.8)</td><td>20 (4.9)</td><td>20 (4.6)</td></tr><tr><td>2</td><td>89 (10.6)</td><td>41 (10.1)</td><td>48 (11.1)</td></tr><tr><td>3</td><td>201 (24.0)</td><td>106 (26.2)</td><td>95 (21.9)</td></tr><tr><td>4</td><td>241 (28.8)</td><td>118 (29.1)</td><td>123 (28.4)</td></tr><tr><td>5</td><td>187 (22.3)</td><td>76 (18.8)</td><td>111 (25.6)</td></tr><tr><td>6</td><td>62 (7.4)</td><td>35 (8.6)</td><td>27 (6.2)</td></tr><tr><td>7</td><td>4 (0.5)</td><td>3 (0.7)</td><td>1 (0.2)</td></tr><tr><td>Schooling years, categorized</td><td></td><td></td><td></td></tr><tr><td>≤2 <i>y</i></td><td>143 (17.1)</td><td>67 (16.5)</td><td>76 (17.6)</td></tr><tr><td>3+ <i>y</i></td><td>695 (82.9)</td><td>338 (83.5)</td><td>357 (82.4)</td></tr></table> |
7b7a5e0e90ba8224623a21cd5c71ba1b6c7e33e4193706012ef484e455e50f38.png | complex | <table><tr><td></td><td colspan="2">Model 1</td><td colspan="2">Model 2</td><td colspan="2">Model 3</td></tr><tr><td>Explanatory variables</td><td>OR (95% CI)</td><td>P</td><td>OR (95% CI)</td><td>P</td><td>OR (95% CI)</td><td>P</td></tr><tr><td>PTH</td><td>1.69 (1.12–2.56)</td><td>0.013</td><td>2.25 (1.34–3.78)</td><td>0.002</td><td>2.62 (1.52–4.53)</td><td>0.001</td></tr><tr><td>25(OH)D</td><td>0.86 (0.62–1.20)</td><td>0.383</td><td>0.96 (0.65–1.44)</td><td>0.860</td><td>1.06 (0.69–1.63)</td><td>0.783</td></tr><tr><td>Magnesium</td><td>0.02 (0.00–0.15)</td><td><0.001</td><td>0.04 (0.00–0.47)</td><td>0.010</td><td>0.22 (0.02–2.54)</td><td>0.224</td></tr></table> |
c9d3236612fe3d3a7b01927fba667526972eae7362edb0e1c6031785d70847cf.png | simple | <table><tr><td>Transposon</td><td>Primer 5'-3'</td><td><i>Tm </i>(°C)</td></tr><tr><td>IAP-RTF1</td><td>TCAAGGACAGGGTATTGTTG</td><td>For reverse transcription</td></tr><tr><td>IAP-RTR2</td><td>TATTGACGCCCTGGACATCAC</td><td>For reverse transcription</td></tr><tr><td>IAP-PCRF3</td><td>GGGTATTGTTGAGCGTGCGC</td><td>56</td></tr><tr><td>IAP-PCRR4</td><td>TCGGGTGAGTCTTTCTGGTAC</td><td>56</td></tr><tr><td>MuERV-RTF1</td><td>CAAAGTGGCCATGGTGGTCG</td><td>For reverse transcription</td></tr><tr><td>MuERV-RTR2</td><td>GTACCATATATCGAGCGCTG</td><td>For reverse transcription</td></tr><tr><td>MuERV-PCRF3</td><td>TGCTTGGGCTCAGCAACATGG</td><td>56</td></tr><tr><td>MuERV-PCRR4</td><td>GACAGAATGCCTCATCTATCGT</td><td>56</td></tr></table> |
69a0fe8c7c224169bb86241ac09dde0b4a4a7f4dcf05c44241e1c865daaa2b3d.png | complex | <table><tr><td>Variable</td><td>Deceased patients<i>n</i> = 91</td><td>Surviving patients<i>n</i> = 1660</td><td><i>P</i> value</td></tr><tr><td>Age [years (mean ± SD)]</td><td>54 ± 17</td><td>45 ± 15</td><td><0.0001</td></tr><tr><td>Male gender [<i>n</i> (%)]</td><td>46 (51)</td><td>766 (46)</td><td>0.42</td></tr><tr><td>SAPS II score, points (mean ± SD)</td><td>69 ± 21</td><td>36 ± 15</td><td><0.0001</td></tr><tr><td colspan="4">Mental disorder [<i>n</i> (%)]</td></tr><tr><td> Schizophrenia</td><td>3 (3)</td><td>94 (6)</td><td>0.48</td></tr><tr><td> Non-schizophrenia psychiatric disorder</td><td>16 (21)</td><td>218 (13)</td><td>0.04</td></tr><tr><td> Depression disorder</td><td>50 (55)</td><td>1008 (60)</td><td>0.27</td></tr><tr><td> Bipolar disorder</td><td>12 (13)</td><td>160 (10)</td><td>0.26</td></tr><tr><td> Anxiety disorder</td><td>7 (8)</td><td>180 (11)</td><td>0.48</td></tr><tr><td>Substance dependence (alcohol and/or drug addiction)</td><td>14 (15)</td><td>478 (29)</td><td>0.003</td></tr><tr><td>Transfer from psychiatric hospital or ward [<i>n</i> (%)]</td><td>14 (15)</td><td>116 (7)</td><td>0.003</td></tr><tr><td colspan="4">Psychoactive medication before admission [<i>n</i> (%)]</td></tr><tr><td> None</td><td>9 (10)</td><td>189 (11)</td><td>0.66</td></tr><tr><td> Benzodiazepines</td><td>58 (64)</td><td>1138 (68)</td><td>0.33</td></tr><tr><td> Neuroleptics</td><td>26 (28)</td><td>471 (28)</td><td>0.97</td></tr><tr><td> Antipsychotics other than neuroleptics</td><td>10 (11)</td><td>165 (10)</td><td>0.74</td></tr><tr><td> Lithium</td><td>3 (3)</td><td>78 (5)</td><td>0.53</td></tr><tr><td> SSRIs</td><td>18 (20)</td><td>402 (24)</td><td>0.33</td></tr><tr><td> SNRIs</td><td>1 (1)</td><td>33 (2)</td><td>0.55</td></tr><tr><td> Tri- or tetracyclics antidepressants</td><td>11 (12)</td><td>215 (13)</td><td>0.81</td></tr><tr><td> MAOIs</td><td>8 (9)</td><td>140 (8)</td><td>0.90</td></tr><tr><td colspan="4">Reason for admission [<i>n</i> (%)]</td></tr><tr><td colspan="4"> Deliberate self-poisoning with psychoactive medications</td></tr><tr><td>Alone</td><td>15 (16)</td><td>1067 (64)</td><td><0.0001</td></tr><tr><td>And/or with non-psychoactive medications</td><td>10 (11)</td><td>129 (8)</td><td>0.27</td></tr><tr><td>And/or with pesticides, household, or industrial products</td><td>0 (0)</td><td>28 (2)</td><td>0.40</td></tr><tr><td>And/or with hanging, drowning, jumping from buildings, or corrosive chemicals ingestion</td><td>13 (14)</td><td>18 (1)</td><td><0.0001</td></tr><tr><td> Respiratory failure</td><td>14 (15)</td><td>151 (9)</td><td>0.06</td></tr><tr><td> Shock</td><td>15 (16)</td><td>50 (3)</td><td><0.0001</td></tr><tr><td> CNS or peripheral disorder</td><td>6 (7)</td><td>76 (6)</td><td>0.31</td></tr><tr><td> Metabolic disorder</td><td>1 (1)</td><td>52 (3)</td><td>0.52</td></tr><tr><td> Out-of-hospital cardiac arrest</td><td>14 (15)</td><td>4 (0.2)</td><td><0.0001</td></tr><tr><td> Acute kidney injury</td><td>0 (0)</td><td>13 (0.5)</td><td>0.99</td></tr><tr><td> Non-deliberate psychoactive medication overdose</td><td>2 (2)</td><td>42 (2.5)</td><td>0.99</td></tr><tr><td> Miscellaneous</td><td>3 (3)</td><td>30 (2)</td><td>0.24</td></tr><tr><td>Chemical pneumonitis and/or aspiration pneumonia [<i>n</i> (%)]</td><td>28 (31)</td><td>451 (27)</td><td>0.45</td></tr><tr><td colspan="4">Organ support in the ICU [<i>n</i> (%)]</td></tr><tr><td> Invasive mechanical ventilation</td><td>91 (100)</td><td>1115 (67)</td><td><0.0001</td></tr><tr><td> Vasopressors</td><td>84 (92)</td><td>294 (18)</td><td><0.0001</td></tr><tr><td> Renal replacement therapy</td><td>38 (42)</td><td>138 (8)</td><td><0.0001</td></tr><tr><td>Acquired infection at any site</td><td>14 (15)</td><td>50 (3)</td><td><0.0001</td></tr></table> |
7b9ddbb490f5f84be3322066c979caf63c9a7589853cb779187866e4c4a3deff.png | simple | <table><tr><td></td><td>Overweight*</td><td>Body fat (%)<sup>+</sup></td><td>Lean body mass (kg)<sup>+</sup></td></tr><tr><td>Birth weight (z)</td><td>1.13 (1.03 to 1.25)</td><td>0.03 (−0.26 to 0.32)</td><td>1.66 (1.36 to 1.95)</td></tr><tr><td> <i>P </i>for trend</td><td>0.01</td><td>0.8</td><td><0.001</td></tr><tr><td>Ponderal index (z)</td><td>1.12 (1.01 to 1.23)</td><td>0.28 (−0.01 to 0.57)</td><td>0.40 (0.10 to 0.71)</td></tr><tr><td> <i>P </i>for trend</td><td>0.03</td><td>0.05</td><td>0.008</td></tr><tr><td>Placental weight (z)</td><td>1.07 (0.97 to 1.18)</td><td>0.02 (−0.28 to 0.31)</td><td>0.99 (0.69 to 1.29)</td></tr><tr><td> <i>P </i>for trend</td><td>0.2</td><td>0.9</td><td><0.001</td></tr><tr><td>Max placental diam (z)</td><td>1.04 (0.94 to 1.14)</td><td>0.00 (−0.30 to 0.29)</td><td>0.64 (0.34 to 0.95)</td></tr><tr><td> <i>p </i>for trend</td><td>0.5</td><td>1.0</td><td><0.001</td></tr><tr><td>Lesser placental diam (z)</td><td>1.07 (0.97 to 1.18)</td><td>0.09 (−0.20 to 0.39)</td><td>0.69 (0.39 to 1.00)</td></tr><tr><td> <i>P </i>for trend</td><td>0.2</td><td>0.5</td><td><0.001</td></tr><tr><td>Placental area (z)</td><td>1.05 (0.95 to 1.15)</td><td>0.05 (−0.24 to 0.34)</td><td>0.69 (0.39 to 0.99)</td></tr><tr><td> <i>P </i>for trend</td><td>0.4</td><td>0.7</td><td><0.001</td></tr></table> |
b53bb94e0e5ae7185e019cfb59cd94e82cb13a5e8345224da2c7637e5203c73f.png | simple | <table><tr><td>Comorbidities</td><td>ICD-9-CM codes</td></tr><tr><td>Schizophrenia</td><td>295.XX</td></tr><tr><td>Bipolar disorder</td><td>296.01, 296.02, 296.03, 296.04, 296.05, 296.06, 296.40, 296.41, 296.42, 296.43, 296.44, 296.45, 296.46, 296.50, 296.51, 296.52, 296.53, 296.54, 296.55, 296.56, 296.60, 296.61, 296.62, 296.63, 296.64, 296.65, 296.66, 296.7, 296.80, 296.89</td></tr><tr><td>Major depressive disorder</td><td>296.2X, 296.3X, 311.XX</td></tr><tr><td>Substance abuse</td><td>296.5x, 303.xx–305.xx</td></tr><tr><td>Hypertension</td><td>401–405</td></tr><tr><td>Hyperlipidemia</td><td>272.2–272.4</td></tr><tr><td>Diabetes</td><td>250.XX</td></tr><tr><td>Chronic obstructive pulmonary disease</td><td>490–496, 500–505, 506.4</td></tr></table> |
311e3494f9febf2458dd80eaa01cd93e4bc4571316adc37ca7e83afb152b3cae.png | simple | <table><tr><td>Paper</td><td>CMR parameters<sup>a</sup></td><td>Description of aneurysm</td></tr><tr><td>Contreras et al. [18]</td><td>Steady-state free precession</td><td>None provided</td></tr><tr><td>Corti et al. [12]</td><td>Turbo field-echo movie reconstruction</td><td>Dimensions: 7 × 5 × 3.5 cm2.8 cm ostiumRight ventricular compressionSysto-diastolic filling of the mass consistent with right atrial filling</td></tr><tr><td>Duran et al. [21]</td><td>Not specified</td><td>Dimensions: 2.5 × 1.5 cm over the tricuspid valveNeck: 11 mmNo thrombus</td></tr><tr><td>Guaricci et al. [10]</td><td>Not specified</td><td>Above tricuspid valve, overlapping with the RV and outflow tract with pulmonary artery</td></tr><tr><td>Gulati et al. [15]</td><td>Cine imaging using balanced steady-state free precession sequence</td><td>Mild tricuspid regurgitationNoncontractile, smooth-walled, pyramidal RAA extending anterior to the body of the right atriumPartially separated from the main atrial chamber by a membraneRight atrial volume 118 mL/m<sup>2</sup>Mild distortion of the RV but no compression</td></tr><tr><td>Le Ven et al. [22]</td><td>Not specified</td><td>None provided</td></tr><tr><td>Sondhi et al. [17]</td><td>Not specified</td><td>Magnetic resonance imaging of the heart and vessels confirmed the connection of the aneurysm to the RAA and also showed slight compression of the descending thoracic aorta by aneurysm</td></tr><tr><td>Xu et al. [8]</td><td>None described</td><td>None provided</td></tr></table> |
ab3dcda09336ede7cfeeca4c0d9defa41b23cae09a43ff8db682f16b72586abe.png | simple | <table><tr><td>Chrom</td><td>Chrom length</td><td># genes</td><td>gene density</td><td># differentially expressed</td><td>% differentially expressed</td><td>up in ko</td><td>down in ko</td><td>fraction up in ko</td></tr><tr><td>1</td><td>197195432</td><td>1272</td><td>155028</td><td>412</td><td>32.4</td><td>134</td><td>278</td><td>0.33</td></tr><tr><td>2</td><td>181748087</td><td>1942</td><td>93588</td><td>555</td><td>28.6</td><td>187</td><td>368</td><td>0.34</td></tr><tr><td>3</td><td>159599783</td><td>1071</td><td>149019</td><td>306</td><td>28.6</td><td>98</td><td>208</td><td>0.32</td></tr><tr><td>4</td><td>155630120</td><td>1410</td><td>110376</td><td>402</td><td>28.5</td><td>151</td><td>251</td><td>0.38</td></tr><tr><td>5</td><td>152537259</td><td>1339</td><td>113919</td><td>424</td><td>31.7</td><td>140</td><td>284</td><td>0.33</td></tr><tr><td>6</td><td>149517037</td><td>1149</td><td>130128</td><td>363</td><td>31.6</td><td>120</td><td>243</td><td>0.33</td></tr><tr><td>7</td><td>152524553</td><td>2026</td><td>75284</td><td>426</td><td>21.0</td><td>207</td><td>219</td><td>0.49</td></tr><tr><td>8</td><td>131738871</td><td>1121</td><td>117519</td><td>318</td><td>28.4</td><td>102</td><td>216</td><td>0.32</td></tr><tr><td>9</td><td>124076172</td><td>1289</td><td>96258</td><td>372</td><td>28.9</td><td>129</td><td>243</td><td>0.35</td></tr><tr><td>10</td><td>129993255</td><td>1042</td><td>124754</td><td>319</td><td>30.6</td><td>117</td><td>202</td><td>0.37</td></tr><tr><td>11</td><td>121843856</td><td>1748</td><td>69704</td><td>490</td><td>28.0</td><td>182</td><td>308</td><td>0.37</td></tr><tr><td>12</td><td>121257530</td><td>733</td><td>165426</td><td>270</td><td>36.8</td><td>63</td><td>207</td><td>0.23</td></tr><tr><td>13</td><td>120284312</td><td>882</td><td>136377</td><td>253</td><td>28.7</td><td>85</td><td>168</td><td>0.34</td></tr><tr><td>14</td><td>125194864</td><td>879</td><td>142429</td><td>251</td><td>28.6</td><td>79</td><td>172</td><td>0.31</td></tr><tr><td>15</td><td>103494974</td><td>835</td><td>123946</td><td>289</td><td>34.6</td><td>115</td><td>174</td><td>0.40</td></tr><tr><td>16</td><td>98319150</td><td>706</td><td>139262</td><td>244</td><td>34.6</td><td>78</td><td>166</td><td>0.32</td></tr><tr><td>17</td><td>95272651</td><td>1096</td><td>86928</td><td>285</td><td>26.0</td><td>125</td><td>160</td><td>0.44</td></tr><tr><td>18</td><td>90772031</td><td>528</td><td>171917</td><td>173</td><td>32.8</td><td>37</td><td>136</td><td>0.21</td></tr><tr><td>19</td><td>61342430</td><td>758</td><td>80927</td><td>239</td><td>31.5</td><td>89</td><td>150</td><td>0.37</td></tr><tr><td>x</td><td>166650296</td><td>965</td><td>172695</td><td>160</td><td>16.6</td><td>144</td><td>16</td><td>0.90</td></tr><tr><td>y</td><td>15902555</td><td>12</td><td>1325213</td><td>0</td><td>0</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>Total A</td><td>Average A</td><td>Total A</td><td>Total A</td><td>Average A</td></tr><tr><td></td><td></td><td></td><td></td><td>6391</td><td>30.1</td><td>2238</td><td>4153</td><td>0.35</td></tr></table> |
f694f1059c6eae9ad9cca45d995ceb3550ca1ae697d87a1415c1a5c80636254c.png | complex | <table><tr><td></td><td></td><td colspan="4">ELISA Antigen Titer after Four iImmunizations *</td></tr><tr><td>Animal a</td><td>Immunogen</td><td>Bridging Sheet</td><td>gp120-SF162</td><td>gp140DV2-SF162</td><td>E2 Protein</td></tr><tr><td>Mouse1</td><td>E2-BS1</td><td>100,000</td><td><20</td><td>--</td><td>500,000</td></tr><tr><td>Mouse2</td><td>E2-BS1</td><td>100,000</td><td><20</td><td>--</td><td>1,000,000</td></tr><tr><td>Mouse3</td><td>E2-BS1</td><td>50,000</td><td><20</td><td>--</td><td>500,000</td></tr><tr><td>Mouse4</td><td>E2</td><td><20</td><td><20</td><td>--</td><td>1,000,000</td></tr><tr><td>Mouse5</td><td>E2</td><td><20</td><td><20</td><td>--</td><td>1,000,000</td></tr><tr><td>Mouse6</td><td>E2</td><td><20</td><td><20</td><td>--</td><td>500,000</td></tr><tr><td>Rabbit1 (#E2-BS60 male)</td><td>E2-BS1</td><td>500,000</td><td>400 b</td><td>--</td><td>1,000,000</td></tr><tr><td>Rabbit2 (#E2-BS60 female)</td><td>E2-BS1</td><td>2000</td><td>200 b</td><td>--</td><td>500,000</td></tr><tr><td>Rabbit3 (#E2-BS male)</td><td>E2-BS1</td><td>500,000</td><td>400 c</td><td>--</td><td>1,000,000</td></tr><tr><td>Rabbit4 (#E2-BS female)</td><td>E2-BS1</td><td>150,000</td><td>20,000 c</td><td>--</td><td>1,000,000</td></tr><tr><td>Rabbit5 (#5/76)</td><td>E2-BS1</td><td>100,000</td><td>5000 c</td><td>3000 c</td><td>500,000</td></tr><tr><td>Rabbit6 (#6/76)</td><td>E2-BS1</td><td>100</td><td><20</td><td><20</td><td>75,000</td></tr><tr><td>Rabbit7 (#1/76)</td><td>E2</td><td><20</td><td><20</td><td><20</td><td>500,000</td></tr><tr><td>Rabbit8 (#3/76)</td><td>E2</td><td><20</td><td><20</td><td><20</td><td>1,000,000</td></tr><tr><td>Rabbit9 (#E2-wt female)</td><td>E2</td><td><20</td><td><20</td><td>--</td><td>1,000,000</td></tr><tr><td>Rabbit10 (#E2-wt male)</td><td>E2</td><td><20</td><td><20</td><td>--</td><td>500,000</td></tr></table> |
8217970aff4821ff39338913f94839b88c3bdd3c6806d7d78da17c0ad1474be3.png | complex | <table><tr><td></td><td>2012</td><td>2013</td><td>2014</td><td>Overall</td></tr><tr><td colspan="5">Dog vaccination costs for Laoag City</td></tr><tr><td>Total cost of dog vaccination (PHP)</td><td>1,110,365</td><td>1,040,485</td><td>1,054,202</td><td>3,205,053</td></tr><tr><td>Total cost of dog vaccination (USD)</td><td>24,428</td><td>22,891</td><td>23,192</td><td>70,511</td></tr><tr><td>Number of dogs vaccinated</td><td>3,476</td><td>4,527</td><td>7,513</td><td>15,516</td></tr><tr><td>Cost/dog (USD)</td><td>7.03</td><td>5.06</td><td>3.09</td><td>4.54</td></tr><tr><td colspan="5">Dog vaccination costs for Dingras Municipality</td></tr><tr><td>Total cost of dog vaccination (PHP)</td><td>591,155</td><td>751,045</td><td>648,821</td><td>1,991,021</td></tr><tr><td>Total cost of dog vaccination (USD)</td><td>13,005</td><td>16,523</td><td>14,274</td><td>43,802</td></tr><tr><td>Number of dogs vaccinated</td><td>726</td><td>2,982</td><td>1,357</td><td>5,065</td></tr><tr><td>Cost/dog (USD)</td><td>17.91</td><td>5.54</td><td>10.52</td><td>8.65</td></tr><tr><td colspan="5">PEP costs for Laoag City</td></tr><tr><td>Total cost for PEP (PHP)</td><td>2,156,857</td><td>2,297,622</td><td>2,755,215</td><td>7,209,695</td></tr><tr><td>Total cost for PEP (USD)</td><td>47,451</td><td>50,548</td><td>60,615</td><td>158,613</td></tr><tr><td>Number of PEP doses provided</td><td>2,295</td><td>2,402</td><td>3,397</td><td>8093.13</td></tr><tr><td>Number of patients vaccinated</td><td>636</td><td>726</td><td>913</td><td>2,275</td></tr><tr><td>Average doses/patient</td><td>3.61</td><td>3.31</td><td>3.72</td><td>3.56</td></tr><tr><td>Cost per PEP dose (USD)</td><td>20.68</td><td>21.05</td><td>17.85</td><td>19.60</td></tr><tr><td>Cost per patient (USD)</td><td>74.61</td><td>69.62</td><td>66.39</td><td>69.72</td></tr><tr><td colspan="5">PEP provision cost for Dingras Municipality</td></tr><tr><td>Total cost for PEP (PHP)</td><td>183,976</td><td>404,390</td><td>755,128</td><td>1,343,494</td></tr><tr><td>Total cost for PEP (USD)</td><td>4,047</td><td>8,897</td><td>16,613</td><td>29,557</td></tr><tr><td>Number of PEP doses provided</td><td>202</td><td>507</td><td>1,207</td><td>1,917</td></tr><tr><td>Number of patients vaccinated</td><td>63</td><td>158</td><td>382</td><td>603</td></tr><tr><td>Average doses/patient</td><td>3.21</td><td>3.21</td><td>3.16</td><td>3.18</td></tr><tr><td>Cost per PEP dose (USD)</td><td>20.01</td><td>17.54</td><td>13.76</td><td>17.11</td></tr><tr><td>Cost per patient (USD)</td><td>64.25</td><td>56.31</td><td>43.49</td><td>49.02</td></tr></table> |
9b51fbaa5081474368daf33ec7167a16a3c5816e8090ba50e7953cf102fff8c0.png | simple | <table><tr><td>Localization sites</td><td>No.</td></tr><tr><td>cytoplasmic</td><td>248</td></tr><tr><td>inner membrane</td><td>268</td></tr><tr><td>periplasmic</td><td>244</td></tr><tr><td>outmembrane</td><td>352</td></tr><tr><td>extracellular</td><td>190</td></tr><tr><td>cytoplasmic / inner membrane</td><td>14</td></tr><tr><td>membrane / periplasmic</td><td>49</td></tr><tr><td>outer membrane / extracellular</td><td>76</td></tr><tr><td>All sites</td><td>1441</td></tr></table> |
a3411aad5e8ec2ef053c0730d2da36f53d2eb873b33105319abd4aa50504fd5b.png | simple | <table><tr><td>MIF overexpression</td><td>Comments</td><td>Ref</td></tr><tr><td>Childhood rhabdomyosarcoma</td><td>Human RMS cells express and secrete MIF</td><td>[137]</td></tr><tr><td>Melanoma</td><td>MIF levels increase in advanced stages</td><td>[18]</td></tr><tr><td>Uveal melanoma</td><td>MIF prevents NK cell-mediated lysis</td><td>[138]</td></tr><tr><td>Gastric cancer</td><td>Serum MIF levels increase in advanced stages</td><td>[44]</td></tr><tr><td>Pancreatic ductal adenocarcinoma</td><td>Higher MIF levels correlate with poor prognosis</td><td>[42]</td></tr><tr><td>Hepatocellular carcinoma</td><td>Serum MIF levels are higher in HCC patientsMIF levels are increaed in tumor compared to adjiacent non tumor tissueMIF levels correlate with TNM</td><td>[40]</td></tr><tr><td>Malignant glioma</td><td>MIF levels increase wuth tumor gradeMIF counteract NK cell-mediated lysis</td><td>[83]</td></tr><tr><td>Lung adenocarcinoma</td><td>MIF distribution predicts patient prognosis</td><td>[38]</td></tr><tr><td>Non-small cell lung cancer</td><td>Higher MIF levels are found in tumor tissue. Higher expression of MIF correlate with poor prognosis</td><td>[39]</td></tr><tr><td>Oral cavity squamous cell carcinoma</td><td>Higher MIF levels are assocated to worse prognosis</td><td>[41]</td></tr><tr><td>Head and neck squamous cell carcinoma</td><td>Tumor tissue MIF expression and plasma levels correlated with tumor recurrence and metastasis, and overall survival.</td><td>[35, 43]</td></tr><tr><td>Osteosarcoma</td><td>MIF levels are increased in the tissue and serum samples of patients and correlate with tumour size, pulmonary metastasis and survival rate</td><td>[139]</td></tr></table> |
31dc4e86c5e7a4358a29dcacf273fc58f995f37036f854933288f173d68d13c7.png | complex | <table><tr><td rowspan="2"></td><td rowspan="2">DN</td><td rowspan="2">GN</td><td rowspan="2">GO</td><td rowspan="2">Control</td><td>ANOVA</td></tr><tr><td><i>P</i> value</td></tr><tr><td>AST (IU/L)</td><td>353.7 ± 165.45</td><td>403.4 ± 169.31</td><td>363.4 ± 174.53</td><td>273.0 ± 193.34</td><td>0.861</td></tr><tr><td>ALT (IU/L)</td><td>89.0 ± 37.46</td><td>102.2 ± 43.10</td><td>113.5 ± 72.89</td><td>123.3 ± 70.19</td><td>0.763</td></tr><tr><td>ALP (IU/L)</td><td>183.1<sup>a</sup> ± 42.44</td><td>285.1<sup>b</sup> ± 61.57</td><td>182.8<sup>a</sup> ± 25.74</td><td>175.5<sup>a</sup> ± 25.08</td><td>0.000</td></tr><tr><td>Glucose (mg/dL)</td><td>145.7 <sup>b</sup> ± 32.89</td><td>138.1<sup>b</sup> ± 19.78</td><td>144.4<sup>b</sup> ± 24.59</td><td>218.8<sup>a</sup> ± 56.77</td><td>0.003</td></tr><tr><td>Creatinine (mg/dL)</td><td>0.36<sup>a</sup> ± 0.205</td><td>0.29<sup>b</sup> ± 0.147</td><td>0.49<sup>a</sup> ± 0.098</td><td>0.54<sup>a</sup> ± 0.100</td><td>0.023</td></tr><tr><td>BUN (mg/dL)</td><td>49.4 ± 4.37</td><td>55.3 ± 10.16</td><td>50.9 ± 5.16</td><td>53.2 ± 11.29</td><td>0.634</td></tr><tr><td>TP (g/L)</td><td>57.2 ± 3.06</td><td>55.3 ± 3.33</td><td>55.3 ± 5.57</td><td>59.0 ± 5.22</td><td>0.440</td></tr><tr><td>Albumin (g/L)</td><td>48.5 ± 4.04</td><td>48.2 ± 3.60</td><td>49.8 ± 5.27</td><td>49.8 ± 5.19</td><td>0.882</td></tr><tr><td>LDH (U/L)</td><td>1496 ± 420.7</td><td>1468 ± 313.3</td><td>1516 ± 297.3</td><td>1209 ± 463.5</td><td>0.481</td></tr><tr><td>TG (mg/dL)</td><td>135.4 ± 34.97</td><td>99.6 ± 30.18</td><td>117.1 ± 24.63</td><td>103.4 ± 26.48</td><td>0.175</td></tr></table> |
02b13d7a86b8cccdd02f5873cc922e9de9c34f2e95f60111573287a4395952cc.png | complex | <table><tr><td rowspan="2">Characteristics</td><td>Total</td><td rowspan="2">n<sup>d</sup> (%)</td><td></td><td colspan="2">Physical activity</td><td></td></tr><tr><td>N</td><td>COR(95%CI)</td><td><i>P</i> Value</td><td>AOR(95%CI)</td><td><i>P</i> value</td></tr><tr><td>Total</td><td>3600</td><td>3411 (94.7)</td><td></td><td></td><td></td><td></td></tr><tr><td colspan="7">Age groups</td></tr><tr><td> 18–29</td><td>1346</td><td>1268 (94.2)</td><td>1.0</td><td></td><td></td><td></td></tr><tr><td> 30–39</td><td>1065</td><td>1015 (95.3)</td><td>1.24 (0.86–1.79)</td><td>0.232</td><td></td><td></td></tr><tr><td> 40–49</td><td>641</td><td>608 (94.9)</td><td>1.13 (0.74–1.72)</td><td>0.558</td><td></td><td></td></tr><tr><td> 50–59</td><td>414</td><td>394 (95.2)</td><td>1.21 (0.73–2.00)</td><td>0.455</td><td></td><td></td></tr><tr><td> 60+</td><td>134</td><td>126 (94.0)</td><td>0.96 (0.45–2.05)</td><td>0.934</td><td></td><td></td></tr><tr><td colspan="7">Education level</td></tr><tr><td> No education</td><td>1287</td><td>1245 (96.7)</td><td>1.0</td><td></td><td></td><td></td></tr><tr><td> Primary</td><td>2073</td><td>1950 (94.1)</td><td>0.53 (0.37–0.76)</td><td>0.001</td><td></td><td></td></tr><tr><td> Secondary</td><td>240</td><td>216 (90.0)</td><td>0.30 (0.18–0.51)</td><td><0.001</td><td></td><td></td></tr><tr><td colspan="7">Occupation</td></tr><tr><td> Professionals</td><td>82</td><td>76 (92.7)</td><td>1.0</td><td></td><td>1.0</td><td></td></tr><tr><td> Farming</td><td>2643</td><td>2588 (97.9)</td><td>3.71 (1.55–8.89)</td><td>0.003</td><td>2.83 (1.17–6.86)***</td><td>0.021</td></tr><tr><td> Business</td><td>652</td><td>536 (82.2)</td><td>0.36 (0.15–0.85)</td><td>0.021</td><td>0.39 (0.16–0.92)***</td><td>0.032</td></tr><tr><td> Skilled work</td><td>73</td><td>68 (93.2)</td><td>1.07 (0.31–3.67)</td><td>0.910</td><td>1.04 (0.30–3.60)</td><td>0.942</td></tr><tr><td> Unskilled work</td><td>119</td><td>113 (95.0)</td><td>1.48 (0.46–4.78)</td><td>0.506</td><td>1.38 (0.42–4.47)</td><td>0.586</td></tr><tr><td colspan="7">Residence</td></tr><tr><td> Urban</td><td>1358</td><td>1223 (90.1)</td><td>1.0</td><td></td><td>1.0</td><td></td></tr><tr><td> Rural</td><td>2240</td><td>2186 (97.6)</td><td>4.46 (3.23–6.17)</td><td></td><td>2.27 (1.59–3.24)***</td><td>< 0.001</td></tr><tr><td colspan="7">Marital status</td></tr><tr><td> Single/never married</td><td>273</td><td>258 (94.5)</td><td>1.0</td><td></td><td></td><td></td></tr><tr><td> Married</td><td>3327</td><td>3153 (94.8)</td><td>1.05 (0.61–1.81)</td><td></td><td></td><td></td></tr></table> |
a1d1926e2e561d3127dc3319fdf47f12491d07b5952ee2d689712496c2c4838f.png | complex | <table><tr><td rowspan="2">Characteristic</td><td rowspan="2">Newly diagnosed (age > 14 years old)</td><td colspan="2">Initial CD4 cell count within one month</td><td colspan="2">Initial CD4 cell count within one year</td><td colspan="2">Initial CD4 cell counts < 200 cell/ul within one year</td></tr><tr><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td colspan="8">Year of HIV diagnosis</td></tr><tr><td> 2006</td><td>26,027</td><td>4950</td><td>19.0</td><td>9129</td><td>35.1</td><td>3901</td><td>42.7</td></tr><tr><td> 2007</td><td>32,538</td><td>8856</td><td>27.2</td><td>15,621</td><td>48.0</td><td>6282</td><td>40.2</td></tr><tr><td> 2008</td><td>40,690</td><td>14,475</td><td>35.6</td><td>23,979</td><td>58.9</td><td>8491</td><td>35.4</td></tr><tr><td> 2009</td><td>48,163</td><td>20,327</td><td>42.2</td><td>32,083</td><td>66.6</td><td>11,321</td><td>35.3</td></tr><tr><td> 2010</td><td>53,375</td><td>25,110</td><td>47.0</td><td>40,073</td><td>75.1</td><td>13,511</td><td>33.7</td></tr><tr><td> 2011</td><td>67,256</td><td>35,950</td><td>53.5</td><td>54,378</td><td>80.9</td><td>18,002</td><td>33.1</td></tr><tr><td> 2012</td><td>76,716</td><td>45,550</td><td>59.4</td><td>66,064</td><td>86.1</td><td>20,444</td><td>30.9</td></tr><tr><td> 2013</td><td>85,518</td><td>54,931</td><td>64.2</td><td>76,191</td><td>89.1</td><td>23,474</td><td>30.8</td></tr><tr><td> 2014</td><td>97,951</td><td>64,403</td><td>65.8</td><td>86,482</td><td>88.3</td><td>25,669</td><td>29.7</td></tr><tr><td colspan="8">Route of HIV infection</td></tr><tr><td> Heterosexual</td><td>333,753</td><td>183,602</td><td>55.0</td><td>264,332</td><td>79.2</td><td>96,527</td><td>36.5</td></tr><tr><td> Homosexual</td><td>85,252</td><td>57,299</td><td>67.2</td><td>78,895</td><td>92.5</td><td>15,515</td><td>19.7</td></tr><tr><td> Injection drug use</td><td>73,834</td><td>21,958</td><td>29.7</td><td>40,713</td><td>55.1</td><td>9168</td><td>22.5</td></tr><tr><td> Sexual contact and injection drug use</td><td>5257</td><td>1760</td><td>33.5</td><td>3257</td><td>62.0</td><td>777</td><td>23.9</td></tr><tr><td> Blood or plasma transfusion</td><td>16,767</td><td>7006</td><td>41.8</td><td>11,833</td><td>70.6</td><td>7142</td><td>60.4</td></tr><tr><td colspan="8">Sites of diagnosis</td></tr><tr><td> VCT centers</td><td>150,157</td><td>91,425</td><td>60.9</td><td>124,603</td><td>83.0</td><td>39,141</td><td>31.4</td></tr><tr><td> Hospitals</td><td>236,047</td><td>118,702</td><td>50.3</td><td>176,834</td><td>74.9</td><td>73,114</td><td>41.3</td></tr><tr><td> Detention centers</td><td>43,231</td><td>12,397</td><td>28.7</td><td>23,395</td><td>54.1</td><td>3196</td><td>13.7</td></tr><tr><td> others</td><td>98,799</td><td>52,028</td><td>52.7</td><td>79,168</td><td>80.1</td><td>15,644</td><td>19.8</td></tr><tr><td> Total</td><td>528,234</td><td>274,552</td><td>52.0</td><td>404,000</td><td>76.5</td><td>131,095</td><td>32.4</td></tr></table> |
3673d7be470c3d03cdd9d12eb80106145f80fd0cbb0f0725cbf0d2be349f1d6c.png | complex | <table><tr><td rowspan="2">Mycotoxin</td><td rowspan="2">Correlation Coefficient (r)</td><td colspan="2">Repeatability (RSD<sub>r</sub>, %) <sup>a</sup></td><td colspan="2">Reproducibility (RSD<sub>R</sub>, %) <sup>a</sup></td><td rowspan="2">LOD (ng/g)</td><td rowspan="2">LOQ (ng/g)</td><td rowspan="2">SSE (%)</td></tr><tr><td>25 ng/g <sup>b</sup></td><td>50 ng/g <sup>b</sup></td><td>25 ng/g <sup>b</sup></td><td>50 ng/g <sup>b</sup></td></tr><tr><td>AOH</td><td>0.998</td><td>81 (6)</td><td>82 (4)</td><td>84 (8)</td><td>89 (6)</td><td>1.40</td><td>3.50</td><td>65</td></tr><tr><td>AME</td><td>0.996</td><td>86 (4)</td><td>89 (7)</td><td>90 (7)</td><td>93 (10)</td><td>1.40</td><td>3.50</td><td>80</td></tr><tr><td>TEN</td><td>0.995</td><td>91 (9)</td><td>94 (6)</td><td>94 (15)</td><td>90 (12)</td><td>0.70</td><td>1.75</td><td>78</td></tr></table> |
066532c0ff0db1e6199505a0a094492e2ea83cd6a1e1d41ea647a2534c00914e.png | complex | <table><tr><td rowspan="2">Number of requests</td><td colspan="2">One Tomcat server</td><td colspan="2">Two Tomcat servers</td></tr><tr><td>Mean time (seconds)</td><td>Total time (seconds)</td><td>Mean time (seconds)</td><td>Total time (seconds)</td></tr><tr><td>1</td><td>1.661</td><td>1.661</td><td>1.994</td><td>1.994</td></tr><tr><td>10</td><td>1.300</td><td>13</td><td>1.200</td><td>12</td></tr><tr><td>20</td><td>1.500</td><td>30</td><td>1.100</td><td>22</td></tr><tr><td>30</td><td>1.400</td><td>42</td><td>1.133</td><td>34</td></tr><tr><td>40</td><td>1.400</td><td>56</td><td>1.250</td><td>50</td></tr><tr><td>50</td><td>1.380</td><td>69</td><td>1.140</td><td>57</td></tr><tr><td>60</td><td>1.367</td><td>82</td><td>1.150</td><td>69</td></tr><tr><td>70</td><td>1.371</td><td>96</td><td>1.157</td><td>81</td></tr><tr><td>80</td><td>1.400</td><td>112</td><td>1.275</td><td>102</td></tr><tr><td>90</td><td>1.489</td><td>134</td><td>1.267</td><td>114</td></tr><tr><td>100</td><td>1.600</td><td>160</td><td>1.170</td><td>117</td></tr></table> |
4976468e6f5dcfa882fb3789474753aa16291cd8f360ee61981ca4a406f1aa2d.png | simple | <table><tr><td>Burnout Subscale</td><td>Low</td><td>Moderate</td><td>High</td></tr><tr><td>Emotional exhaustion</td><td>37 (34%)</td><td>39 (35%)</td><td>34 (31%)</td></tr><tr><td>Depersonalization</td><td>93 (77%)</td><td>22 (18%)</td><td>6 (5%)</td></tr><tr><td>Personal accomplishment</td><td>42 (45%)</td><td>26 (28%)</td><td>25 (27%)</td></tr></table> |
0c0057242a4f680f2e650161c7156d2e8260c80bc63bcb7175cb45bceeeebceb.png | complex | <table><tr><td rowspan="2">Gene</td><td rowspan="2">Genotype</td><td>Time to progression</td><td rowspan="2">HR (95% CI)</td><td rowspan="2"><i>p</i></td><td>Overall survival</td><td rowspan="2">HR (95% CI)</td><td rowspan="2"><i>p</i></td></tr><tr><td>Median (25%–75%)</td><td>Median (25%–75%)</td></tr><tr><td><i>MMP2</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="4">rs243865</td><td>CC</td><td>8.83 (6.43–15.03)</td><td>Ref.</td><td></td><td>17.43 (10.60–27.27)</td><td>Ref.</td><td></td></tr><tr><td>CT</td><td>10.17 (6.00–16.33)</td><td>0.88 (0.63–1.22)</td><td>0.437</td><td>17.47 (9.47–31.17)</td><td>0.96 (0.68–1.36)</td><td>0.826</td></tr><tr><td>TT</td><td>14.97 (8.20–44.57)</td><td>0.54 (0.17–1.75)</td><td>0.305</td><td>30.00 (22.03–30.00)</td><td>0.44 (0.11–1.81)</td><td>0.255</td></tr><tr><td>CT + TT</td><td>10.20 (6.27–16.33)</td><td>0.85 (0.61–1.18)</td><td>0.334</td><td>18.07 (9.63–31.17)</td><td>0.92 (0.66–1.30)</td><td>0.653</td></tr><tr><td rowspan="4">rs243849</td><td>CC</td><td>9.87 (6.13–16.67)</td><td>Ref.</td><td></td><td>19.10 (9.83–28.13)</td><td>Ref.</td><td></td></tr><tr><td>CT</td><td>8.67 (6.67–14.30)</td><td>1.30 (0.91–1.86)</td><td>0.144</td><td>16.23 (10.80–29.03)</td><td>1.26 (0.86–1.85)</td><td>0.227</td></tr><tr><td>TT</td><td>7.33 (3.27–11.80)</td><td>2.16 (1.02–4.55)</td><td>0.043</td><td>17.63 (7.33–36.73)</td><td>1.18 (0.51–2.72)</td><td>0.698</td></tr><tr><td>CT + TT</td><td>8.67 (6.60–14.30)</td><td>1.38 (0.98–1.94)</td><td>0.064</td><td>16.63 (10.80–30.27)</td><td>1.25 (0.87–1.80)</td><td>0.225</td></tr><tr><td rowspan="4">rs7201</td><td>AA</td><td>9.27 (6.37–16.93)</td><td>Ref.</td><td></td><td>16.23 (10.63–28.03)</td><td>Ref.</td><td></td></tr><tr><td>AC</td><td>10.00 (6.73–15.03)</td><td>0.87 (0.61–1.24)</td><td>0.441</td><td>19.30 (10.80–30.00)</td><td>0.89 (0.62–1.29)</td><td>0.547</td></tr><tr><td>CC</td><td>8.00 (5.50–12.63)</td><td>1.15 (0.73–1.80)</td><td>0.551</td><td>14.20 (9.23–26.17)</td><td>1.20 (0.74–1.95)</td><td>0.467</td></tr><tr><td>AC + CC</td><td>9.80 (6.43–14.57)</td><td>0.93 (0.67–1.30)</td><td>0.684</td><td>18.07 (9.63–29.03)</td><td>0.96 (0.67–1.36)</td><td>0.803</td></tr><tr><td><i>MMP9</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="4">rs17576</td><td>AA</td><td>9.27 (6.13–13.53)</td><td>Ref.</td><td></td><td>13.57 (9.83–23.90)</td><td>Ref.</td><td></td></tr><tr><td>AG</td><td>10.73 (6.80–18.47)</td><td>0.84 (0.60–1.17)</td><td>0.303</td><td>21.20 (12.17–32.53)</td><td>0.72 (0.50–1.03)</td><td>0.070</td></tr><tr><td>GG</td><td>8.50 (6.00–16.67)</td><td>1.17 (0.69–1.98)</td><td>0.558</td><td>16.63 (8.27–26.60)</td><td>0.96 (0.54–1.68)</td><td>0.881</td></tr><tr><td>AG + GG</td><td>10.00 (6.67–16.90)</td><td>0.89 (0.65–1.23)</td><td>0.478</td><td>19.30 (11.33–31.17)</td><td>0.76 (0.54–1.06)</td><td>0.106</td></tr><tr><td rowspan="2">rs2250889</td><td>CC</td><td>10.03 (6.73–16.67)</td><td>Ref.</td><td></td><td>19.10 (11.33–30.00)</td><td>Ref.</td><td></td></tr><tr><td>CG</td><td>6.07 (4.07–7.90)</td><td>2.32 (1.34–4.03)</td><td>0.003</td><td>9.23 (4.53–14.20)</td><td>2.52 (1.42–4.46)</td><td>0.002</td></tr><tr><td rowspan="4">rs17577</td><td>GG</td><td>10.00 (6.60–16.33)</td><td>Ref.</td><td></td><td>18.07 (10.60–28.30)</td><td>Ref.</td><td></td></tr><tr><td>GA</td><td>8.33 (5.50–14.57)</td><td>1.20 (0.84–1.72)</td><td>0.319</td><td>17.63 (9.47–32.87)</td><td>0.82 (0.56–1.20)</td><td>0.311</td></tr><tr><td>AA</td><td>8.83 (8.00–19.43)</td><td>1.02 (0.32–3.25)</td><td>0.977</td><td>13.50 (9.97–25.93)</td><td>1.58 (0.49–5.04)</td><td>0.444</td></tr><tr><td>GA + AA</td><td>8.50 (5.53–14.57)</td><td>1.19 (0.84–1.68)</td><td>0.339</td><td>17.63 (9.63–32.53)</td><td>0.85 (0.59–1.24)</td><td>0.403</td></tr><tr><td rowspan="4">rs20544</td><td>CC</td><td>7.53 (5.53–11.53)</td><td>Ref.</td><td></td><td>13.50 (8.13–21.20)</td><td>Ref.</td><td></td></tr><tr><td>CT</td><td>10.93 (7.37–19.97)</td><td>0.60 (0.40–0.90)</td><td>0.014</td><td>20.67 (11.33–32.53)</td><td>0.59 (0.39–0.91)</td><td>0.018</td></tr><tr><td>TT</td><td>9.40 (6.27–14.30)</td><td>0.67 (0.43–1.03)</td><td>0.069</td><td>15.40 (10.80–25.67)</td><td>0.70 (0.44–1.11)</td><td>0.132</td></tr><tr><td>CT + TT</td><td>10.13 (6.73–16.20)</td><td>0.62 (0.43–0.92)</td><td>0.016</td><td>19.30 (10.80–31.17)</td><td>0.63 (0.42–0.95)</td><td>0.025</td></tr><tr><td><i>MMP14</i></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="4">rs1042703</td><td>TT</td><td>9.27 (6.67–16.33)</td><td>Ref.</td><td></td><td>17.50 (9.97–29.13)</td><td>Ref.</td><td></td></tr><tr><td>TC</td><td>10.17 (6.27–14.53)</td><td>1.36 (0.94–1.96)</td><td>0.100</td><td>19.30 (9.47–29.03)</td><td>1.25 (0.87–1.81)</td><td>0.229</td></tr><tr><td>CC</td><td>8.70 (5.13–16.20)</td><td>2.09 (1.06–4.12)</td><td>0.032</td><td>12.70 (7.07–20.60)</td><td>2.14 (1.12–4.06)</td><td>0.020</td></tr><tr><td>TC + CC</td><td>10.17 (6.03–14.97)</td><td>1.44 (1.01–2.03)</td><td>0.042</td><td>17.63 (8.30–28.30)</td><td>1.36 (0.97–1.92)</td><td>0.076</td></tr><tr><td rowspan="4">rs1042704</td><td>GG</td><td>9.80 (6.73–14.90)</td><td>Ref.</td><td></td><td>17.50 (10.80–31.17)</td><td>Ref.</td><td></td></tr><tr><td>GA</td><td>8.30 (5.70–16.20)</td><td>1.05 (0.74–1.49)</td><td>0.780</td><td>17.47 (9.10–24.23)</td><td>1.40 (0.98–2.00)</td><td>0.068</td></tr><tr><td>AA</td><td>7.87 (6.00–16.90)</td><td>0.90 (0.45–1.82)</td><td>0.777</td><td>20.27 (13.57–25.93)</td><td>1.22 (0.59–2.53)</td><td>0.598</td></tr><tr><td>GA + AA</td><td>8.30 (5.93–16.90)</td><td>1.03 (0.74–1.42)</td><td>0.881</td><td>18.07 (9.63–24.57)</td><td>1.37 (0.97–1.92)</td><td>0.072</td></tr><tr><td rowspan="4">rs743257</td><td>CC</td><td>9.87 (7.07–14.07)</td><td>Ref.</td><td></td><td>13.50 (9.97–27.27)</td><td>Ref.</td><td></td></tr><tr><td>CT</td><td>9.40 (5.97–19.43)</td><td>1.08 (0.72–1.64)</td><td>0.700</td><td>15.40 (6.80–28.13)</td><td>0.98 (0.65–1.49)</td><td>0.931</td></tr><tr><td>TT</td><td>9.70 (6.60–14.53)</td><td>1.15 (0.75–1.76)</td><td>0.535</td><td>20.17 (12.53–31.17)</td><td>0.87 (0.56–1.36)</td><td>0.544</td></tr><tr><td>CT + TT</td><td>9.43 (6.07–16.33)</td><td>1.11 (0.76–1.63)</td><td>0.588</td><td>19.30 (9.83–30.27)</td><td>0.93 (0.63–1.37)</td><td>0.722</td></tr></table> |
1f215c98adae14e1f867feca9b523cabddf001c8d90700ca5817179cdac0c4aa.png | simple | <table><tr><td>Gene associated with presence in East Asia clade and absence in USA clade</td><td>Antibiotic(s) to which resistance conferred</td></tr><tr><td><i>catA</i></td><td>Chloramphenicol</td></tr><tr><td><i>ermB</i></td><td>Macrolides, lincosamides, streptogramins B</td></tr><tr><td><i>mecA</i></td><td>Beta-lactams</td></tr><tr><td><i>tetK</i></td><td>Tetracyclines</td></tr><tr><td><i>ant(6)-Ia</i></td><td>Aminoglycosides</td></tr><tr><td><i>aph(3)-III</i></td><td>Aminoglycosides</td></tr></table> |
9d713993fc43663930489426094863a64057b264d5d407efe9ac665945437f1b.png | simple | <table><tr><td>Transcript(Primer Name)</td><td>Forward Primer</td><td>Reverse Primer</td><td>Product Size</td></tr><tr><td>H. E4BP4(HUMANE4BP4-742 & 991)</td><td>5'ATGGGGAATTCTTTCTCTGG3'</td><td>5'CTTTGATCCGGAGCTTGTGT3'</td><td>250 bp</td></tr><tr><td>M. E4BP4(Mouse E4BP4-742 &1117)</td><td>5'ATGGGAAGCTCTTTCTCCACT3'</td><td>5'TACCCGAGGTTCCATGTTTC3'</td><td>376 bp</td></tr><tr><td>Bim(BIM 5/6 SENSE & ANTI)</td><td>5'CAGATATGCGCCCAGAGATA3'</td><td>5'ACCAGGCGGACAATGTAAC3'</td><td>163 bp</td></tr><tr><td>Puma(PUMA SENSE & ANTI)</td><td>5'AAGAGCAAATGAGCCAAACG3'</td><td>5'GCAGAGCACAGGATTCACAG3'</td><td>181 bp</td></tr><tr><td>β-actin(B-ACTIN-130 SENSE & ANTI)</td><td>5'AGTCCTCTCCCAAGTCCACA3'</td><td>5'CACGAAGGCTCATCATTCAA3'</td><td>130 bp</td></tr></table> |
401e1231d508617d7b11a0ed6c974450b3d632e909cd0cc1ab956d52754e4a66.png | simple | <table><tr><td>Variable</td><td>18–49 years(<i>n</i> = 263)</td><td>50–64 years(<i>n</i> = 142)</td><td>65+ years(<i>n</i> = 77)</td><td>Chi-Square<i>P</i>-value</td></tr><tr><td>Exhaustion (% yes)</td><td>139 (52.9%)</td><td>34 (24.0%)</td><td>8 (11.0%)</td><td><0.001</td></tr><tr><td>Physical activity (% inactive)<sup>a</sup></td><td>-</td><td>-</td><td>-</td><td><0.001</td></tr><tr><td>Mobility function (gait speed proxy, % mobility impairment)</td><td>13 (4.9%)</td><td>13 (9.3%)</td><td>7 (9.7%)</td><td><0.001</td></tr><tr><td>Unintentional weight loss (% yes)</td><td>127 (48.1%)</td><td>29 (20.1%)</td><td>5 (7.1%)</td><td><0.001</td></tr><tr><td>Weak grip strength (% yes)</td><td>33 (12.6%)</td><td>17 (12.2%)</td><td>9 (11.9%)</td><td><0.001</td></tr></table> |
c00428d674d41ed1b772191c40285c512193917bd495dc97e7569eb5e744aa84.png | simple | <table><tr><td>Clinical manifestations</td><td>Kidney and ureter stones</td><td>Simple kidney stones</td><td>Unilateral ureteral calculi</td><td>Simple bilateral ureteral calculi</td><td>Bladder calculi</td><td>Urinary tract stones</td><td>Total</td></tr><tr><td>Anuria</td><td>13</td><td>1</td><td>1</td><td>5</td><td>1</td><td>0</td><td>21</td></tr><tr><td>Oliguria</td><td>1</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td><td>2</td></tr><tr><td>Dysuria</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>2</td><td>2</td></tr><tr><td>Others</td><td>1</td><td>0</td><td>1</td><td>0</td><td>1</td><td>0</td><td>3</td></tr><tr><td>Total</td><td>15</td><td>1</td><td>2</td><td>5</td><td>3</td><td>2</td><td>28</td></tr></table> |
3775313ca5ac61261170f61b27290980b7aafef5978f7115a1befadf1d1ec240.png | simple | <table><tr><td>Questions:</td><td>T0 Mean ± SD</td><td>T1 Mean ± SD</td></tr><tr><td>Training/learning to use the device is not complicated</td><td>4.67 ± 0.58</td><td>4.33 ± 0.58</td></tr><tr><td>Wearing/adjusting the device is relatively simple</td><td>4.33 ± 0.58</td><td>4.33 ± 1.15</td></tr><tr><td>It was comfortable to exercise with the device</td><td>4.67 ± 0.58</td><td>4.33 ± 0.58</td></tr><tr><td>The usage of the device did not cause considerable pain</td><td>5.00 ± 0.00</td><td>4.67 ± 0.58</td></tr><tr><td>I did not feel excessive fatigue while excessive with the device</td><td>4.00 ± 1.00</td><td>4.00 ± 1.00</td></tr><tr><td>After completing the training period I felt comfortable using the device</td><td>4.67 ± 0.58</td><td>4.67 ± 0.58</td></tr><tr><td>Training with the device diminishes the spasticity in my legs</td><td>5.00 ± 0.00</td><td>5.00 ± 0.00</td></tr><tr><td>I did not have breathing difficulties while training with the device</td><td>5.00 ± 0.00</td><td>5.00 ± 0.00</td></tr><tr><td>I felt improvement in my bowel movement during the training program</td><td>3.33 ± 1.53</td><td>4.00 ± 1.00</td></tr><tr><td>After completing the training I felt safe using the device</td><td>3.00 ± 2.00</td><td>4.67 ± 0.58</td></tr></table> |
fa6bcdd7bf3356915631ba4587c9aac44f7d3ed2da8b38888a90f3e58ae4ea8b.png | simple | <table><tr><td> </td><td>MQ2 Aspect ratio</td><td>HD magnet Aspect ratio</td><td>Difference</td></tr><tr><td>Top & Bottom</td><td>0.204</td><td>0.123</td><td>–40.7%</td></tr><tr><td>Middle</td><td>0.203</td><td>0.081</td><td>–60.9%</td></tr><tr><td>Left & Right</td><td>0.194</td><td>0.120</td><td>–38.1%</td></tr><tr><td>Corners</td><td>0.201</td><td>0.116</td><td>–42.2%</td></tr><tr><td>Average</td><td>0.200</td><td>0.110</td><td>–45.1%</td></tr></table> |
48469bab67567c8d0e258c4e06da97642c525afaeb7328753c7ebf5a67be7dd6.png | complex | <table><tr><td>Treatment</td><td colspan="2">Total episodes</td><td colspan="2">1st episode</td><td colspan="2">2nd and subsequent episodes</td></tr><tr><td></td><td></td><td></td><td>mild</td><td>severe</td><td>mild</td><td>severe</td></tr><tr><td>Total</td><td>781</td><td></td><td>575 (96%)</td><td>22 (4%)</td><td>177 (96%)</td><td>7 (4%)</td></tr><tr><td>No treatment</td><td>464</td><td>59%</td><td>327 (57%)</td><td>11 (44%)</td><td>123 (70%)</td><td>3 (43%)</td></tr><tr><td>Antimotility agents</td><td>231</td><td>30%</td><td>178 (31%)</td><td>7 (32%)</td><td>46 (26%)</td><td>0</td></tr><tr><td>ORS</td><td>116</td><td>15%</td><td>92 (16%)</td><td>6 (27%)</td><td>16 (9%)</td><td>2 (29%)</td></tr><tr><td>Antibiotic</td><td>36</td><td>5%</td><td>30 (5%)</td><td>1 (5%)</td><td>3 (2%)</td><td>2 (29%)</td></tr><tr><td>Alternative antidiarrhoeal drugs</td><td>22</td><td>3%</td><td>18 (3%)</td><td>1 (5%)</td><td>3 (2%)</td><td>0</td></tr><tr><td>Visited physician for diarrhoea</td><td>25</td><td>3%</td><td>18 (3%)</td><td>1 (5%)</td><td>5 (3%)</td><td>1 (14%)</td></tr></table> |
845931b25288705d00bbfd8bc0847dfe023b65341f1169108fd91fc92c32416f.png | complex | <table><tr><td></td><td>ICD Codes/Conditions</td><td>Frequency of Admissions</td><td>Percentage of Total Admissions</td></tr><tr><td colspan="4">Top Reasons for Primary Admission (<1 YEAR)</td></tr><tr><td> Lower respiratory tract infection</td><td></td><td>44</td><td>40.8</td></tr><tr><td></td><td>Lower respiratory tract infection (J22)</td><td>42</td><td></td></tr><tr><td></td><td>Bronchiolitis (J21.9)</td><td>2</td><td></td></tr><tr><td> Gastroenteritis</td><td></td><td>28</td><td>25.9</td></tr><tr><td></td><td>Infectious gastroenteritis (A09.9)</td><td>27</td><td></td></tr><tr><td></td><td>Vomiting (R11)</td><td>1</td><td></td></tr><tr><td> Upper respiratory tract infection</td><td></td><td>10</td><td>9.3</td></tr><tr><td></td><td>Otitis media (H66.3, H66.9)</td><td>5</td><td></td></tr><tr><td></td><td>Upper respiratory tract infection (J06.9)</td><td>4</td><td></td></tr><tr><td></td><td>Croup (J05.0)</td><td>1</td><td></td></tr><tr><td> Genitourinary</td><td>Urinary Tract Infection (N39.0)</td><td>5</td><td>4.6</td></tr><tr><td> Injury</td><td>Traumatic brain injury (S06.01), head injury (S09.9), fractured femur (S72.9), dog or snake bite (T14.1)</td><td>4</td><td>3.6</td></tr><tr><td>Subtotal admission reason</td><td></td><td>92</td><td>84.2</td></tr><tr><td> Other</td><td></td><td>16</td><td>15.8</td></tr><tr><td>Total Primary admission reason</td><td></td><td>108</td><td>100</td></tr><tr><td colspan="4">Top Comorbidities at Admission</td></tr><tr><td> Upper respiratory tract infection</td><td>H66.3, H66.9, J06.9</td><td>9</td><td>33.3</td></tr><tr><td> Failure to thrive</td><td>R62.8</td><td>5</td><td>18.5</td></tr><tr><td> Anaemia</td><td>D64.9</td><td>5</td><td>18.5</td></tr><tr><td>Subtotal comorbidities</td><td></td><td>19</td><td>70.3</td></tr><tr><td> Other</td><td></td><td>8</td><td>29.7</td></tr><tr><td>Total comorbidities</td><td></td><td>27</td><td>100</td></tr></table> |
af10a554a4fa0b6896e78e21ad1f5366908ce42ba701f3d0071900d82b906b3b.png | simple | <table><tr><td> </td><td>Val/Val n = 60</td><td>Met carriers n = 41</td></tr><tr><td>Age (mean ± SD) (years)</td><td>38.1 ± 8.5</td><td>39.7 ± 10.7</td></tr><tr><td>Gender, males n (%)</td><td>24 (40)</td><td>21 (51)</td></tr><tr><td>Smoking habit, n (%)</td><td>17 (28)</td><td>12 (29)</td></tr></table> |
7b838d97c889a09bf48d64b33f86dcb0b131d36378aa88f3aecb68b4fbed27ce.png | complex | <table><tr><td rowspan="2">Number of metabolic syndrome components (number of girls/boys)</td><td colspan="2">HOMA-IR</td></tr><tr><td>Girls</td><td>Boys</td></tr><tr><td>0 (468/301 girls/boys)</td><td>2.12 (1.53; 2.84)</td><td>1.90 (1.42; 2.61)</td></tr><tr><td>1 ( 381/359 girls/boys)</td><td>2.55 (1.80; 3.45)</td><td>2.28 (1.65; 3.11)</td></tr><tr><td>2 (174/168 girls/boys)</td><td>2.85 (2.09; 4.37)</td><td>3.19 (2.20; 5.03)</td></tr><tr><td>3 (54/76 girls/boys)</td><td>3.60 (2.56; 5.69)</td><td>4.44 (2.88; 6.25)</td></tr><tr><td>4 (4/29 girls/boys)</td><td>5.86 (4.90; 9.19)</td><td>6.38 (4.26; 7.98)</td></tr><tr><td>5 (0/3 girls/boys)</td><td>---</td><td>7.19 (4.33; 13.93)</td></tr></table> |
932d85f3f4228171e21147fe0f414ec3e9d1bb655c73f591d69510519b01ae6b.png | complex | <table><tr><td>`Parameter</td><td>Time</td><td>Placebo (SCG-P) (n = 14)</td><td>Cromolyn 20 mg (SCG-20) (n = 14)</td><td>Cromolyn 40 mg (SCG-40) (n = 12)</td><td>p-value </td></tr><tr><td rowspan="4">FEV1 </td><td>Baseline</td><td>60.07 ± 3.29 </td><td>57.33 ± 3.54 </td><td>67.49 ±2.04 </td><td>NS</td></tr><tr><td>15 min</td><td>60.56 ± 3.29 </td><td>58.85 ± 3.22 </td><td>66.97 ± 1.99 </td><td>NS</td></tr><tr><td>30 min</td><td>60.46 ± 3.27 </td><td>58.41 ± 2.90 </td><td>67.29 ± 2.00 </td><td>NS</td></tr><tr><td>60 min</td><td>62.06 ± 3.17 </td><td>59.49 ± 3.40</td><td>67.97 ± 2.04 </td><td>NS</td></tr><tr><td rowspan="4">FVC </td><td>Baseline</td><td>71.17 ± 3.30 </td><td>70.17 ± 3.23 </td><td>73.45 ±7.40 </td><td>NS</td></tr><tr><td>15 min</td><td>71.71 ± 3.37 </td><td>71.30 ± 3.23</td><td>73.75 ±2.52 </td><td>NS</td></tr><tr><td>30 min</td><td>71.94 ± 3.24 </td><td>71.22 ±2.63 </td><td>73.02 ± 2.72 </td><td>NS</td></tr><tr><td>60 min</td><td>72.77 ± 3.76 </td><td>72.53 ± 2.85 </td><td>74.33 ± 2.61</td><td>NS</td></tr><tr><td rowspan="4">PEF </td><td>Baseline </td><td>59.19 ±4.91 </td><td>56.02 ± 4.62 </td><td>64.79 ± 2.71 </td><td>NS</td></tr><tr><td>15 min</td><td>57.85 ± 4.68 </td><td>58.93 ± 4.48 </td><td>65.10 ±3.60 </td><td>NS</td></tr><tr><td>30 min</td><td>58.66 ± 5.68 </td><td>58.74 ± 4.51 </td><td>65.50 ±3.40 </td><td>NS</td></tr><tr><td>60 min</td><td>58.56 ± 5.23 </td><td>60.69 ± 4.76 </td><td>65.20 ± 3.13 </td><td>NS</td></tr><tr><td rowspan="4">MEF75% </td><td>Baseline</td><td>41.52 ±5.45 </td><td>38.86 ± 4.41 </td><td>54.37 ± 3.21* </td><td>S</td></tr><tr><td>15 min</td><td>41.87 ± 4.56 </td><td>39.73 ± 4.47 </td><td>52.93 ± 3.38 </td><td>-</td></tr><tr><td>30 min</td><td>42.81 ± 3.88 </td><td>38.69 ±3.94 </td><td>52.59 ± 3.55 </td><td>-</td></tr><tr><td>60 min</td><td>44.31 ± 3.80 </td><td>38.37 ± 4.17 </td><td>53.91 ± 3.49 </td><td>-</td></tr><tr><td rowspan="4">MEF50% </td><td>Baseline</td><td>34.87 ± 4.89 </td><td>29.96 ± 3.75 </td><td>45.62 ± 3.25* </td><td>S</td></tr><tr><td>15 min</td><td>33.73 ± 3.79 </td><td>31.67 ± 3.68 </td><td>44.30 ± 2.49 </td><td>-</td></tr><tr><td>30 min</td><td>32.78 ± 2.82 </td><td>30.30 ± 3.41 </td><td>44.97 ± 2.58 </td><td>-</td></tr><tr><td>60 min</td><td>36.64 ±3.18 </td><td>29.91 ± 3.13 </td><td>45.68 ± 2.63 </td><td>-</td></tr><tr><td rowspan="4">MEF25% </td><td>Baseline</td><td>30.78 ± 4.91 </td><td>24.76 ± 2.64 </td><td>39.76 ± 2.24* </td><td>S</td></tr><tr><td>15 min</td><td>29.79 ± 4.63 </td><td>26.89 ± 3.31 </td><td>39.80 ± 2.69 </td><td>-</td></tr><tr><td>30 min</td><td>27.48 ± 3.48 </td><td>26.25 ± 2.76 </td><td>42.24 ±2.50 </td><td>-</td></tr><tr><td>60 min</td><td>30.66 ± 3.95 </td><td>25.22 ± 2.56 </td><td>39.56 ± 2.62 </td><td>-</td></tr></table> |
5a7ff5105e8811464b75cfc3a9e4c700c7785e7ec2aeda0b8ce931c415508e6d.png | simple | <table><tr><td>Fold Change</td><td>Method</td><td>Accuracy %</td><td>Sensitivity %</td><td>PPV %</td><td>F-Score %</td></tr><tr><td></td><td>FishersTotal</td><td>70.41%</td><td>70.79%</td><td>91.24%</td><td>79.72%</td></tr><tr><td></td><td>FishersHousekeeping</td><td>65.60%</td><td>65.22%</td><td>95.05%</td><td>77.36%</td></tr><tr><td>1</td><td>GFOLD</td><td>78.13%</td><td>80.06%</td><td>92.67%</td><td>85.90%</td></tr><tr><td></td><td>Cuffdiff</td><td>11.37%</td><td>6.96%</td><td>100.00%</td><td>13.01%</td></tr><tr><td></td><td>edgeR</td><td>73.03%</td><td>73.26%</td><td>95.56%</td><td>82.94%</td></tr><tr><td></td><td>IsoDE-Match</td><td>82.63%</td><td>87.46%</td><td>83.70%</td><td>85.54%</td></tr><tr><td></td><td>IsoDE-All</td><td>82.22%</td><td>87.17%</td><td>82.82%</td><td>84.94%</td></tr><tr><td></td><td>FishersTotal</td><td>74.05%</td><td>78.20%</td><td>84.85%</td><td>81.39%</td></tr><tr><td></td><td>FishersHousekeeping</td><td>76.68%</td><td>73.61%</td><td>93.67%</td><td>82.44%</td></tr><tr><td>1.5</td><td>GFOLD</td><td>79.15%</td><td>79.35%</td><td>90.41%</td><td>84.52%</td></tr><tr><td></td><td>Cuffdiff</td><td>28.43%</td><td>8.60%</td><td>100.00%</td><td>15.85%</td></tr><tr><td></td><td>edgeR</td><td>80.01%</td><td>79.92%</td><td>92.07%</td><td>85.57%</td></tr><tr><td></td><td>IsoDE-Match</td><td>78.98%</td><td>86.23%</td><td>84.62%</td><td>85.42%</td></tr><tr><td></td><td>IsoDE-All</td><td>79.01%</td><td>86.42%</td><td>84.49%</td><td>85.44%</td></tr><tr><td></td><td>FishersTotal</td><td>78.43%</td><td>81.86%</td><td>82.44%</td><td>82.15%</td></tr><tr><td></td><td>FishersHousekeeping</td><td>81.20%</td><td>80.00%</td><td>88.21%</td><td>83.90%</td></tr><tr><td>2</td><td>GFOLD</td><td>82.94%</td><td>78.84%</td><td>92.37%</td><td>85.07%</td></tr><tr><td></td><td>Cuffdiff</td><td>40.96%</td><td>10.47%</td><td>100.00%</td><td>18.95%</td></tr><tr><td></td><td>edgeR</td><td>83.67%</td><td>81.63%</td><td>91.17%</td><td>86.13%</td></tr><tr><td></td><td>IsoDE-Match</td><td>82.04%</td><td>85.58%</td><td>85.19%</td><td>85.38%</td></tr><tr><td></td><td>IsoDE-All</td><td>81.20%</td><td>86.74%</td><td>83.07%</td><td>84.87%</td></tr></table> |
37c3339a89087709d3cd8de91aaf754d17d12d3a25b61ef2ac2d2fd090997bec.png | complex | <table><tr><td>Application</td><td colspan="3">Method (Sample Size)</td></tr><tr><td></td><td>MOAT (240)</td><td>Importance Measures (400)</td><td>VBD (2000)</td></tr><tr><td>Watershed</td><td>15 681</td><td>27 078</td><td>150 890</td></tr><tr><td>Level Set</td><td>6,825</td><td>22 696</td><td>211 912</td></tr></table> |
65e732c14ed1bf687837592146e01f5c70ff6c80afcdaded22daccf26e3b2e8c.png | complex | <table><tr><td>Variable</td><td>OR</td><td>CI</td><td>p-value</td></tr><tr><td>Age</td><td>1.15</td><td>0.86-1.54</td><td>0.53</td></tr><tr><td>Gender</td><td></td><td></td><td rowspan="3">0.07</td></tr><tr><td>Male</td><td>Ref</td><td></td></tr><tr><td>Female</td><td>0.28</td><td>——0.07-1.13</td></tr><tr><td>Marital status</td><td></td><td></td><td rowspan="3">0.03</td></tr><tr><td>Not marries</td><td>Ref</td><td></td></tr><tr><td>Married</td><td>4.99</td><td>——1.23-20.24</td></tr><tr><td>Alcohol use, past month</td><td></td><td></td><td rowspan="3">0.11</td></tr><tr><td>No</td><td>Ref</td><td></td></tr><tr><td>Yes</td><td>2.81</td><td>——0.79-9.98</td></tr><tr><td>Ecstasy use, lifetime</td><td></td><td></td><td rowspan="3">0.70</td></tr><tr><td>No</td><td>Ref</td><td></td></tr><tr><td>Yes</td><td>1.24</td><td>——0.42-3.70</td></tr><tr><td>Sexually active, lifetime</td><td></td><td>-</td><td rowspan="3">0.84</td></tr><tr><td>No</td><td>Ref</td><td></td></tr><tr><td>Yes</td><td>0.84</td><td>—0.19-3.67</td></tr><tr><td>HIV stigmatizing attitude</td><td></td><td></td><td rowspan="3">0.03</td></tr><tr><td>Yes</td><td>Ref</td><td></td></tr><tr><td>No</td><td>0.33</td><td>——0.12-0.89</td></tr><tr><td>Activity involvement:</td><td></td><td></td><td></td></tr><tr><td>Read fiction literature for entertainment</td><td>1.46</td><td>1.10-1.99</td><td>0.02</td></tr><tr><td>Go to parties, café, bar or disco in the evening</td><td>1.54</td><td>1.05-2.24</td><td>0.03</td></tr><tr><td>Pass time with neighborhood friends/neighbors</td><td>1.35</td><td>1.01-1.82</td><td>0.05</td></tr></table> |
03292b05a9b9f9692e74cafe3b2104a2111715a1c8dea64cc76b7b4f63104d96.png | complex | <table><tr><td>Variable</td><td>Description</td><td>Type</td><td>Values</td><td>Frequency</td><td>Percent</td></tr><tr><td rowspan="3">High Blood Pressure (mmHg) Diastolic Systolic </td><td rowspan="3">Blood pressure measured around the arm above the elbow; it detects the amount of pressure in the blood flowing in the vein (in mm of mercury)</td><td rowspan="3">Nominal</td><td>1 ≤ 120/80 = Normal</td><td>336</td><td>77.6</td></tr><tr><td>2 = 120–139/80–89 = Pre-hypertension</td><td>84</td><td>19.4</td></tr><tr><td>3 = 140+/90+ = High Blood Pressure</td><td>13</td><td>3.0</td></tr><tr><td rowspan="6">BMI (weight in kg/squared height in meters)</td><td rowspan="6">Calculated based on calibrated measurements performed by school nurse</td><td rowspan="6">Continuous Ordinal</td><td>0.0–60++</td><td></td><td></td></tr><tr><td>1 ≤ 18.5 Underweight</td><td>76</td><td>17.6</td></tr><tr><td>2 = 18.5–25.0 Normal</td><td>185</td><td>42.7</td></tr><tr><td>3 = 26.0–30.0 </td><td>55</td><td>12.7</td></tr><tr><td>Overweight</td><td></td><td></td></tr><tr><td>4 ≥ 30.0 Obese</td><td>117</td><td>27.0</td></tr><tr><td rowspan="2">Tobacco Use</td><td rowspan="2">Do you smoke</td><td rowspan="2">Dichotomous</td><td>1 = Yes</td><td>63</td><td>14.5</td></tr><tr><td>2 = No</td><td>370</td><td>85.5</td></tr><tr><td rowspan="2">Alcohol Use</td><td rowspan="2">Do you drink alcoholic beverages?</td><td rowspan="2">Dichotomous</td><td>1 = Yes</td><td>127</td><td>29.3</td></tr><tr><td>2 = No</td><td>306</td><td>70.7</td></tr><tr><td rowspan="2">Optimistic Bias</td><td rowspan="2">Do you think it is possible that you could develop cardiovascular disease? </td><td rowspan="2">Dichotomous</td><td>1 = Yes</td><td>166</td><td>38.3</td></tr><tr><td>2 = No</td><td>267</td><td>61.7</td></tr></table> |
1fb2a296309c99de66cb9ab5bb836597e6286987bb55d722f8f65a35b55cb4bd.png | complex | <table><tr><td>Variables</td><td>Baseline</td><td>Post-treatment</td></tr><tr><td colspan="3">OHRQoL scores</td></tr><tr><td> Total score</td><td>16.67 (12.10)</td><td>7.05 (7.16) **</td></tr><tr><td> Functional limitation</td><td>1.83 (2.21)</td><td>1.08 (1.48) **</td></tr><tr><td> Physical pain</td><td>3.55 (1.81)</td><td>1.52 (1.53) **</td></tr><tr><td> Psychological discomfort</td><td>2.59 (2.26)</td><td>0.91 (1.33) **</td></tr><tr><td> Physical disability</td><td>2.68 (2.09)</td><td>1.25 (1.49) **</td></tr><tr><td> Psychological disability</td><td>2.43 (2.01)</td><td>0.99 (1.27) **</td></tr><tr><td> Social disability</td><td>1.67 (1.93)</td><td>0.61 (1.10) **</td></tr><tr><td> Handicap</td><td>1.93 (1.96)</td><td>0.69 (1.14) **</td></tr><tr><td colspan="3">Periodontal parameters</td></tr><tr><td> No. of teeth (<i>n</i>)</td><td>26.96 (2.24)</td><td>26.39 (2.71) **</td></tr><tr><td> PD (mm)</td><td>3.00 (0.75)</td><td>2.53 (0.65) **</td></tr><tr><td> CAL (mm)</td><td>2.66 (1.46)</td><td>2.50 (1.47) *</td></tr><tr><td> FMBS (%)</td><td>35.07 (23.52)</td><td>19.99 (16.13) **</td></tr><tr><td> PD ≥ 4 mm (%)</td><td>25.83 (19.34)</td><td>12.93 (12.74) **</td></tr><tr><td> PCR (%)</td><td>56.66 (20.75)</td><td>37.57 (15.51) **</td></tr></table> |
308c65710b4fa995af627ec51c10ec1124f043b17686f222c48c97b761f2a7ed.png | simple | <table><tr><td>Sample name</td><td>Silicon-rich concentration(volume percentage v%)</td><td>Sample structure/thickness (nm)</td></tr><tr><td>SRC80</td><td>80</td><td>Single layer/approximately 600</td></tr><tr><td>SRC70</td><td>70</td><td>Single layer/approximately 600</td></tr><tr><td>SRC60</td><td>60</td><td>Single layer/approximately 600</td></tr><tr><td>SRC50</td><td>50</td><td>Single layer/approximately 600</td></tr><tr><td>SiC</td><td>0</td><td>Single layer/approximately 600</td></tr></table> |
26fbb4e71faf4bc811cc943ddadca07f6ada3da00882b1e13eaf387e4bdd6f43.png | complex | <table><tr><td> </td><td colspan="3">Control subjects</td><td colspan="3">STAMPEDE subjects</td><td colspan="3">Subset of STAMPEDE subjects</td><td>STAMPEDE vs CONTROLS</td><td>STAMPEDE subset vs controls</td></tr><tr><td>Entrez ID</td><td>Mean</td><td>ST DEV</td><td>CV, %</td><td>Mean</td><td>ST DEV</td><td>CV, %</td><td>Mean</td><td>ST DEV</td><td>CV, %</td><td>p value</td><td>p value</td></tr><tr><td>A1AG1</td><td>18.69</td><td>0.40</td><td>2.1</td><td>19.49</td><td>0.52</td><td>2.7</td><td>19.98</td><td>0.44</td><td>2.2</td><td>0.00055429</td><td>5.95509E-07</td></tr><tr><td>A1BG</td><td>18.95</td><td>0.32</td><td>1.7</td><td>19.20</td><td>0.33</td><td>1.7</td><td>19.52</td><td>0.13</td><td>0.6</td><td>0.0001927</td><td>4.63441E-05</td></tr><tr><td>AACT</td><td>17.34</td><td>0.50</td><td>2.9</td><td>17.99</td><td>0.35</td><td>2.0</td><td>18.37</td><td>0.13</td><td>0.7</td><td>0.0010359</td><td>6.39218E-06</td></tr><tr><td>ANT3</td><td>17.62</td><td>0.39</td><td>2.2</td><td>18.15</td><td>0.35</td><td>1.9</td><td>18.50</td><td>0.17</td><td>0.9</td><td>0.00037815</td><td>3.80627E-06</td></tr><tr><td>HEMO</td><td>18.74</td><td>0.29</td><td>1.5</td><td>19.07</td><td>0.31</td><td>1.6</td><td>19.37</td><td>0.27</td><td>1.4</td><td>2.7297E-05</td><td>0.000126029</td></tr><tr><td>APOA1</td><td>17.42</td><td>1.22</td><td>7.0</td><td>18.53</td><td>0.91</td><td>4.9</td><td>19.10</td><td>0.52</td><td>2.7</td><td>9.4027E-05</td><td>0.000842961</td></tr><tr><td>APOA2</td><td>15.72</td><td>1.26</td><td>8.0</td><td>16.65</td><td>1.18</td><td>7.1</td><td>17.09</td><td>1.08</td><td>6.3</td><td>0.00057807</td><td>0.018670507</td></tr><tr><td>PZP</td><td>17.01</td><td>0.99</td><td>5.8</td><td>17.86</td><td>0.71</td><td>4.0</td><td>18.27</td><td>0.57</td><td>3.1</td><td>3.3055E-05</td><td>0.003711976</td></tr><tr><td>A2MG</td><td>16.74</td><td>0.85</td><td>5.1</td><td>17.24</td><td>0.63</td><td>3.6</td><td>17.56</td><td>0.59</td><td>3.4</td><td>1.9526E-05</td><td>0.024453179</td></tr><tr><td>HBA</td><td>16.29</td><td>1.93</td><td>11.9</td><td>17.48</td><td>1.60</td><td>9.1</td><td>18.29</td><td>1.78</td><td>9.8</td><td>1.4869E-05</td><td>0.025085649</td></tr><tr><td>HBB</td><td>15.96</td><td>1.94</td><td>12.1</td><td>17.67</td><td>1.51</td><td>8.6</td><td>18.42</td><td>1.71</td><td>9.3</td><td>7.2466E-06</td><td>0.006838885</td></tr><tr><td>HBD</td><td>16.42</td><td>2.08</td><td>12.7</td><td>17.90</td><td>1.71</td><td>9.5</td><td>18.64</td><td>2.24</td><td>12.0</td><td>5.1691E-07</td><td>0.014381261</td></tr></table> |
d8fec0b1beb7274784ac007a44e3f5b58d26ce472e978665965b67836f1cef69.png | complex | <table><tr><td>Patients</td><td>Sex</td><td>Age</td><td>pH juice</td><td>Sample</td><td>Log10 CFU/g or ml</td><td><i>Bifidobacteriaceae</i> species</td></tr><tr><td colspan="6">AAG groups (2 of 10 patients)</td><td></td></tr><tr><td>1</td><td>F</td><td>60</td><td>7.84</td><td>Juice</td><td>5.30</td><td>Sca.</td></tr><tr><td></td><td></td><td></td><td></td><td>Corpus</td><td>4.30</td><td>Sca.</td></tr><tr><td>2</td><td>M</td><td>33</td><td>8.11</td><td>Juice</td><td>4.30</td><td>Par.</td></tr><tr><td colspan="6">OME groups (7 of 13 patients)</td><td></td></tr><tr><td>3</td><td>M</td><td>52</td><td>7.80</td><td>Antrum</td><td>4.30</td><td>Par.</td></tr><tr><td>4</td><td>M</td><td>55</td><td>6.75</td><td>Antrum</td><td>3.00</td><td>Bif.d.</td></tr><tr><td>5</td><td>M</td><td>46</td><td>8.08</td><td>Juice</td><td>2.69</td><td>Par.</td></tr><tr><td></td><td></td><td></td><td></td><td>Corpus</td><td>4.00</td><td>Par.</td></tr><tr><td>6</td><td>F</td><td>44</td><td>7.41</td><td>Juice</td><td>5.30</td><td>Bif.d.;Par.;Sca.</td></tr><tr><td></td><td></td><td></td><td></td><td>Antrum</td><td>4.07</td><td>Par.</td></tr><tr><td></td><td></td><td></td><td></td><td>Corpus</td><td>4.00</td><td>Par.</td></tr><tr><td>7</td><td>F</td><td>70</td><td>7.83</td><td>Juice</td><td>4.00</td><td>Bif.d.;Par.;Sca.</td></tr><tr><td></td><td></td><td></td><td></td><td>Antrum</td><td>3.60</td><td>Bif.d.</td></tr><tr><td>8</td><td>M</td><td>50</td><td>5.02</td><td>Antrum</td><td>4.00</td><td>Bif.ilon.</td></tr><tr><td>9</td><td>F</td><td>43</td><td>6.48</td><td>Juice</td><td>4.00</td><td>Un.Bif.</td></tr></table> |
acd376b5ce65bbaf4d8d531c60564a43acfd180e914746c45aa01c08fd8f0553.png | complex | <table><tr><td>Date, meal, food item</td><td colspan="3">Exposed</td><td colspan="3">Not exposed</td><td>RR</td><td>95% CI</td><td>AF</td></tr><tr><td></td><td>ill</td><td>not ill</td><td>AR (%)</td><td>ill</td><td>not ill</td><td>AR (%)</td><td></td><td></td><td></td></tr><tr><td colspan="10">Cohort from units 1 and 9, n = 181 (variable denominator due to missing data), only those with RR>2 shown:</td></tr><tr><td> 5-Aug, lunch, "light meal"</td><td>10</td><td>63</td><td>15.9</td><td>9</td><td>118</td><td>7.6</td><td>2.08</td><td>0.89–4.86</td><td>28%</td></tr><tr><td> 5-Aug, afternoon, cake</td><td>17</td><td>128</td><td>13.3</td><td>2</td><td>53</td><td>3.8</td><td>3.52</td><td>0.84–14.70</td><td>64%</td></tr><tr><td> 6-Aug, lunch, "light meal"</td><td>11</td><td>47</td><td>23.4</td><td>8</td><td>134</td><td>6.0</td><td>3.92</td><td>1.68–9.15</td><td>43%</td></tr><tr><td> 6-Aug, afternoon, cake</td><td>17</td><td>125</td><td>13.6</td><td>2</td><td>56</td><td>3.6</td><td>3.81</td><td>0.91–15.93</td><td>66%</td></tr><tr><td> 6-Aug, dinner, cold cuts</td><td>16</td><td>116</td><td>13.8</td><td>3</td><td>65</td><td>4.6</td><td>2.99</td><td>0.91–9.87</td><td>56%</td></tr><tr><td> 7-Aug, afternoon, cake</td><td>16</td><td>125</td><td>12.8</td><td>3</td><td>56</td><td>5.47</td><td>2.39</td><td>0.73–7.87</td><td>49%</td></tr><tr><td colspan="10">Cohort from units 1, 2, 4 and 9, n = 378 (variable denominator due to missing data), all food items shown:</td></tr><tr><td> 5-Aug, afternoon, cake</td><td>38</td><td>306</td><td>13.3</td><td>4</td><td>70</td><td>5.7</td><td>2.17</td><td>0.80–5.89</td><td>49%</td></tr><tr><td> 6-Aug, afternoon, cake</td><td>38</td><td>303</td><td>13.3</td><td>4</td><td>69</td><td>5.5</td><td>2.29</td><td>0.84–6.21</td><td>51%</td></tr><tr><td> 7-Aug, afternoon, cake</td><td>37</td><td>303</td><td>12.2</td><td>5</td><td>68</td><td>6.8</td><td>1.78</td><td>0.73–4.38</td><td>39%</td></tr><tr><td> 6-Aug, lunch, "light meal"</td><td>20</td><td>123</td><td>16.3</td><td>22</td><td>253</td><td>8.7</td><td>1.87</td><td>1.06–3.29</td><td>22%</td></tr></table> |
53fdcbf708a726bcb86b79c01fa59b7746f2ed8ebcca5791874965bee2f79307.png | simple | <table><tr><td>No.</td><td>MCs tot <sup>a,b</sup></td><td>ANA-a <sup>a</sup></td><td>ANA-a</td><td>DH-ANA-a <sup>c</sup></td><td>E-ANA-a <sup>c</sup></td><td>MC-RR</td><td>MC-YR</td><td>MC-LR</td><td>MC-LA</td><td>MC-LY</td><td>MC-LW</td><td>MC-LF</td><td>CYN</td><td>STX</td><td>BMAA</td></tr><tr><td>1</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>2</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>3</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>4</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>5</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>7.2</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>6</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>7</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>8</td><td>0.25 (10)</td><td>ND</td><td>ND</td><td>0.41</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>0.3 (13)</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>9</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>10</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>11</td><td>2.5 (104)</td><td>ND</td><td>ND</td><td>ND</td><td>8.1</td><td>ND</td><td>1.6 (67)</td><td>0.06 (3)</td><td>0.08 (3)</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>12</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>13</td><td>0.6 (25)</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>0.03 (1)</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>14</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>15</td><td>16.4 (683)</td><td>ND</td><td>0.30 (5)</td><td>2.2</td><td>1.8</td><td>0.8 (33)</td><td>ND</td><td>8.6 (358)</td><td>2.2 (92)</td><td>0.04 (17)</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>0.08</td></tr><tr><td>16</td><td>4.5 (188)</td><td>ND</td><td>ND</td><td>ND</td><td>0.28</td><td>ND</td><td>ND</td><td>3.6 (150)</td><td>1.2 (50)</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>17</td><td>3.3 (138)</td><td>0.35 (6)</td><td>0.32 (5)</td><td>5.8</td><td>ND</td><td>ND</td><td>0.18 (8)</td><td>0.04 (17)</td><td>2.6 (108)</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>0.44</td></tr><tr><td>18</td><td>0.8 (33)</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>0.52 (22)</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr></table> |
a21874207b0bc0f2b25cc7e1b69f13bfce8ef5247e49c1df08f063a3f8223909.png | simple | <table><tr><td>Cr</td><td>Co</td><td>Mo</td><td>Al</td><td>Ti</td><td>C</td><td>B</td><td>Ni</td></tr><tr><td>19.5</td><td>13.5</td><td>4.3</td><td>1.3</td><td>3</td><td>0.08</td><td>0.006</td><td>Bal</td></tr></table> |
92f136fd51e7db2261a1dfff264b92ef8a3cc91246bf4696bf14bc0c5f245e67.png | simple | <table><tr><td>Name</td><td>Thermal Treatment</td><td>Surface * (m<sup>2</sup>/g)</td><td>D90 ** (μm)</td><td>D50 ** (μm)</td><td>D10 ** (μm)</td><td>S (%)</td><td>N (%)</td><td>Fe (%)</td><td>Si (%)</td><td>Ni (%)</td><td>P (ppm)</td><td>B (ppm)</td></tr><tr><td>CNF A</td><td>no</td><td>103</td><td>2.2</td><td>1.6</td><td>0.7</td><td><0.010</td><td>0.017</td><td>0.008</td><td>0.020</td><td>1.29</td><td>5.0</td><td>0.7</td></tr><tr><td>CNF B</td><td>yes</td><td>61</td><td>2.2</td><td>1.9</td><td>1.6</td><td><0.010</td><td>0.016</td><td>0.023</td><td>0.012</td><td>0.070</td><td>3.8</td><td>2.0</td></tr><tr><td>CNF C</td><td>no</td><td>124</td><td>2.6</td><td>1.7</td><td>0.8</td><td>0.095</td><td>0.037</td><td>0.148</td><td>0.056</td><td>4.97</td><td>8.1</td><td>7.6</td></tr><tr><td>CNF D</td><td>yes</td><td>56</td><td>2.5</td><td>1.5</td><td>0.6</td><td><0.010</td><td>0.012</td><td>0.002</td><td>0.004</td><td>0.036</td><td>0.3</td><td>0.3</td></tr><tr><td>CB</td><td>no</td><td>321</td><td>6.9</td><td>3.2</td><td>1.3</td><td>0.45</td><td>0.121</td><td>0.003</td><td><0.03</td><td><0.0003</td><td>1.1</td><td><1.0</td></tr></table> |
effe759ac96d5a05967765a094d2878374b1f3dd511e7fe0488cd1aa58c58984.png | complex | <table><tr><td colspan="2">Course level</td></tr><tr><td>Level 1</td><td>Text, images, audio, simple interactivities for content presentation. Template layout</td></tr><tr><td>Level 2</td><td>Level 1+video and simple animations. Fewer pages with template layout</td></tr><tr><td>Level 3</td><td>Complex animation, high-fidelity/3D graphics, complex multilevel, and multivariable interaction</td></tr></table> |
247f146bbbde8386577557aaed56fcb371dc156fbbb90fcc9f9c7bf44e271474.png | complex | <table><tr><td> </td><td colspan="2">Underweight (<i>n</i> = 39)</td><td colspan="2">Normal (<i>n</i> = 280)</td><td colspan="2">Overweight (<i>n</i> = 121)</td><td colspan="2">Obese (<i>n</i> = 304)</td></tr><tr><td> </td><td>Estimates (SE)</td><td><i>p</i> value</td><td>Estimates (SE)</td><td><i>p</i> value</td><td>Estimates (SE)</td><td><i>p</i> value</td><td>Estimates (SE)</td><td><i>p</i> value</td></tr><tr><td>Age (per year)</td><td>−0.26 (0.18)</td><td>0.16</td><td>−0.07 (0.08)</td><td>0.37</td><td>−0.07 (0.13)</td><td>0.52</td><td>0.02 (0.07)</td><td>0.84</td></tr><tr><td>Sex (boys versus girls)</td><td>0.23 (0.29)</td><td>0.43</td><td>−0.26 (0.09)</td><td>0.006<sup><i>∗</i></sup></td><td>−0.49 (0.14)</td><td>0.004<sup><i>∗</i></sup></td><td>−0.09 (0.10)</td><td>0.34</td></tr><tr><td>BMI (per unit)</td><td>0.16 (0.17)</td><td>0.35</td><td>−0.02 (0.03)</td><td>0.42</td><td>0.06 (0.07)</td><td>0.4</td><td>−0.01 (0.01)</td><td>0.54</td></tr><tr><td>Insulin (per SD)</td><td>0.52 (0.73)</td><td>0.48</td><td>0.16 (0.08)</td><td>0.06</td><td>0.25 (0.11)</td><td>0.02<sup><i>∗</i></sup></td><td>0.15 (0.04)</td><td><0.0001<sup><i>∗</i></sup></td></tr><tr><td>VEGFA (per SD)</td><td>0.16 (0.18)</td><td>0.38</td><td>0.07 (0.06)</td><td>0.26</td><td>−0.08 (0.12)</td><td>0.53</td><td>0.10 (0.04)</td><td>0.01<sup><i>∗</i></sup></td></tr><tr><td>IL-12p70 (per SD)</td><td>−0.06 (0.13)</td><td>0.66</td><td>−0.07 (0.05)</td><td>0.13</td><td>−0.005 (0.06)</td><td>0.93</td><td>−0.14 (0.05)</td><td>0.01<sup><i>∗</i></sup></td></tr><tr><td>Governorate </td><td> </td><td>0.12<sup>a</sup></td><td> </td><td><0.0001<sup>a,<i>∗</i></sup></td><td> </td><td><0.0001<sup>a,<i>∗</i></sup></td><td> </td><td><0.0001<sup>a,<i>∗</i></sup></td></tr></table> |
bad037f3ba0f02119f4fe4a40135b3f851a2f9d4d802c398269859d8328f7241.png | simple | <table><tr><td>Grade</td><td>Forequarter%</td><td>Ribs/Flank%</td><td>Rump/Round%</td><td>Loin%</td><td>T. Coxae (hip)%</td><td>T. Ischiadicum (rear)%</td><td>Total%</td></tr><tr><td>1</td><td>12.2</td><td>7.9</td><td>8.3</td><td>5.5</td><td>20.0</td><td>14.9</td><td>68.7</td></tr><tr><td>2</td><td>10.2</td><td>6.3</td><td>1.9</td><td>1.3</td><td>9.3</td><td>2.4</td><td>31.3</td></tr><tr><td>Total</td><td>22.4</td><td>14.1</td><td>10.1</td><td>6.8</td><td>29.3</td><td>17.3</td><td>100</td></tr></table> |
9e14ef36dfd87fb4ed689ac0b80037a988968680af98d631d2916b30470e2851.png | simple | <table><tr><td>Characteristics</td><td>HR<sup>*</sup> (95% CI)</td><td><i>P</i></td></tr><tr><td><i>EGFR CNG</i></td><td>2.31 (1.44-3.69)</td><td>0.001</td></tr><tr><td><i>HER2 CNG</i></td><td>1.21 (0.75-1.92)</td><td>0.44</td></tr><tr><td><i>HER3 CNG</i></td><td>1.36 (0.85-2.15)</td><td>0.19</td></tr><tr><td><i>HER4 CNG</i></td><td>1.29 (0.82-2.03)</td><td>0.28</td></tr><tr><td>Gender</td><td>0.82 (0.52-1.30)</td><td>0.39</td></tr><tr><td>Age<sup>1</sup></td><td>1.52 (1.16-1.98)</td><td>0.002</td></tr><tr><td>WHO grade<sup>2</sup></td><td>1.92 (1.47-2.48)</td><td>0.001</td></tr><tr><td>KPS score<sup>3</sup></td><td>1.38 (0.86-2.21)</td><td>0.18</td></tr><tr><td>Recurrence</td><td>44.86 (6.16-327.00)</td><td><0.001</td></tr><tr><td>Radiotherapy</td><td>0.47 (0.30-0.75)</td><td><0.001</td></tr><tr><td>Chemotherapy</td><td>1.45 (0.92-2.30)</td><td>0.11</td></tr><tr><td>Smoking</td><td>1.55 (0.96-2.50)</td><td>0.07</td></tr><tr><td>Drinking</td><td>0.84 (0.31-2.30)</td><td>0.73</td></tr><tr><td>Epilepsy</td><td>0.41 (0.25-0.66)</td><td><0.001</td></tr><tr><td><i>IDH1</i> mutations</td><td>0.30 (0.17-0.53)</td><td><0.001</td></tr></table> |
fbeb81d6f940fc1a1e96e21485531f36fa779ab3900f55ed8c70019b17431f70.png | complex | <table><tr><td rowspan="2">Gene</td><td rowspan="2">Location</td><td colspan="5">Length (bp)</td></tr><tr><td>Exon I</td><td>Intron I</td><td>Exon II</td><td>Intron II</td><td>Exon III</td></tr><tr><td><i>rps12</i></td><td>LSC</td><td>114</td><td>-</td><td>270</td><td></td><td></td></tr><tr><td><i>ndhB</i></td><td>LSC</td><td>729</td><td>629</td><td>780</td><td></td><td></td></tr><tr><td><i>ycf66</i></td><td>LSC</td><td>106</td><td>591</td><td>320</td><td></td><td></td></tr><tr><td><i>rpoC1</i></td><td>LSC</td><td>423</td><td>789</td><td>1614</td><td></td><td></td></tr><tr><td><i>atpF</i></td><td>LSC</td><td>411</td><td>654</td><td>135</td><td></td><td></td></tr><tr><td><i>ycf3</i></td><td>LSC</td><td>126</td><td>684</td><td>228</td><td>739</td><td>153</td></tr><tr><td><i>clpP</i></td><td>LSC</td><td>69</td><td>687</td><td>291</td><td>483</td><td>234</td></tr><tr><td><i>rpl2</i></td><td>LSC</td><td>396</td><td>637</td><td>438</td><td></td><td></td></tr><tr><td><i>ndhA</i></td><td>SSC</td><td>556</td><td>731</td><td>551</td><td></td><td></td></tr><tr><td><i>trnK-UUU</i></td><td>LSC</td><td>37</td><td>2272</td><td>42</td><td></td><td></td></tr><tr><td><i>trnL-UAA</i></td><td>LSC</td><td>38</td><td>262</td><td>50</td><td></td><td></td></tr><tr><td><i>trnV-UAC</i></td><td>LSC</td><td>37</td><td>542</td><td>37</td><td></td><td></td></tr><tr><td><i>trnI-GAU</i></td><td>IR</td><td>42</td><td>769</td><td>35</td><td></td><td></td></tr><tr><td><i>trnA-UGC</i></td><td>IR</td><td>38</td><td>763</td><td>35</td><td></td><td></td></tr></table> |
e6d9cd80b841ded256e444a8b47a8dd5c9fd99bfb83dc7b95d33616923ad75e8.png | complex | <table><tr><td> </td><td colspan="2"><i>“At”</i></td><td colspan="2"><i>“From”</i></td><td> </td><td> </td></tr><tr><td>Method</td><td>M</td><td>SD</td><td>M</td><td>SD</td><td>t</td><td>P</td></tr><tr><td>Persuasive Communication</td><td>4.85</td><td>0.37</td><td>4.15</td><td>1.14</td><td>2.77</td><td>.01</td></tr><tr><td>Tailoring</td><td>4.20</td><td>1.01</td><td>4.40</td><td>0.99</td><td>−0.66</td><td>.52</td></tr><tr><td>Modeling</td><td>4.30</td><td>0.66</td><td>4.55</td><td>0.69</td><td>−1.56</td><td>.14</td></tr><tr><td>Feedback</td><td>4.35</td><td>0.93</td><td>4.65</td><td>0.59</td><td>−1.19</td><td>.25</td></tr><tr><td>Reinforcement/Punishment</td><td>3.65</td><td>1.04</td><td>4.05</td><td>0.89</td><td>−2.03</td><td>.06</td></tr><tr><td>Facilitation</td><td>4.50</td><td>0.89</td><td>4.45</td><td>1.00</td><td>0.25</td><td>.80</td></tr><tr><td>Consciousness Raising</td><td>4.60</td><td>0.82</td><td>4.15</td><td>1.18</td><td>1.69</td><td>.11</td></tr><tr><td>Direct Experience</td><td>3.70</td><td>1.22</td><td>4.10</td><td>1.07</td><td>−2.18</td><td>.04</td></tr><tr><td>Info about others’ approval</td><td>4.35</td><td>0.88</td><td>4.05</td><td>0.76</td><td>1.19</td><td>.25</td></tr><tr><td>Resistance to Social Pressure</td><td>3.30</td><td>1.13</td><td>3.60</td><td>0.88</td><td>−0.88</td><td>.39</td></tr><tr><td>Goal Setting</td><td>4.15</td><td>0.99</td><td>4.55</td><td>0.60</td><td>−1.71</td><td>.10</td></tr><tr><td>Systems Change</td><td>3.95</td><td>1.15</td><td>3.95</td><td>1.15</td><td>0.00</td><td>.00</td></tr><tr><td>Participatory Problem Solving</td><td>4.25</td><td>0.72</td><td>3.90</td><td>0.91</td><td>1.44</td><td>.17</td></tr><tr><td>Coercion</td><td>1.95</td><td>1.05</td><td>2.10</td><td>1.21</td><td>−0.57</td><td>.58</td></tr><tr><td>Advocacy and Lobbying</td><td>4.25</td><td>0.72</td><td>2.85</td><td>1.31</td><td>4.63</td><td>.00</td></tr><tr><td>Technical Assistance</td><td>4.45</td><td>0.83</td><td>4.35</td><td>0.81</td><td>0.57</td><td>.58</td></tr><tr><td>Sense-making</td><td>3.55</td><td>1.00</td><td>3.65</td><td>0.88</td><td>−0.44</td><td>.67</td></tr><tr><td>Organ. Diagnosis and Feedback</td><td>4.45</td><td>0.76</td><td>3.45</td><td>1.19</td><td>3.25</td><td>.00</td></tr><tr><td>Team Building</td><td>3.70</td><td>1.13</td><td>3.65</td><td>1.31</td><td>0.16</td><td>.87</td></tr><tr><td>Structural Redesign</td><td>3.45</td><td>1.15</td><td>3.70</td><td>1.13</td><td>−0.69</td><td>.50</td></tr><tr><td>Increasing Stakeholder Influence</td><td>3.70</td><td>1.13</td><td>3.10</td><td>1.37</td><td>1.71</td><td>.10</td></tr><tr><td>Social Action</td><td>2.90</td><td>1.33</td><td>2.60</td><td>1.27</td><td>1.45</td><td>.16</td></tr><tr><td>Forming Coalitions</td><td>3.65</td><td>0.93</td><td>3.10</td><td>1.02</td><td>2.77</td><td>.01</td></tr><tr><td>Reporting, Social Planning</td><td>3.70</td><td>1.03</td><td>3.20</td><td>1.11</td><td>1.88</td><td>.08</td></tr><tr><td>Media Advocacy</td><td>3.35</td><td>1.18</td><td>2.95</td><td>1.36</td><td>1.57</td><td>.13</td></tr></table> |
374e5a20b3c9ee9092cfbe0ebcf122218feb1d1d884d329671a01dd00ba538b1.png | simple | <table><tr><td><i>PML isoform</i></td><td><i>Wild type</i></td><td><i>Nuclear import-defective mutant</i></td></tr><tr><td>PML I</td><td>PML NBs</td><td>Early endosomes</td></tr><tr><td>PML II</td><td>Nuclear periphery</td><td>Nuclear periphery</td></tr><tr><td>PML III</td><td>PML NBs</td><td>Late endosomes/lysosomes</td></tr><tr><td>PML IV</td><td>PML NBs</td><td>Late endosomes/lysosomes</td></tr><tr><td>PML V</td><td>PML NBs</td><td>Late endosomes/lysosomes</td></tr><tr><td>PML VII</td><td>Late endosomes/lysosomes</td><td>Not applicable</td></tr></table> |
52fd0bae8df0d1b362e6edb3c9071a00a35ef5a72695d358144820d3ad68434c.png | simple | <table><tr><td>Species</td><td>m</td><td>M</td><td>N-M</td><td>n</td><td>Adjusted p-value</td></tr><tr><td><i>Dengue virus</i></td><td>14</td><td>41</td><td>55016</td><td>550</td><td>0.00E+00</td></tr><tr><td><i>Deer tick virus</i></td><td>5</td><td>10</td><td>55047</td><td>550</td><td>8.20E-06</td></tr><tr><td><i>Mycoplasma</i></td><td>4</td><td>55</td><td>55002</td><td>550</td><td>0.5073</td></tr><tr><td><i>A</i>-<i>2 plaque virus</i></td><td>2</td><td>8</td><td>55049</td><td>550</td><td>0.6017</td></tr><tr><td><i>Phytomyza</i></td><td>5</td><td>100</td><td>54957</td><td>550</td><td>0.6325</td></tr><tr><td><i>Orf virus</i></td><td>6</td><td>150</td><td>54907</td><td>550</td><td>0.6859</td></tr><tr><td><i>Brevibacterium</i></td><td>3</td><td>41</td><td>55016</td><td>550</td><td>0.9211</td></tr></table> |
d6aade23d4eacb0953aedb701f2050b2b7df28f1f0555340b41e12c55289a1a1.png | simple | <table><tr><td>Gene</td><td>Complex</td><td>SNP</td><td>Major/minor allele</td><td>Location</td><td>MAF</td></tr><tr><td>NDUFS2</td><td>I</td><td>rs33941127</td><td>C/T</td><td>Promoter</td><td>T - 0.21</td></tr><tr><td>NDUFS2</td><td>I</td><td>rs3813623</td><td>G/T</td><td>5′-UTR</td><td>T - 0.15</td></tr><tr><td>NDUFS2</td><td>I</td><td>rs11538340</td><td>C/A</td><td>Coding P20T</td><td>A - 0.06</td></tr><tr><td>NDUFS2</td><td>I</td><td>rs11576415</td><td>C/G</td><td>Coding P352A</td><td>G - 0.09</td></tr><tr><td>NDUFS2</td><td>I</td><td>rs1136224</td><td>A/G</td><td>3′-UTR</td><td>G - 0.17</td></tr><tr><td>UQCRB</td><td>III</td><td>rs7836698</td><td>C/T</td><td>3′-UTR</td><td>T - 0.42</td></tr><tr><td>UQCRB</td><td>III</td><td>rs10504961</td><td>C/T</td><td>3′-UTR</td><td>T - 0.50</td></tr><tr><td>COX5B</td><td>IV</td><td>rs11904110</td><td>T/C</td><td>Promoter</td><td>C – 0.06</td></tr><tr><td>COX6B1</td><td>IV</td><td>rs6510502</td><td>A/C</td><td>Promoter</td><td>C - 0.13</td></tr><tr><td>COX6B1</td><td>IV</td><td>rs10420252</td><td>G/A</td><td>5′-UTR</td><td>A - 0.10</td></tr><tr><td>ATP5C1</td><td>V</td><td>rs11255367</td><td>G/A</td><td>Promoter</td><td>A - 0.12</td></tr><tr><td>ATP5C1</td><td>V</td><td>rs2802460</td><td>T/C</td><td>Promoter</td><td>C - 0.26</td></tr><tr><td>ATP5C1</td><td>V</td><td>rs4655</td><td>T/C</td><td>3′-UTR</td><td>C - 0.36</td></tr><tr><td>GAPDH</td><td> </td><td>rs7971637</td><td>C/T</td><td>Promoter</td><td>T - 0.19</td></tr><tr><td>GAPDH</td><td> </td><td>rs1136666</td><td>C/G</td><td>5′-UTR</td><td>G - 0.26</td></tr><tr><td>HSPD1</td><td> </td><td>rs1116734</td><td>C/G</td><td>Promoter</td><td>G - 0.33</td></tr></table> |
1d478f15f76bfa2fcede7f7ce8cf063b45369af9863df11ca31e24a526914261.png | simple | <table><tr><td>MIGS ID</td><td>Property</td><td>Term</td></tr><tr><td>MIGS-31</td><td>Finishing quality</td><td>Finished</td></tr><tr><td>MIGS-28</td><td>Libraries used</td><td>Three genomic libraries:two Sanger libraries – 8 kb pMCL200 and fosmid pcc1FOSand one 454 pyrosequece standard library</td></tr><tr><td>MIGS-29</td><td>Sequencing platforms</td><td>ABI3730, 454 GS FLX</td></tr><tr><td>MIGS-31.2</td><td>Sequencing coverage</td><td>7.1× Sanger; 1.1× pyrosequence pseudo-reads</td></tr><tr><td>MIGS-30</td><td>Assemblers</td><td>Newbler version 1.1.02.15, phrap</td></tr><tr><td>MIGS-32</td><td>Gene calling method</td><td>Prodigal, GenePRIMP</td></tr><tr><td></td><td>INSDC ID</td><td>CP001874</td></tr><tr><td></td><td>Genbank Date of Release</td><td>May 17, 2010</td></tr><tr><td></td><td>GOLD ID</td><td>Gc01281</td></tr><tr><td></td><td>NCBI project ID</td><td>469371</td></tr><tr><td></td><td>Database: IMG-GEBA</td><td>2501651196</td></tr><tr><td>MIGS-13</td><td>Source material identifier</td><td>DSM 43833</td></tr><tr><td></td><td>Project relevance</td><td>Tree of Life, GEBA</td></tr></table> |
cbcefea2a06965db77a889b2601e7deda3f5c946b06bcea7a3ef6816fa418797.png | simple | <table><tr><td>Plot properties with increasing accelerator</td><td>Mechanistic conclusions</td></tr><tr><td>PAA saturates to 100%</td><td><i>d</i> is before or at <i>j</i></td></tr><tr><td>PAA does not saturate to 100%</td><td><i>d</i> is after <i>j</i></td></tr><tr><td>Saturated PAA less than 100%</td><td>1. Equilibrium constant of antagonist at step <i>d</i> is less than that of agonist at step <i>d</i> and <i>d</i> is after <i>j</i>. Product is mostly derived from steps after <i>d</i>.2. Equilibrium constant of antagonist is greater than agonist and <i>d</i> is after <i>j</i>. Product is mostly derived from steps before <i>d</i>.</td></tr><tr><td>Saturated PAA greater than 100%</td><td>1. Equilibrium constant of antagonist is greater than agonist and <i>d</i> is after <i>j</i>. Product is mostly derived from steps after <i>d</i>.2. Equilibrium constant of antagonist is less than agonist and <i>d</i> is after <i>j</i>. Product is mostly derived from steps before <i>d</i>.</td></tr><tr><td>PAA increases as linear-fractional function to maximum of 100%</td><td>Equilibrium constant of antagonist is less than agonist and <i>d</i> is before or at concentration limiting step (CLS)</td></tr><tr><td>PAA decreases as linear-fractional function to minimum of 100%</td><td>Equilibrium constant of antagonist is greater than agonist and <i>d</i> is before or at CLS</td></tr><tr><td>PAA is not a linear-fractional function</td><td><i>d</i> is after CLS</td></tr><tr><td>PP increases</td><td>Equilibrium constant of antagonist is less than agonist</td></tr><tr><td>PP decreases</td><td>Equilibrium constant of antagonist is greater than agonist</td></tr><tr><td>PAA/PP does not change</td><td><i>d</i> is before or at CLS</td></tr><tr><td>PAA/PP increases</td><td>Equilibrium constant of antagonist is greater than agonist and <i>d</i> is after CLS</td></tr><tr><td>PAA/PP decreases</td><td>Equilibrium constant of antagonist is less than agonist and <i>d</i> is after CLS</td></tr><tr><td>EC<sub>50</sub> of PAA as function of receptor number decreases</td><td><i>d</i> is before or at CLS</td></tr></table> |
0c1d87969be7f778f4bdf3e8dc1f5c3ceeea739f9cd4efa745d14eb313bbe264.png | complex | <table><tr><td>Village HAT status</td><td>Intervention participation</td><td>Cattle sampled (<i>n</i>)</td><td>TBSL + (<i>n</i>)</td><td>% TBSL +</td><td>SRA + (<i>n</i>)</td><td>% SRA +</td><td>TV + (<i>n</i>)</td><td>% TV +</td><td>TC + (<i>n</i>)</td><td>% TC +</td></tr><tr><td rowspan="4">HAT + villages</td><td></td><td>956</td><td>195</td><td>20.4</td><td>12</td><td>1.3</td><td>0</td><td>0</td><td>108</td><td>11.3</td></tr><tr><td>Unknown</td><td>32</td><td>5</td><td>15.6</td><td>0</td><td>0</td><td>0</td><td>0</td><td>3</td><td>9.4</td></tr><tr><td>Intervention</td><td>486</td><td>89</td><td>18.3</td><td>4</td><td>0.8</td><td>0</td><td>0</td><td>56</td><td>11.5</td></tr><tr><td>No intervention</td><td>438</td><td>101</td><td>23.1</td><td>8</td><td>1.8</td><td>0</td><td>0</td><td>49</td><td>11.2</td></tr><tr><td rowspan="4">HAT - villages</td><td></td><td>935</td><td>147</td><td>15.7</td><td>2</td><td>0.2</td><td>1</td><td>0.1</td><td>123</td><td>13.2</td></tr><tr><td>Unknown</td><td>27</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>4</td><td>14.8</td></tr><tr><td>Intervention</td><td>558</td><td>86</td><td>15.4</td><td>1</td><td>0.2</td><td>1</td><td>0.2</td><td>83</td><td>14.9</td></tr><tr><td>No intervention</td><td>350</td><td>61</td><td>17.4</td><td>1</td><td>0.3</td><td>0</td><td>0</td><td>36</td><td>10.3</td></tr></table> |
b59f7d99fe9a926efd3af6baa1cefb42c7ce233ad152db9e1e1b379d3c4230c5.png | simple | <table><tr><td>Variables</td><td>Percentages (%) ± SD</td><td>Normal Range †</td><td>P value</td></tr><tr><td>Total Carbohydrates</td><td>47.8%* ± 1.70</td><td>55 - 65%</td><td>.000</td></tr><tr><td>Total Fat</td><td>35.6%* ± 1.66</td><td>25 - 35%</td><td>.000</td></tr><tr><td>Saturated Fat</td><td>16.5%* ± .84</td><td>7-10%</td><td>.000</td></tr><tr><td>Monounsaturated Fat</td><td>11.1%* ± .46</td><td>5-10%</td><td>.000</td></tr><tr><td>Polyunsaturated Fat</td><td>8.0%* ± .64</td><td>5-7%</td><td>.000</td></tr><tr><td>Total Protein</td><td>16.6%* ± .80</td><td>10 - 15%</td><td>.000</td></tr></table> |
1e3310f5af69cb82d03f31340ebbe281190cb6ed21e1dab9d2c8d3921d1ab77c.png | complex | <table><tr><td rowspan="2">Species</td><td colspan="2">Mondragón-Jacobo et al. [11]</td><td colspan="2">Griffith and Porter [13]</td><td colspan="2">This protocol</td></tr><tr><td>DNA yield (ng/μl)</td><td>OD ratio <sub>260.280</sub></td><td>DNA yield (ng/μl)</td><td>OD ratio <sub>260.280</sub></td><td>DNA yield (ng/μl)</td><td>OD ratio <sub>260.280</sub></td></tr><tr><td>1. <i>Opuntia auberi</i> Pfeiff.</td><td>256</td><td>1.4</td><td>423</td><td>1.7</td><td>1600</td><td>1.9</td></tr><tr><td>2. <i>Opuntia decumbens</i> Salm-Dyck</td><td>35</td><td>1.7</td><td>30</td><td>1.9</td><td>2930</td><td>1.9</td></tr><tr><td>3. <i>Opuntia delafuentiana</i> Martínez-González et al.</td><td>75</td><td>1.6</td><td>56</td><td>1.9</td><td>4937</td><td>1.8</td></tr><tr><td>4. <i>Opuntia depressa</i> Britton and Tose</td><td>95</td><td>1.9</td><td>73</td><td>1.8</td><td>8755</td><td>1.9</td></tr><tr><td>5. <i>Opuntia durangensis</i> Britton and Tose</td><td>134</td><td>1.5</td><td>123</td><td>1.7</td><td>5835</td><td>1.9</td></tr><tr><td>6. <i>Opuntia ficus</i>-<i>indica</i> Mill.</td><td>34</td><td>1.8</td><td>258</td><td>1.8</td><td>3829</td><td>2.0</td></tr><tr><td>7. <i>Opuntia heliabravoana</i> Scheinvar</td><td>198</td><td>1.6</td><td>43</td><td>1.8</td><td>8743</td><td>1.8</td></tr><tr><td>8. <i>Opuntia huajuapensis</i> Bravo</td><td>57</td><td>1.5</td><td>78</td><td>1.7</td><td>1573</td><td>1.9</td></tr><tr><td>9. <i>Opuntia joconostle</i> F.A.C. Weber</td><td>86</td><td>1.9</td><td>196</td><td>1.0</td><td>8375</td><td>1.8</td></tr><tr><td>10. <i>Opuntia lasiacantha</i> Pfeiff.</td><td>67</td><td>1.7</td><td>356</td><td>1.7</td><td>2943</td><td>1.9</td></tr><tr><td>11. <i>Opuntia leiascheinvariana</i> Martínez-González</td><td>110</td><td>1.8</td><td>98</td><td>1.9</td><td>3980</td><td>1.9</td></tr><tr><td>12. <i>Opuntia leucotricha</i> DC.</td><td>248</td><td>1.5</td><td>34</td><td>1.8</td><td>3789</td><td>1.9</td></tr><tr><td>13. <i>Opuntia matudae</i> Scheinvar</td><td>93</td><td>1.7</td><td>63</td><td>1.8</td><td>7947</td><td>1.9</td></tr><tr><td>14. <i>Opuntia megacantha</i> Salm-Dyck</td><td>117</td><td>1.6</td><td>78</td><td>1.8</td><td>7000</td><td>1.8</td></tr><tr><td>15. <i>Opuntia microdasys</i> Pfeiff.</td><td>44</td><td>1.5</td><td>39</td><td>1.7</td><td>6578</td><td>1.9</td></tr><tr><td>16. <i>Opuntia oligacantha</i> Förster</td><td>87</td><td>1.8</td><td>70</td><td>1.9</td><td>2395</td><td>1.8</td></tr><tr><td>17. <i>Opuntia olmeca</i> Joel Pérez et al.</td><td>94</td><td>1.5</td><td>57</td><td>1.7</td><td>9200</td><td>1.9</td></tr></table> |
2e7e4c103a829f9d600519ea25840e75582149b50a026af6429e965d6303a3ab.png | simple | <table><tr><td>Variables</td><td>2009–2010 Pandemic (<i>n</i> = 16)</td><td>2012–2016 Postpandemic (<i>n</i> = 60)</td><td><i>p</i> value</td></tr><tr><td>Male sex</td><td>8 (50)</td><td>42 (70)</td><td>0.15</td></tr><tr><td>Age, years</td><td>43 (32–53)</td><td>60 (50–65)</td><td>< 0.001</td></tr><tr><td>BMI</td><td>29.7 (24.0–36.1)</td><td>27.1 (24.5–32.4)</td><td>0.55</td></tr><tr><td>BMI 30–40</td><td>6 (37)</td><td>13 (22)</td><td></td></tr><tr><td>BMI > 40</td><td>2 (12.5)</td><td>6 (10.2)</td><td>0.4</td></tr><tr><td>Chronic underlying disease</td><td>14 (87.5)</td><td>49 (83)</td><td>0.7</td></tr><tr><td> Cardiovascular</td><td>1 (6.3)</td><td>24 (40)</td><td>0.015</td></tr><tr><td> COPD/asthma</td><td>5 (31,3)</td><td>18 (30.0)</td><td>>0.9</td></tr><tr><td> Diabetes</td><td>6 (37.5)</td><td>9 (15.0)</td><td>0.07</td></tr><tr><td> Malignancy or immuno- suppressive medication<sup>a</sup></td><td>1 (6.3)</td><td>9 (15.0)</td><td>0.7</td></tr><tr><td> Epilepsy or other neurological disease</td><td>6 (37.5)</td><td>5 (8.3)</td><td>0.009</td></tr><tr><td>APACHE II score on admission</td><td>14 (10–17)</td><td>17 (13–22)</td><td>0.002</td></tr><tr><td>SAPS II score on admission</td><td>31 (25–35)</td><td>40 (31–51)</td><td>0.002</td></tr><tr><td>SOFA score on admission</td><td>5 (3–7)</td><td>6 (3–9)</td><td>0.31</td></tr><tr><td>SOFA score max</td><td>5 (4–9)</td><td>9 (5–12)</td><td>0.03</td></tr><tr><td>TISS score</td><td>34 (28–42)</td><td>39 (28–53)</td><td>0.40</td></tr><tr><td>LOS in ICU, days</td><td>1.9 (1.1–4.8)</td><td>4.3 (2.3–10.7)</td><td>0.31</td></tr><tr><td>LOS in hospital, days</td><td>8.2 (4.6–10)</td><td>13.0 (6.9–23.3)</td><td>0.009</td></tr><tr><td>ICU mortality</td><td>0</td><td>6 (10)</td><td>0.33</td></tr><tr><td>Hospital mortality</td><td>0</td><td>10 (16.7)</td><td>0.11</td></tr><tr><td>6-month mortality</td><td>2 (12.5)</td><td>15 (25)</td><td>0.5</td></tr></table> |
b91e8ed59bbf85d60f24f1e161fcafc0e24c8c58adfa369d41820bee2fc08612.png | simple | <table><tr><td>OverallAge range</td><td>Transported patients/population</td><td>Transport rate(per 1000/year)</td><td>Rate ratio (95% CI)</td></tr><tr><td>85–99</td><td>59 570/237 873</td><td>250</td><td>reference</td></tr><tr><td>65–84</td><td>185 871/2 055 439</td><td>90</td><td>2.78 (2.17–3.58)</td></tr><tr><td>45–64</td><td>135 135/3 258 801</td><td>41</td><td>6.10 (4.37–8.70)</td></tr><tr><td>25–44</td><td>147 928/4 014 081</td><td>37</td><td>6.76 (4.77–9.82)</td></tr><tr><td>5–24</td><td>114 260/2 847 377</td><td>40</td><td>6.25 (4.46–8.96)</td></tr><tr><td>0–4</td><td>29 807/476 692</td><td>63</td><td>3.97 (3.00–5.32)</td></tr><tr><td>MalesAge range</td><td>Transported patients/population</td><td>Transport rate(per 1000/year)</td><td>Rate ratio (95% CI)</td></tr><tr><td>85–99</td><td>21 151/72 432</td><td>292</td><td>reference</td></tr><tr><td>65–84</td><td>95 700/918 229</td><td>104</td><td>2.81 (2.24–3.55)</td></tr><tr><td>45–64</td><td>84 491/1 641 695</td><td>51</td><td>5.73 (4.24–7.87)</td></tr><tr><td>25–44</td><td>79 809/2 071 599</td><td>39</td><td>7.49 (5.35–10.75)</td></tr><tr><td>5–24</td><td>62 777/1 467 004</td><td>43</td><td>6.79 (4.92–9.58)</td></tr><tr><td>0–4</td><td>16 889/243 648</td><td>69</td><td>4.23 (3.25–5.58)</td></tr><tr><td>FemalesAge range</td><td>Transported patients/population</td><td>Transport rate(per 1000/year)</td><td>Rate ratio (95% CI)</td></tr><tr><td>85–99</td><td>38 419/165 441</td><td>232</td><td>reference</td></tr><tr><td>65–84</td><td>90 171/1 137 210</td><td>79</td><td>2.94 (2.27–3.84)</td></tr><tr><td>45–64</td><td>50 644/1 617 106</td><td>31</td><td>7.48 (5.13–11.27)</td></tr><tr><td>25–44</td><td>68 119/1 942 482</td><td>35</td><td>6.63 (4.63–9.75)</td></tr><tr><td>5–24</td><td>51 483/1 380 373</td><td>37</td><td>6.27 (4.42–9.13)</td></tr><tr><td>0–4</td><td>12 918/233 044</td><td>55</td><td>4.22 (3.13–5.77)</td></tr></table> |
3273caa1cb3cd550d3f8aafddbf5cd13f1653a91c77ce8f74be7595606650341.png | simple | <table><tr><td></td><td>Women of reproductive age (20–49 years)</td><td>Men (20–59 years)</td><td>Adolescent girls (15–19 years)</td><td>Adolescent boys (15–19 years)</td><td>Caregivers/family members</td><td>Total</td></tr><tr><td>Kenya</td><td>41</td><td>23</td><td>20</td><td>11</td><td>17</td><td>112</td></tr><tr><td>Nepal</td><td>40</td><td>29</td><td>10</td><td>10</td><td>15</td><td>104</td></tr><tr><td>Uganda</td><td>50</td><td>17</td><td>24</td><td>12</td><td>33</td><td>136</td></tr><tr><td>Total</td><td>131</td><td>69</td><td>54</td><td>33</td><td>65</td><td>352</td></tr></table> |
f366d85031f859fae3b0c8673e40aafdf475da2e4a04bf33380b844ecbbff832.png | complex | <table><tr><td>Study</td><td>Penetration</td><td>Genital contact</td><td>Exposure of genitals to child</td><td>Attempted penetration</td><td>Exploitation: prostitution or pornography</td></tr><tr><td colspan="6">TYPE OF ABUSE</td></tr><tr><td>NIS-1</td><td>0.3/1,000</td><td>0.2/1,000</td><td>0.1/1,000</td></tr><tr><td>NIS-2</td><td>0.8/1,000</td><td>0.9/1,000</td><td>0.5/1,000</td></tr><tr><td>CIS-1998</td><td>0.29/1,000</td><td>0.82/1,000</td><td>0.21/1,000</td><td>0.29/1,000</td><td>0.1/1,000</td></tr><tr><td>Finkelhor et al. (2005)</td><td>4/1,000</td><td>32/1,000</td><td>4/1,000</td><td>18/1,000</td><td></td></tr></table> |
9d5bcaa81496e68ff6d16509681ba3b6ae977a8053434c929991aa99c0bcc706.png | simple | <table><tr><td>Tissue</td><td>Number of Genes</td><td>Number of <i>Z</i>+</td><td>Number of <i>Z</i>-</td><td>AVG (Number of <i>Z</i>+ with H3K4me3)</td><td>Number of Expected <i>Z</i>+</td><td>AVG (Number of <i>Z</i>− with H3K4me3)</td><td>Number of Expected <i>Z</i>-</td><td><i>χ</i><sup>2</sup><i>P</i>-Value</td></tr><tr><td>Astrocytes-cerebellar</td><td>12,418</td><td>5,923</td><td>6,495</td><td>5,108</td><td>4,812.38</td><td>4,981.5</td><td>5,277.12</td><td>3.806E−09</td></tr><tr><td>Cardiac fibroblasts</td><td>12,098</td><td>5,605</td><td>6,493</td><td>4,702</td><td>4,548.21</td><td>5,115</td><td>5,268.78</td><td>0.00185</td></tr><tr><td>Cardiac myocytes</td><td>12,098</td><td>5,605</td><td>6,493</td><td>4,920.5</td><td>4,759.71</td><td>5,353</td><td>5,513.79</td><td>0.00146</td></tr></table> |
2866236e264526013aac84521d67b8df237dd77a531a8f576bdcf83c4c32d0c8.png | complex | <table><tr><td>Nuclei/field</td><td colspan="2">Central retina</td><td colspan="2">Paracentral retina</td><td colspan="2">Peripheral retina</td></tr><tr><td></td><td>Control</td><td>Scrapie</td><td>Control</td><td>Scrapie</td><td>Control</td><td>Scrapie</td></tr><tr><td>Outer nuclearlayer</td><td>5.9 ± 0.7</td><td>4.7 ± 1.1**</td><td>5.8 ± 0.6</td><td>4.9 ± 0.8*</td><td>5.3 ± 0.9</td><td>5.1 ± 1.5</td></tr><tr><td>Inner nuclearlayer</td><td>1.5 ± 0.2</td><td>1.0 ± 0.2**</td><td>1.4 ± 0.2</td><td>1.0 ± 0.2*</td><td>1.5 ± 0.2</td><td>1.3 ± 0.4</td></tr></table> |
4304e4d2671d37bc761e8488704ae7c72c539ed52181989a1d74e5c71be8c1ee.png | simple | <table><tr><td>Ref nr</td><td>Authors</td><td>Title</td><td>Journal</td><td>Year of publ</td></tr><tr><td>31</td><td>A.Ekström, A.Matthiesen, A.Widström, E.Nissen</td><td>Breastfeeding attitudes among counselling health professionals. Development of an instrument to describe breastfeeding attitudes.</td><td>Scandinavian Journal of Public Health, 33(5), 353–359.</td><td>2005</td></tr><tr><td>22</td><td>A.Ekström, A.Matthiesen, A.Widström, E.Nissen</td><td>Process-oriented Training in Breastfeeding Alters Attitudes to Breastfeeding in Health Professionals.</td><td>Scand. J of Public Health, 33(6), 424–431.</td><td>2005</td></tr><tr><td>28</td><td>A.Ekström, A.Matthiesen, A.Widström, E.Nissen</td><td>Does Continuity of Care by Well‐Trained Breastfeeding Counselors Improve a Mother’s Perception of Support?</td><td>Birth, 33(2), 123-130</td><td>2006</td></tr><tr><td>15</td><td>A.Ekström, E.Nissen</td><td>A mothers’s feelings for her baby are strenghten by excellent breastfeeding counseling and continuity of care.</td><td>Peadiatrics, 118(2), e309-e314.</td><td>2006</td></tr><tr><td>27</td><td>A.Ekström, E.Nissen</td><td>Process-Oriented Training in Breastfeeding Attitudes and Continuity of Care Improve Mothers Perception of Support.</td><td>Health Education Research Trends. Nova Publishers. NY.</td><td>2007</td></tr><tr><td>25</td><td>A.Ekström, K.Guttke, M.Lenz, E.Hertfelt Wahn</td><td>Long term effects of professional breastfeeding support - An intervention.</td><td>International Journal of Nursing and Midwifery, Vol. 3(8), pp. 109–117.</td><td>2011</td></tr><tr><td>26</td><td>A.Ekström, E.Kylberg E.Nissen,</td><td>A process-oriented breastfeeding training for health professionals to promote breastfeeding.</td><td>Breastfeeding Medicine. 7(2), 85–92.</td><td>2012</td></tr><tr><td>17</td><td>S.Thorstensson, E.Nissen, A.Ekström</td><td>Professional support in pregnancy influence maternal relation to and feelings for the baby after Cesarean birth; an intervention study.</td><td>Journal of Nursing & Care 1:112.</td><td>2012</td></tr><tr><td>23</td><td>I.Blixt, L.B.Mårtensson, A.Ekström</td><td>Process-oriented training in breast feeding for health professionals decreases breastfeeding challenges.</td><td>International Breastfeeding Journal, 9:15</td><td>2014</td></tr><tr><td>24</td><td>A.Ekström, H.Abrahamsson, R-M.Eriksson L.B.Mårtensson,</td><td>Women’s use of nipple shields - its influences on breastfeeding duration after a process oriented education for health professionals.</td><td>Breastfeeding Medicine, 9(9), 458-466</td><td>2014</td></tr></table> |
32dbbe20a8c9627c3bd0b1ba3b884a1ae6031d87b8522f90dabb218532bfd95f.png | complex | <table><tr><td></td><td>2003</td><td>2009</td><td>2010</td><td>2012</td><td><i>p</i>-trend</td></tr><tr><td colspan="6">Total:</td></tr><tr><td colspan="6"> PD<sup>a</sup> (95% CI)</td></tr><tr><td>Low education</td><td>23.1 (19.4–26.9)</td><td>26.9 (24.4–29.4)</td><td>28.3 (25.9–30.8)</td><td>32.2 (29.0–35.5)</td><td><0.001</td></tr><tr><td>Medium education</td><td>12.5 (9.2–15.8)</td><td>12.8 (10.9–14.7)</td><td>13.7 (11.9–15.5)</td><td>14.4 (12.5–16.4)</td><td>0.225</td></tr><tr><td>High education (ref.)</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td></td></tr><tr><td> SII<sup>b</sup> (95% CI)</td><td>0.30 (0.25–0.35)</td><td>0.34 (0.31–0.38)</td><td>0.38 (0.34–0.41)</td><td>0.41 (0.37–0.45)</td><td>0.001</td></tr><tr><td colspan="6">Men:</td></tr><tr><td colspan="6"> PD<sup>a</sup> (95% CI)</td></tr><tr><td>Low education</td><td>22.9 (17.9–28.0)</td><td>26.4 (22.8–30.1)</td><td>29.0 (25.4–32.5)</td><td>33.6 (29.3–37.9)</td><td>0.001</td></tr><tr><td>Medium education</td><td>15.6 (10.9–20.3)</td><td>15.1 (12.1–18.1)</td><td>17.6 (14.8–20.5)</td><td>17.8 (15.0–20.6)</td><td>0.299</td></tr><tr><td>High education (ref.)</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td></td></tr><tr><td> SII<sup>c</sup> (95% CI)</td><td>0.30 (0.23–0.38)</td><td>0.36 (0.30–0.41)</td><td>0.39 (0.34–0.44)</td><td>0.44 (0.39–0.49)</td><td>0.004</td></tr><tr><td colspan="6">Women:</td></tr><tr><td colspan="6"> PD<sup>a</sup> (95% CI)</td></tr><tr><td>Low education</td><td>23.2 (17.5–28.9)</td><td>27.3 (23.8–30.8)</td><td>27.7 (24.3–31.1)</td><td>30.7 (25.8–35.6)</td><td>0.041</td></tr><tr><td>Medium education</td><td>10.3 (5.4–15.1)</td><td>11.6 (9.1–14.0)</td><td>11.2 (8.9–13.6)</td><td>11.4 (8.7–14.2)</td><td>0.637</td></tr><tr><td>High education (ref.)</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td></td></tr><tr><td> SII<sup>c</sup> (95% CI)</td><td>0.29 (0.22–0.37)</td><td>0.33 (0.29–0.38)</td><td>0.36 (0.32–0.41)</td><td>0.37 (0.32–0.43)</td><td>0.077</td></tr></table> |
c05ee35aa037a119596fe6b73c15ae585f586d58a8a63f8e07bcfbed31acf0d8.png | complex | <table><tr><td>Parameter</td><td>Total (<i>n</i> = 273)<i>N</i> (%)</td><td>Recurrence (<i>n</i> = 81)</td><td>Non-recurrence (<i>n</i> = 192)</td><td><i>P</i>Re versus non-re</td></tr><tr><td>Age (years)</td><td>19.8 ± 3.5</td><td>19.4 ± 4.3</td><td>20.1 ± 4.6</td><td>0.242</td></tr><tr><td>Male, <i>n</i> (%)</td><td>221 (81.0%)</td><td>63 (28.5%)</td><td>158 (71.5%)</td><td>0.386</td></tr><tr><td>Height (cm)</td><td>173.6 ± 4.7</td><td>174.3 ± 4.1</td><td>173.0 ± 4.5</td><td>0.026</td></tr><tr><td>Weight (kg)</td><td></td><td></td><td></td><td></td></tr><tr><td>BMI (kg/m<sup>2</sup>), <i>n</i> (%)</td><td>59.2 ± 7.3</td><td>57.1 ± 5.0</td><td>62.2 ± 6.9</td><td><0.001</td></tr><tr><td> Underweight</td><td>75 (27.5%)</td><td>46 (61.3%)</td><td>29 (38.7%)</td><td></td></tr><tr><td> Normal</td><td>192 (70.3%)</td><td>34 (17.7%)</td><td>158 (82.3%)</td><td></td></tr><tr><td> Overweight</td><td>6 (2.2%)</td><td>1 (16.7%)</td><td>5 (83.3%)</td><td></td></tr><tr><td> Obese</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td><td></td></tr><tr><td>Smoking history, <i>n</i> (%)</td><td></td><td></td><td></td><td>0.850</td></tr><tr><td> Yes</td><td>19 (7.0%)</td><td>6 (31.6%)</td><td>13 (68.4%)</td><td></td></tr><tr><td> No</td><td>254 (93.0%)</td><td>75 (29.5%)</td><td>179 (70.5%)</td><td></td></tr><tr><td>Location of pneumothorax, <i>n</i> (%)</td><td></td><td></td><td></td><td>0.490</td></tr><tr><td> Right</td><td>145 (53.1%)</td><td>39 (26.9%)</td><td>106 (73.1%)</td><td></td></tr><tr><td> Left</td><td>126 (46.2%)</td><td>41 (32.5%)</td><td>85 (67.5%)</td><td></td></tr><tr><td> Bilateral</td><td>2 (0.7%)</td><td>1 (50%)</td><td>1 (50%)</td><td></td></tr><tr><td>Size of pneumothorax, <i>n</i> (%)</td><td></td><td></td><td></td><td>0.002</td></tr><tr><td> <50</td><td>171 (62.6%)</td><td>27 (33.3%)</td><td>137 (71.4%)</td><td></td></tr><tr><td> ≥50</td><td>102 (37.4%)</td><td>54 (52.9%)</td><td>48 (47.1%)</td><td></td></tr><tr><td>Treatment, <i>n</i> (%)</td><td></td><td></td><td></td><td><0.001</td></tr><tr><td> Non-surgery</td><td>97 (35.5%)</td><td>57 (58.8%)</td><td>40 (41.2%)</td><td></td></tr><tr><td> Surgery</td><td>176 (64.5%)</td><td>24 (13.6%)</td><td>152 (86.4%)</td><td></td></tr><tr><td colspan="5">Overall recurrence rate (year)</td></tr><tr><td> 1</td><td>57 (20.9%)</td><td>–</td><td>–</td><td>–</td></tr><tr><td> 2</td><td>65 (23.8%)</td><td>–</td><td>–</td><td>–</td></tr><tr><td> 5</td><td>81 (28.7%)</td><td>–</td><td>–</td><td>–</td></tr></table> |
9b4a98bebb2581f9ac322e5f2f8f595b61382cbb3aa13700ec5b7a7cd8b7deee.png | simple | <table><tr><td>Two-stage period</td><td>Possible counts</td><td>Percentages</td></tr><tr><td>Blastula-early gastrula</td><td>(0:0:0)</td><td>(0:0:0)</td></tr><tr><td>Early gastrula-mid gastrula</td><td>(4:2:0)</td><td>(67:33:0)</td></tr><tr><td>Mid gastrula-late gastrula</td><td>(5:1:0)</td><td>(83:17:0)</td></tr><tr><td>Late gastrula-early planula</td><td>(6:1:0)</td><td>(86:14:0)</td></tr><tr><td>Early planula-planula</td><td>(5:1:0)</td><td>(83:17:0)</td></tr><tr><td>Planula-late planula</td><td>(2:1:0)</td><td>(67:33:0)</td></tr></table> |
263f0e456100ee8b0286451f0fcce732f5ca91cabd32e1c3232b73db49a8b5a4.png | simple | <table><tr><td>GeneID</td><td>Protein description</td><td>Pathway</td><td>Fold change for transcripts</td><td>Fold change for proteins</td></tr><tr><td>Entcl_0332</td><td>Phosphoenolpyruvate carboxykinase (ATP) (complement(365954..367573))</td><td>Citrate cycle (TCA cycle)</td><td>2.670</td><td>3.102</td></tr><tr><td>Entcl_3179</td><td>UspA domain-containing protein (3394773..3395201)</td><td>None given</td><td>3.080</td><td>2.953</td></tr><tr><td>Entcl_4175</td><td>Periplasmic binding protein/LacI transcriptional regulator (complement(4503494..4504456))</td><td>ABC transporters</td><td>2.170</td><td>2.796</td></tr><tr><td>Entcl_3779</td><td>Carbon starvation protein CstA (4066791..4068944)</td><td>None given</td><td>2.670</td><td>2.701</td></tr><tr><td>Entcl_1304</td><td>Malic protein NAD-binding (1376647..1378926)</td><td>Pyruvate metabolism</td><td>3.770</td><td>2.490</td></tr><tr><td>Entcl_0617</td><td>AI-2 transport system substrate-binding protein (642484..643485)</td><td>ABC transporters</td><td>3.180</td><td>1.780</td></tr><tr><td>Entcl_4402</td><td>Periplasmic binding protein/LacI transcriptional regulator (complement(4764359..4765249))</td><td>ABC transporters</td><td>2.020</td><td>1.704</td></tr><tr><td>Entcl_1207</td><td>ABC transporter, substrate-binding protein (complement(1260320..1261303))</td><td>ABC transporters</td><td>2.380</td><td>1.564</td></tr><tr><td>Entcl_2658</td><td>Isocitrate dehydrogenase, NADP-dependent (complement(2808830..2810080))</td><td>Glutathione metabolism</td><td>2.010</td><td>1.091</td></tr><tr><td>Entcl_0176</td><td>D-xylose ABC transporter, periplasmic substrate-binding protein (complement(183475..184470))</td><td>ABC transporters</td><td>2.410</td><td>1.035</td></tr><tr><td>Entcl_3614</td><td>2-oxo-acid dehydrogenase E1 subunit, homodimeric type (complement(3877006..3879669))</td><td>Glycolysis/Gluconeogenesis</td><td>2.500</td><td>−0.229</td></tr><tr><td>Entcl_1941</td><td>Phosphoribosylglycinamide formyltransferase 2 (complement(2053388..2054566))</td><td>Purine metabolism</td><td>−2.080</td><td>−0.779</td></tr><tr><td>Entcl_1559</td><td>Cytidine deaminase (complement(1657176..1658060))</td><td>Pyrimidine metabolism</td><td>−3.710</td><td>−1.169</td></tr><tr><td>Entcl_0641</td><td>Cys/Met metabolism pyridoxal-phosphate-dependent protein (complement(670311..671459))</td><td>None given</td><td>−2.000</td><td>−1.757</td></tr><tr><td>Entcl_3443</td><td>Taurine dioxygenase (complement(3672816..3673664))</td><td>Taurine and hypotaurine metabolism</td><td>−14.850</td><td>−2.995</td></tr></table> |
18f2a6501116f5819b788f02e7d22d0e669ed06de638af2b3bd7f429600c89e8.png | complex | <table><tr><td></td><td>Original = cardio-vascular</td><td>Oncology</td><td>Psychiatric</td><td>Anti-viral</td><td>Anti-bacterial/fungal</td><td>Monogenetic orphans</td></tr><tr><td colspan="7"><i>Aspect</i></td></tr><tr><td colspan="7">Starting evidence</td></tr><tr><td>In vitro data including animal genetics</td><td>2</td><td>2</td><td>1</td><td><i>9</i></td><td>3</td><td>2</td></tr><tr><td>In vivo data including animal genetics</td><td>3</td><td><i>1</i></td><td><i>1</i></td><td><i>1</i></td><td><i>5</i></td><td>2</td></tr><tr><td>Animal disease models</td><td>3</td><td><i>5</i></td><td><i>1</i></td><td><i>1</i></td><td><i>5</i></td><td>2</td></tr><tr><td>Data from multiple species</td><td>3</td><td><i>1</i></td><td><i>1</i></td><td><i>1</i></td><td><i>1</i></td><td>2</td></tr><tr><td colspan="7">Human evidence</td></tr><tr><td>Genetics</td><td>5</td><td>5</td><td>4</td><td>4</td><td>4</td><td><i>20</i></td></tr><tr><td>Model compounds</td><td>13</td><td><i>10</i></td><td><i>26</i></td><td>12</td><td>12</td><td><i>2</i></td></tr><tr><td>Clinical trials</td><td>13</td><td><i>11</i></td><td><i>26</i></td><td>12</td><td>12</td><td><i>10</i></td></tr><tr><td colspan="7">Biomarkers for efficacy and safety prediction</td></tr><tr><td>Biomarker grading</td><td>24</td><td><i>28</i></td><td><i>10</i></td><td>23</td><td><i>22</i></td><td>23</td></tr><tr><td>Biomarker development</td><td>13</td><td><i>17</i></td><td><i>5</i></td><td>12</td><td><i>11</i></td><td>12</td></tr><tr><td colspan="7">Proof-of-mechanism, proof-of-principle and proof of concept testing</td></tr><tr><td>Biomarker strategy</td><td>5</td><td>5</td><td><i>7</i></td><td>5</td><td>5</td><td>5</td></tr><tr><td>Surrogate or endpoint strategy</td><td>8</td><td><i>2</i></td><td><i>12</i></td><td>7</td><td>7</td><td>7</td></tr><tr><td colspan="7">Personalized medicine aspects</td></tr><tr><td>Disease sub-classification and responder concentration</td><td>3</td><td><i>7</i></td><td>2</td><td><i>9</i></td><td><i>9</i></td><td><i>9</i></td></tr><tr><td>Pharmacogenetics</td><td>5</td><td>6</td><td>4</td><td>4</td><td>4</td><td>4</td></tr><tr><td><i>Sum</i></td><td>100</td><td>100</td><td>100</td><td>100</td><td>100</td><td>100</td></tr></table> |
ddb21eeed8390e2c800c826f9066221a9ea72291ac2faeaf75a53c187ab1c55b.png | complex | <table><tr><td rowspan="3">Treatment</td><td colspan="6">Dry leaf yield (t ha<sup>−1</sup>)</td><td colspan="6">Dry stem yield (t ha<sup>−1</sup>)</td><td colspan="6">Harvest Index (HI)</td></tr><tr><td colspan="2">CSIR-IHBT</td><td colspan="2">RHRS</td><td colspan="2">PAU</td><td colspan="2">CSIR-IHBT</td><td colspan="2">RHRS</td><td colspan="2">PAU</td><td colspan="2">CSIR-IHBT</td><td colspan="2">RHRS</td><td colspan="2">PAU</td></tr><tr><td>2010</td><td>2011</td><td>2010</td><td>2011</td><td>2010</td><td>2011</td><td>2010</td><td>2011</td><td>2010</td><td>2011</td><td>2010</td><td>2011</td><td>2010</td><td>2011</td><td>2010</td><td>2011</td><td>2010</td><td>2011</td></tr><tr><td>Nitrogen Level</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>N<sub>30</sub></td><td>1.24</td><td>1.34</td><td>0.79</td><td>0.91</td><td>0.39</td><td>0.6</td><td>1.83</td><td>1.99</td><td>1.42</td><td>1.43</td><td>0.78</td><td>1.19</td><td>0.41</td><td>0.42</td><td>0.36</td><td>0.39</td><td>0.34</td><td>0.33</td></tr><tr><td>N<sub>60</sub></td><td>1.56</td><td>1.69</td><td>0.93</td><td>1.04</td><td>0.52</td><td>0.81</td><td>2.19</td><td>2.48</td><td>1.47</td><td>1.56</td><td>0.76</td><td>1.47</td><td>0.42</td><td>0.41</td><td>0.39</td><td>0.4</td><td>0.4</td><td>0.35</td></tr><tr><td>N<sub>90</sub></td><td>1.69</td><td>1.91</td><td>1.03</td><td>1.19</td><td>0.53</td><td>0.83</td><td>2.35</td><td>2.65</td><td>1.56</td><td>1.69</td><td>0.74</td><td>1.53</td><td>0.42</td><td>0.42</td><td>0.39</td><td>0.41</td><td>0.41</td><td>0.35</td></tr><tr><td>SEm(±)</td><td>0.04</td><td>0.03</td><td>0.03</td><td>0.02</td><td>0.02</td><td>0.04</td><td>0.04</td><td>0.05</td><td>0.03</td><td>0.03</td><td>0.03</td><td>0.08</td><td>0.007</td><td>0.004</td><td>0.009</td><td>0.007</td><td>0.007</td><td>0.011</td></tr><tr><td>CD(P = 0.05)</td><td>0.10</td><td>0.09</td><td>0.08</td><td>0.06</td><td>0.05</td><td>0.13</td><td>0.12</td><td>0.14</td><td>0.08</td><td>0.08</td><td>NS</td><td>0.22</td><td>NS</td><td>NS</td><td>0.025</td><td>NS</td><td>0.021</td><td>NS</td></tr><tr><td>Phosphorus Level</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>P<sub>20</sub></td><td>1.44</td><td>1.55</td><td>0.87</td><td>1.01</td><td>0.47</td><td>0.68</td><td>1.94</td><td>2.22</td><td>1.48</td><td>1.55</td><td>0.73</td><td>1.35</td><td>0.42</td><td>0.41</td><td>0.37</td><td>0.39</td><td>0.39</td><td>0.34</td></tr><tr><td>P<sub>40</sub></td><td>1.55</td><td>1.74</td><td>0.98</td><td>1.08</td><td>0.48</td><td>0.8</td><td>2.3</td><td>2.52</td><td>1.49</td><td>1.56</td><td>0.79</td><td>1.45</td><td>0.4</td><td>0.41</td><td>0.39</td><td>0.41</td><td>0.38</td><td>0.35</td></tr><tr><td>SEm (±)</td><td>0.03</td><td>0.03</td><td>0.02</td><td>0.02</td><td>0.01</td><td>0.04</td><td>0.03</td><td>0.04</td><td>0.02</td><td>0.02</td><td>0.03</td><td>0.06</td><td>0.006</td><td>0.003</td><td>0.007</td><td>0.006</td><td>0.006</td><td>0.009</td></tr><tr><td>CD(P = 0.05)</td><td>0.08</td><td>0.07</td><td>0.06</td><td>0.05</td><td>NS</td><td>0.11</td><td>0.10</td><td>0.12</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>0.016</td><td>NS</td><td>0.020</td><td>0.016</td><td>NS</td><td>NS</td></tr><tr><td>Potassium Level</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>K<sub>20</sub></td><td>1.38</td><td>1.51</td><td>0.84</td><td>0.99</td><td>0.47</td><td>0.74</td><td>1.91</td><td>2.20</td><td>1.49</td><td>1.53</td><td>0.75</td><td>1.31</td><td>0.41</td><td>0.41</td><td>0.37</td><td>0.39</td><td>0.38</td><td>0.36</td></tr><tr><td>K<sub>40</sub></td><td>1.62</td><td>1.74</td><td>0.98</td><td>1.08</td><td>0.49</td><td>0.76</td><td>2.11</td><td>2.44</td><td>1.52</td><td>1.59</td><td>0.77</td><td>1.48</td><td>0.43</td><td>0.42</td><td>0.39</td><td>0.4</td><td>0.38</td><td>0.34</td></tr><tr><td>K<sub>60</sub></td><td>1.50</td><td>1.69</td><td>0.95</td><td>1.07</td><td>0.49</td><td>0.73</td><td>2.34</td><td>2.48</td><td>1.54</td><td>1.56</td><td>0.76</td><td>1.41</td><td>0.39</td><td>0.41</td><td>0.38</td><td>0.4</td><td>0.39</td><td>0.34</td></tr><tr><td>SEm (±)</td><td>0.04</td><td>0.03</td><td>0.03</td><td>0.02</td><td>0.02</td><td>0.04</td><td>0.04</td><td>0.05</td><td>0.03</td><td>0.03</td><td>0.03</td><td>0.08</td><td>0.007</td><td>0.004</td><td>0.009</td><td>0.007</td><td>0.007</td><td>0.011</td></tr><tr><td>CD(P = 0.05)</td><td>0.10</td><td>0.09</td><td>0.08</td><td>0.06</td><td>NS</td><td>NS</td><td>0.12</td><td>0.14</td><td>0.08</td><td>NS</td><td>NS</td><td>NS</td><td>0.02</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td></tr><tr><td>Interaction effect</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>CD of N × P</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>0.16</td><td>0.20</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td></tr><tr><td>CD of N × K</td><td>0.18</td><td>0.16</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>0.20</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>0.04</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td></tr><tr><td>CD of P × K</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>0.16</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>0.03</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td></tr><tr><td>CD of N × P × K</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td><td>NS</td></tr></table> |
1635a3d9d3e782c3d2c1a7f1d34c9114c6798e1d673d0480852550ab0c37cbc2.png | simple | <table><tr><td>Authors, year of publication</td><td>Samples</td><td><i>PIK3CA</i> mutations</td><td>Ref.</td></tr><tr><td>Campbell <i>et al.</i>, 2004</td><td>167 primary epithelial ovarian carcinomas, of which, 40 were samples of EnOC and OCCC and 88 were samples of serous ovarian carcinomas (all coding exons of <i>PIK3CA</i> analyzed)</td><td><i>PIK3CA</i> mutations in 8 (20%) of 40 EnOC and OCCC compared to only 2 (2.3%) of 88 in serous ovarian carcinomas (<i>p</i> = 0.001); mutation or gene amplification of <i>PIK3CA</i> was found in a total of 45% of OCCC and EnOC</td><td>[135]</td></tr><tr><td>Wang <i>et al.</i>, 2005</td><td>109 advanced ovarian carcinomas, including <i>inter alia</i> 2 OCCC and 5 EnOC, as well as 90 serous and 4 mucinous ovarian carcinomas (<i>PIK3CA</i> exon 9 and 20 analyzed)</td><td>A total of 4 activating missense <i>PIK3CA</i> mutations in 109 tumors were found (in 1 of 2 OCCC, 1 mucinous and 2 serous ovarian carcinomas)</td><td>[136]</td></tr><tr><td>Levine <i>et al.</i>, 2005</td><td>198 unselected invasive epithelial ovarian carcinomas (exon 9 and 20 analyzed)</td><td><i>PIK3CA</i> mutations in 24 of 198 (12%) ovarian carcinomas (not significantly different between different histological subtypes)</td><td>[137]</td></tr><tr><td>Willner <i>et al.</i>, 2007</td><td>12 OCCC, 26 EnOC and 51 serous ovarian carcinomas</td><td>Mutations in 3 of 12 (25%) OCCC, in 3 of 26 (12%) EnOC, but in none of 51 serous ovarian carcinomas<i>PIK3CA</i> gene amplification found in 0/22 EnOC and OCCC compared to 19/94 (20%) in SC</td><td>[138]</td></tr><tr><td>Kuo <i>et al.</i>, 2009</td><td>97 OCCC (18 OCCC with affinity-purified tumor cells from fresh specimen, 69 microdissected tumors from paraffin tissues, 10 tumor cell lines)</td><td><i>PIK3CA</i> mutations in 33% of the 97 OCCC (46% of the 28 affinity-purified OCCC and OCCC cell lines)</td><td>[129]</td></tr><tr><td>Jones <i>et al.</i>, 2010</td><td>Whole exome sequencing in 8 OCCC samples and validation in 42 OCCC (including the 8 tumor samples of the discovery cohort) by Sanger sequencing of all exon</td><td>Mutations of <i>PIK3CA</i> in 40% of the 42 tumors (a total of 17 mutations), the majority at codons 542, 545, 546 or 1,047</td><td>[2]</td></tr><tr><td>Yamamoto <i>et al.</i>, 2011</td><td>23 OCCC (sequencing of <i>PIK3CA</i> exons 9 and 20)</td><td><i>PIK3CA</i> mutations in 10 (43%) of 23 OCCC (H1047R mutations in the kinase domain in all cases)</td><td>[134]</td></tr><tr><td>Yamamoto <i>et al.</i>, 2012</td><td>42 OCCC (28 endometriosis-associated cases and 14 clear-cell adenofibroma-associated carcinoma cases (sequencing of exons 9 and 20)</td><td>17 (40%) of the 42 OCCC harboring <i>PIK3CA</i> mutations (majority of them ARID1A-deficient carcinomas (71%), suggesting frequent co-occurrence of mutations in these two genes</td><td>[101]</td></tr><tr><td>Yamamoto <i>et al.</i>, 2012</td><td>90 cases of OCCC (including 42 cases previously examined in [101]; sequencing of <i>PIK3CA</i> exons 9 and 20)</td><td><i>PIK3CA</i> mutations found in 34 (39%) of 88 informative OCCC cases</td><td>[102]</td></tr><tr><td>Rahman <i>et al.</i>, 2012</td><td>Mutational analysis of <i>PIK3CA</i> (exons 1, 9, 20) and immunohistochemistry for phospho-AKT and -mTOR in 56 OCCC samples13 ovarian carcinoma cell lines (4 serous, 9 clear cell) for <i>in vitro</i> inhibitor studies</td><td>Missense mutations in 16 (28.6%) of 56 OCCC tumor samplesNo correlation of <i>PIK3CA</i> mutations with the immunohistochemical pattern of phosphorylated AKT or mTORNo correlation of <i>PIK3CA</i> mutations with sensitivity to PI3K/AKT/mTOR inhibitors in OCCC cell lines</td><td>[139]</td></tr><tr><td>McConechy <i>et al.</i>, 2013</td><td>Select exon capture sequencing in 33 EnOC samples in addition to 307 endometrial endometrioid carcinomas</td><td>12 (40%) of 30 EnOC mutated in <i>PIK3CA</i>. 107 (39%) of 307 low-grade endometrial endometrioid carcinomas mutated in <i>PIK3CA</i></td><td>[140]</td></tr></table> |
e4fd1e03b46eed5ccccf0d746e0420e99d7b312fbe1856bb3532948becbb12a7.png | complex | <table><tr><td></td><td colspan="2">NLR</td><td colspan="2">PLR</td><td colspan="2">RDW</td><td colspan="2">SCC-Ag</td></tr><tr><td>Stage</td><td>AUC</td><td><i>P</i> value</td><td>AUC</td><td><i>P</i> value</td><td>AUC</td><td><i>P</i> value</td><td>AUC</td><td><i>P</i> value</td></tr><tr><td>Stage I+IIA</td><td>0.5153</td><td>0.5112</td><td>0.5360</td><td>0.1232</td><td>0.5150</td><td>0.5205</td><td>0.8568</td><td>< 0.0001</td></tr><tr><td>Stage IIB</td><td>0.6144</td><td>< 0.0001</td><td>0.5993</td><td>0.0004</td><td>0.5037</td><td>0.8937</td><td>0.9554</td><td>< 0.0001</td></tr><tr><td>Stage III+IV</td><td>0.7423</td><td>< 0.0001</td><td>0.6381</td><td>0.0012</td><td>0.5612</td><td>0.1510</td><td>0.9673</td><td>< 0.0001</td></tr></table> |
c1b64dce7dfa5b141033b29c04fee6ce77aa2a1077c8ddf6d4d1f4b1254918a8.png | simple | <table><tr><td>Category and Population</td><td>Core</td><td>Flexible</td><td>Odds Ratio</td><td>Significance</td></tr><tr><td>Nonsynonymous mutations in nonmutator populations</td><td>123</td><td>51</td><td>2.41</td><td><i>P</i> < 10<sup>−8</sup></td></tr><tr><td>Synonymous mutations in nonmutator populations</td><td>10</td><td>10</td><td>1.00</td><td><i>P</i> = 1.0000</td></tr><tr><td>Nonsynonymous mutations in mutator populations</td><td>2265</td><td>2510</td><td>0.90</td><td><i>P</i> = 0.1477</td></tr><tr><td>Synonymous mutations in mutator populations</td><td>838</td><td>860</td><td>0.97</td><td><i>P</i> = 0.4814</td></tr></table> |
addd8337e996a946b16cf4ccdcee98a9a2283b480b0440f480101977c584285c.png | complex | <table><tr><td rowspan="2">Materials</td><td>Elastic modulus</td><td>Poisson ratio</td><td>Friction coefficient</td></tr><tr><td><i>E</i> (MPa)</td><td><i>μ</i></td><td><i>f</i></td></tr><tr><td>Titanium plate</td><td>110,000</td><td>0.30</td><td>0.45</td></tr><tr><td>Titanium screw</td><td>110,000</td><td>0.30</td><td>–</td></tr><tr><td>Articular cartilage</td><td>11.9–0.48</td><td>0.40</td><td>0.0024 ~ 0.24</td></tr><tr><td>Cortical bone</td><td>17,000</td><td>0.3</td><td>0.4</td></tr><tr><td>Cancellous bone</td><td>129</td><td>0.2</td><td>0.4</td></tr></table> |
66efeb72740e307fd45e52272b77969516d3635a5d09193154ae79a88ecca778.png | simple | <table><tr><td>Name</td><td>Sequence (5’ --- 3’)</td><td>Length (bp)</td><td>Tm (° C)</td></tr><tr><td><i>flp-14</i> RT F</td><td>GCGAGTCCATGTGTAGCAGCTAAT</td><td>117</td><td>60</td></tr><tr><td><i>flp-14</i> RT R</td><td>GGGAGATGAAGAACGTTTACTACTTTGCC</td><td></td><td></td></tr><tr><td><i>flp-18</i> RT F</td><td>AGGATGACTTATTGCGCCAGGA</td><td>185</td><td>60</td></tr><tr><td><i>flp-18</i> RT R</td><td>TTCCTTTACCGAATCTGAGCACGC</td><td></td><td></td></tr><tr><td><i>18S</i><i></i><i>rRNA</i> Tobacco RT F</td><td>CGCGCGCTACACTGATGTATTCAA</td><td>172</td><td>60</td></tr><tr><td><i>18S</i><i></i><i>rRNA</i> Tobacco RT R</td><td>TACAAAGGGCAGGGACGTAGTCAA</td><td></td><td></td></tr><tr><td><i>18S</i><i></i><i>rRNA</i><i></i><i>M.incognita</i> RT F</td><td>TCAACGTGCTTGTCCTACCCTGAA</td><td>155</td><td>60</td></tr><tr><td><i>18S</i><i></i><i>rRNA</i><i></i><i>M.incognita</i> RT R</td><td>TGTGTACAAAGGGCAGGGACGTAA</td><td></td><td></td></tr></table> |
6848e808044ea655c4e099fbb9f16cc2ce08574234fa4610b69334181622ff15.png | simple | <table><tr><td>Strain</td><td></td><td>Animal No.</td><td>Incidence (%)</td><td>Multiplicity <sup>a)</sup></td></tr><tr><td>FVB/N</td><td>total</td><td>16</td><td>16 (100)</td><td>32.56 ± 3.60</td></tr><tr><td></td><td> female</td><td>9</td><td>9 (100)</td><td>28.22 ± 4.46</td></tr><tr><td></td><td> male</td><td>7</td><td>7 (100)</td><td>38.14 ± 5.36</td></tr><tr><td>PWK/Rbrc</td><td>total</td><td>10</td><td>0 (0)</td><td>0</td></tr><tr><td></td><td> female</td><td>10</td><td>0 (0)</td><td>0</td></tr><tr><td></td><td> male</td><td>10</td><td>0 (0)</td><td>0</td></tr><tr><td>FVB × PWK</td><td>total</td><td>25</td><td>4 (16)</td><td>0.32 ± 0.8</td></tr><tr><td></td><td> female</td><td>14</td><td>4 (28.6)</td><td>0.57 ± 1.01</td></tr><tr><td></td><td> male</td><td>11</td><td>0 (0)</td><td>0</td></tr><tr><td>PWK × FVB</td><td>total</td><td>17</td><td>0 (0)</td><td>0</td></tr><tr><td></td><td> female</td><td>8</td><td>0 (0)</td><td>0</td></tr><tr><td></td><td> male</td><td>9</td><td>0 (0)</td><td>0</td></tr><tr><td>(FxP) × F</td><td>total</td><td>208</td><td>123(56.7)</td><td>4.86 ± 0.56</td></tr><tr><td></td><td> female</td><td>107</td><td>60(56.1)</td><td>3.45 ± 0.64</td></tr><tr><td></td><td> male</td><td>101</td><td>63(62.4)</td><td>6.34 ± 0.92</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.